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Abstract 
Lactoferrin (Lf) is present in milk and body fluid secretions, including tears and has 
antimicrobial, anticancer and anti-inflammatory properties. Insufficient amounts of Lf in some 
secretions also appear to correlate with certain health problems. Protection against gastroenteritis 
is the most likely biologically relevant activity of lactoferrin. Multiple in vitro and animal studies 
have shown a protective effect of lactoferrin on infections with enteric microorganisms, 
including rotavirus, Giardia, Shigella, Salmonella and the diarrheagenic Escherichia coli. 
Lactoferrin has two major effects on enteric pathogens: it inhibits growth and it impairs the 
function of surface expressed virulence factors thereby decreasing their ability to adhere or to 
invade mammalian cells. Lf also inhibits several species of fungi, certain parasites and viruses 
including hepatitis. This study covers the role of bovine Lf (bLf) and buffalo Lf (buLf) in 
clearing parasitic and bacterial infections. The mechanism by which lactoferrin inhibits some 
parasites may be via stimulation of the process of phagocytosis, whereby immune cells engulf 
and digest foreign organisms.  
 
The exciting potentials of employing nanotechnology in advancing drug delivery systems and 
targeting active disease targeting have also shown some encouraging outcomes. Thus, noting the 
additional benefits brought by nanotechnology, it is hypothesized that the multifunctional natural 
bioactive protein lactoferrin, in combination with nanotechnology, can be a remarkable 
therapeutic agent.     
Giardia lamblia, the causative agent of giardiasis, is one of the most common causes of 
worldwide intestinal infections in humans and responsible for multiple outbreaks. The current 
synthetic toxic therapeutic interventions for the cure of giardiasis have shown multiple side 
effects and so far no Giardia vaccines are available for humans. In previous studies bovine 
lactoferrin has demonstrated to have great potential as an antiprotozoal agent including Giardia. 
In Northern India and south east Asia the majority of the population drinks buffalo milk. 
However with the new breeds of buffalos, buffalo milk is also becoming popular in Australia as 
well. The focus of this study was the antimicrobial activity of buLf in vitro and in vivo, 
especially in case of giardiasis. The results for buLf in G. lamblia in vitro cultures show that this 
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protein (IC90 of 200μg/ml) was giardicidal and showed more efficacy compared to the routinely 
used drug metronidazole (IC90 of 40μM). Experimentally it was also observed that oral feeding 
of a buLf diet to BALB/c mice, 7 days after inoculation with Giardia lamblia trophozoites was 
efficient in eliminating G. lamblia parasites from mice in just 4 days of administration reducing 
the duration of the disease. On histological examination, restoration of gut atrophy and less 
infiltrating cells in the small intestine were observed in the buLf diet fed mice compared to the 
control. These findings suggest that lactoferrin has a protective effect against infection with G. 
lamblia. The study concludes that buLf is more effective in the treatment of giardiasis than that 
of the toxic anti-Giardia drug metronidazole dose used in this trial in the animals also.   
The anti-parasitic potential of various forms of bovine Lf in vitro and alginate gel-encapsulated 
ceramic nanocarriers loaded with Fe saturated bovine Lf (Fe-bLf) (AEC-CP-Fe-bLf NPs), in vivo 
as anti-Giardia agents was also evaluated. The aim was to develop a combination of 
nanotherapeutic strategies for drug delivery to provide a more potent and targeted therapy 
especially in case of giardiasis, caused by G. lamblia. The efficacy of bovine lactoferrin was 
evaluated in vitro against Giardia. The protein was found to be either giardicidal or used as an 
iron source for growth, depending on the Lf saturation. BALB/c mice were infected with G. 
lamblia trophozoites by inoculation over 7 days and subsequently treated with a nanoformulated 
Lf diet. So in vivo results showed that this nanoformulated diet was successful in eliminating G. 
lamblia infection when tested in stool samples and small intestinal sections of mice fed during 
infection. The effect of bLf therapy showed better results in the infected group of mice, however 
nanoformulated diet have the maximum effects to completely clear the infection in the diseased 
mice. In addition, an histological examination was carried out on mice tissues and revealed 
amelioration of intestinal pathology in the nanoformulated Lf diet fed mice compared with the 
control. Furthermore, ultrastructural studies by transmission electron microscopy (TEM) further 
confirmed the protection of mice dosed with the nanoformulated Lf diet after being infected with 
Giardia for 7 days. These results suggested that bovine lactoferrin was most effective in 
protecting against infection; however a complete cure was gained when nanoformulated Fe-Lf 
was used in the treatment of giardiasis whereas the metronidazole dose also used in this trial 
proved less effective.   
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Due to the emerging resistance of bacterial strains to the existing antibiotics or multi drug 
resistance (MDR) and chronic toxicity associated with them, the search for alternative 
chemotherapeutic agents against bacteria is the need of the hour. This study also demonstrates 
the potential anti-microbial efficacy of AEC-CP-Fe-bLf NPs. The antimicrobial activity of non- 
nanoformulated apo (iron free), iron saturated (Fe-bLf) and native forms of Australian bLf 
against pathogenic Salmonella typhimurium (ATCC-14028) was studied in vitro. To increase the 
bioavailability and gut enzyme resistance of bLf in vivo, the alginate gel-encapsulated ceramic 
nanocarriers loaded with bovine Fe-bLf were used for in vivo studies using the BALB/c mice 
model. In vitro results revealed that native Australian bLf (IC90<0.2mg/ml) is more effective in 
combating infection than the conventional drug ciprofloxacin (0.2mg/ml <IC90<0.4mg/ml). The 
efficacy of the drug was also revealed in vivo when BALB/c mice, after being challenged with S. 
typhimurium (200μl of 108 CFU/ml suspension) were fed orally with the nanoformulated bLf 
diet and the infection was eliminated. The drug reduced the duration of the disease preventing 
the Salmonella -infected phagocytes to gain access to the lymphatics and bloodstream and spread 
to the liver and the spleen. The same results were observed in the mice fed with bLf alone 3 days 
after infection with the bacteria. These mice became pathogen free within 2 days of treatment/ 6 
days post infection. However, chronic infection developed in the group of infected mice that did 
not receive any drug treatment as well as the mice treated with Ciprofloxacin. Persistence of 
bacteria was observed in the sera, small intestine, liver, spleen and their mesenteric lymph nodes. 
The infection in these mice continued till 20 days post infection, after which the infection was 
almost resolved in all the groups of mice. Histological examination showed the recovery of the 
pathological profile of mice. This further confirmed the protection of mice dosed with the 
nanoformulated Lf diet and bLf after being infected with S. typhimurium after 3 days and 
receiving various treatments thereafter. The immune response to bacterial infection and to 
various drug treatments thereafter was studied in the mice. The study concludes that bovine 
lactoferrin and nanoformulated Fe-Lf are more effective in the treatment of Salmonella infected 
mice than Ciprofloxacin.   
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Chapter 1. Introduction 
1.1 Significance of the study - hypotheses and research question 
Earlier studies have reported the use of Fe-bLf as an anti-tumour agent when fed orally along 
with the monotherapy of the chemotherapeutics or in a combination of two anticancer 
therapeutics to prevent tumourigenesis (Kanwar et al. 2008; Sanchez et al. 2001b). A previous 
report has also suggested the success of development of polymeric-ceramic nanocarriers (NCs) 
in order to achieve oral delivery of the anticancer neutraceutical iron-saturated bovine lactoferrin 
(Fe-bLf) protein. These were the novel alginate-enclosed chitosan–calcium phosphate-loaded 
iron-saturated bovine lactoferrin nanocarriers (AEC-CP-Fe-bLf NCs) which showed promising 
results for oral delivery in colon cancer therapy studied by Kanwar and coworkers (Kanwar, 
Mahidhara & Kanwar 2012). Thus, due to various advantages of nanoparticles like enhanced 
bioavailability, high half lives and resistant to degradation from various enzymes, Fe-bLf was 
loaded on the special novel nanocarriers as drug delivery systems in the treatment of parasitic 
and bacterial infectious disease animal models.  
 
Native bLf is only 15-20% saturated with iron, indicating that the lobes were not fully occupied 
by iron. It has been shown earlier that orally fed bLf resists degradation in the intestine, which 
bears direct relation to the levels of iron saturation (Troost et al. 2001). Fe-bLf can be implicated 
in the efficient delivery of the particles through biological barriers, further improving the 
intestinal uptake of these nanocarriers, when delivered orally. As we have mentioned above, 
Kanwar et al. demonstrated for the first time that iron content is a critical determinant in the 
antitumour activity of bLf. They found that 100% iron-saturated bLf (Fe-bLf) acted as a potent 
natural adjuvant for augmenting cancer chemotherapy (Kanwar et al. 2008). In this regard, this 
study uses the advances in nanotechnology to design an oral delivery platform for encapsulation 
of Fe-bLf, enhancing its bioavailability to infection sites and evaluates its efficacy as an anti-
microbial agent.  
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The hypothesis of the study is that nanoformulated lactoferrin will show more efficacy in 
treatment of microbial infections than Australian native bovine lactoferrin (bLf). 
Furthermore the antimicrobial efficacy of nanoformulated lactoferrin, administered orally to the 
BALB/c mice could be possible because of its iron saturated form (Fe-bLf) when compared to 
conventional drugs used for the treatment of microbial infections. 
The oral route for administration of biomacromolecules is the most convenient route but is 
challenging because of pH variations and enzymatic activity. Therefore taking into consideration 
the above mentioned advantages of nanotechnology, novel alginate enclosed, chitosan coated 
ceramic, antimicrobial nanocarrier (AEC-CP-Fe-bLf) was formulated to achieve safe and 
effective delivery via the gastrointestinal tract. These nanocarriers were loaded with 
multifunctional bovine Lf, a natural milk based protein, for improvement of intestinal absorption, 
in order to develop a novel platform to carry antimicrobial proteins for oral therapy. It was 
assumed that the new formulation developed in this study helped in preserving the stability of Lf, 
enhanced gastric residence time, improving its bioavailability and overcoming all the barriers 
associated with protein absorption.       
 
Thus the question arises of the bioactivity of nanoformulated Fe-bLf in oral administration and 
its efficacy as an  anti-microbial agent . 
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1.2 Aim 
The focus of the study was to elucidate the biochemical and molecular basis of preclinical efficacies 
of the different treatments in anti-microbial activity. Using natural antimicrobial proteins in the 
treatment of infectious diseases like giardiasis and salmonellosis is a better approach, to overcome the 
side effects of present day medications. Nano-carrier based anti-microbial protein delivery could be a 
promising strategy for the better protection and controlled delivery of the protein to the target site. 
Therefore a nano platform was developed that can carry antimicrobial protein for oral administration. 
This study has demonstrated the preparation of novel alginate-enclosed chitosan–calcium phosphate-
loaded iron-saturated bovine lactoferrin nanocarriers (AEC-CP-Fe-bLf NCs) as therapeutics for the 
treatment of protozoal infections due to Giardia lamblia and Salmonella typhimurium.  
 
Like most of the protein drugs, Lf is also poorly absorbed during oral administration by the 
human gastrointestinal tract (GIT) and leads to reduce therapeutic efficiency. As a result, the 
absolute oral bioavailability levels of native Lf may be less than 1 % (Yao et al. 2012). There is a 
growing need to develop novel delivery systems to enhance Lf absorption. The main aim of this 
thesis was to design an ideal formulation for oral delivery of Lf which is safe and biocampatible 
has good entrapment efficiency and helps in the retention or enhancement of the natural 
therapeutic properties of Lf. 
 
The specific aims were: 
1. To prepare encapsulated iron-saturated Lf on the novel alginate-enclosed chitosan–calcium 
phosphate-loaded iron-saturated bovine lactoferrin nanocarriers (AEC-CP-Fe-bLf NCs) form of 
Australian bovine lactoferrin. 
2. To investigate anti-parasitic and anti-bacterial activities AEC-CP-Fe-bLf NCs in cell based assays in 
different strains of parasites and bacteria.  
3. To study the anti-parasitic and anti-bacterial activities of bLf and AEC-CP-Fe-bLf NCs in different 
mice models. 
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Chapter 2: Lactoferrin and its nanoformulation loading on AEC-CP-Fe-bLf NCs 
2.1 Introduction and review 
Lactoferrin (Lf) belongs to the superfamily of various proteins- transferrin (help in iron 
transport), saxyphillin and pacifastin (inhibitors of carbonic anhydrase) etc. (Schanbacher, 
Goodman & Talhouk 1993). It is a cell-secreted molecule, produced by mucosal epithelial cells 
in various mammals including humans, cows etc. (García-Montoya et al. 2012) and present in 
their mucosal secretions like tears, saliva, vaginal fluids, semen, nasal and bronchial secretions, 
bile, gastrointestinal fluids, urine, milk and colostrum (Öztafl & Özgünefl 2005; Rodríguez-
Franco, Vázquez-Moreno & Ramos-Clamont 2005; Van der Strate et al. 2001) (Table 2.1). 
Primates like pigs and mice have significant concentrations of milk Lf (>200 μg/ml), whereas 
rabbits, dogs and rats have been reported to have very little or no Lf (<50μg/ml) in their milk. 
Cows and goats have intermediate levels of <200 μg/ml in their milk (Table 2.1). It is known to 
be an antimicrobial protein and is found abundantly like lysozyme and collectin (Brogan et al. 
1975; Lim et al. 2000).     
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Table 2.1 Occurrence of lactoferrin in biological fluids:  
Biological fluid Amounts reported Reference 
Saliva >7-10 mg/ml (Steijns 2001) 
Tear >2.2 mg/ml, 0.1 mg/ml, 0.7  
mg/ml, 2.2 mg/ml 
(Kijlstra, Jeurissen & Koning 
1983; Moguilevsky, Masson & 
Courtoy 1987; Steijns 2001; 
Takayanagi, Niida & Chiba 1986) 
Seminal plasma >0.4-1.9 mg/ml (Steijns 2001) 
Synovial fluid 10-80 mg/ml (Steijns 2001) 
Nasal 0.1 mg/ml (Masson & Heremans 1971) 
Hepatic bile 10-40 μg/ml (Masson & Heremans 1971) 
Pancreatic 0.5 mg/ml (Masson & Heremans 1971) 
Gastric 0.5-1.0 mg/ml (Masson & Heremans 1971) 
Urine 1 μg/ml (Masson & Heremans 1971) 
Blood 0.1-2.5 μg/ml (MansourEl-Loly & Mahfouz 2011) 
Neutrophil 3.45 μg/ml (Moguilevsky, Masson & Courtoy 
1987) 
Granulocytes 4 μg/ml (Bezwoda & Mansoor 1989) 
Colostral breast milk >7 mg/ml (Steijns & Van Hooijdonk 2000) 
Mature breast milk >1-2 mg/ml (Steijns & Van Hooijdonk 2000) 
Cow's colostral whey 1.5 mg/ml (Steijns & Van Hooijdonk 2000) 
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Cow's milk 20-200 μg/ml (Steijns & Van Hooijdonk 2000) 
Human Colostrum  10 g/l (Suzuki, Lopez & Lönnerdal 2005) 
Human Milk 20 μM (Hamosh 1998) 
Goat milk >200 m μg/ml (Suzuki, Lopez & Lönnerdal 2005) 
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2.2 Structural dynamics 
2.2.1 Amino acid sequence and its characteristics 
Lactoferrin was first identified as a milk protein by Sorenson and Sorenson in 1939(Masson & 
Heremans 1971). It showed 60% sequence identity with transferrin (Wally & Buchanan 2007). 
The nucleotide sequence of human Lf (hLf) was first determined by Rey and Woloshuk in 1990 
(Rey & Woloshuk 1990). Lf genes are highly conserved among species, with an almost identical 
organization and an mRNA of about 1900–2600 bp. When a homology search was done in 
sequence databases, it revealed nucleotide sequences for the Lfs of 13 species: 3 primates, 7 
even-toed ungulates, 1 pig, 1 cat, and 1 mouse. The range of pair wise sequence identities was 
78% to 100%. The main outliers in this group were Lfs from primates, in which human and 
chimpanzee are quite similar (95–98%) when compared to the orangutan (79%). Horse and 
camel; pig, cow; yak; water buffalo; bull and goat Lfs share 81 and 78% of sequence identity 
respectively when compared to human Lf as an out group. Also the property typically predictable 
from their sequence is the very basic character of the Lfs, with a pI typically greater than 9. 
Structurally, it was found that Lfs are distinguishable from Tfs because of the peptide linker 
between the two lobes which might have evolved from an ancient duplication event (Lambert, 
Perri & Meehan 2005). This peptide linker contains several proline residues. 
 
2.2.2 Molecular structure 
The glycoprotein lactoferrin is of 80kDa, hLf contains a polypeptide chain of  ̴700 amino acids 
but bLf has only 689 amino acids (Steijns & Van Hooijdonk 2000). It is folded into two globular 
lobes (N- and C-Terminal), each containing one binding site for Fe+3. A hinge region comprising 
an α-helix between amino acids 333 and 343 connects the two lobes in human Lf (hLf), 
providing flexibility to the molecule (Öztafl & Özgünefl 2005). N-lobe includes the amino acids 
1–332, and 344–703, comprising the C-lobe that constitutes the polypeptide chain. It is made up 
of α-helix and β-pleated sheet structures that create two domains within each lobe (domains I and 
II) (Mazurier & Spik 1980). Iron binding induces a ‘‘closed’’ structure in which the two domains 
[Type text] 
 
8 
 
of each lobe enclose the bound Fe3+ ion, effectively sequestering it from the external 
environment. Four protein ligands, plus the synergistically bound CO32- anion, are covalently 
bound to the metal ion, which thus cross-links the two domains. This explains the high stability 
of this structure and the difficulty of removing the bound metal. Because of its ability to 
reversibly bind Fe+3, Lf can exist free of Fe+3 (apo-Lf, open conformation) or associated with 
Fe+3 (holo-Lf, closed confirmation) (Wally & Buchanan 2007). bLf has a week binding for iron 
and it releases iron more readily than hLf but has pH iron releasing capacity (Moore et al. 1997). 
 
The amino acids directly involved at the iron-binding site in each lobe are Asp60, Tyr92, Tyr192 
and His253, while Arg121 is involved in binding the CO3−2 ion. The primary structure of Lf 
shows the number and position of Cys residues that allow the formation of intramolecular 
disulfide bridges; Asn residues in the N- and C-terminal lobes provide several potential N-
glycosylation sites (Arnold et al. 2009). Human lactoferrin (hLf) has 2 glycan chains with only 
one glycosylation site (Asn476) but bLf has only 4 chains (Moore et al. 1997).  
 
The structure of buffalo lactoferrin was determined by Karthikeyan et al. and found to comprise 
of 5316 protein atoms for all 689 residues, two Fe3+ and two CO32- ions (Fig. 2.1). The folding of 
buffalo lactoferrin was essentially similar to that of the other members of the transferrin family. 
The differences were found in the dimensions of the binding cleft and the interlobe orientation. 
The interlobe interactions were predominantly hydrophobic in nature, thus facilitating the sliding 
of two lobes owing to external forces (Karthikeyan et al. 2000a).  
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Figure 2.1 Predicted structure of lactoferrin. 
a) From EU812318 (bLF) sequence using PDB ID: 1BIY (buffalo) as a template, showing two-
lobe, four-domain polypeptide.  
b) Canonical iron binding pocket site of lactoferrin. Fe+3 (cream), CO3 (gray and red). Modelled 
using Protein Model Portal (Arnold et al. 2009), and viewed using Chimera software 
(http://www.cgl.ucsf.edu/chimera/). (García-Montoya et al. 2012) 
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2.3 Surface properties of Lf: 
Many of the proven or proposed functions of Lf, apart from its iron binding activity, depend on 
its ability to bind to other macromolecules (proteins, DNA). These activities, in turn, must 
depend on surface features of Lf. All Lfs so far characterized have high isoelectric points (pI ~ 9) 
and this strongly cationic nature, which differentiates Lfs from Tfs, must be a major factor in the 
ability of Lf to bind, perhaps rather indiscriminately, to many different cell types and many 
anionic molecules (Baker & Baker 2005; Baker & Baker 2009). 
 
2.4 Biological functions 
Lactoferrin is a highly multifunctional protein due to its wide distribution in various tissues as 
mentioned above. In milk proteins Lf is the most important and widely studied milk protein for 
the human health and treating diseases. Lactoferrin plays an important role in human innate 
defense mechanisms against bacteria, fungi, and viruses (Arnold et al. 1981; Valenti et al. 2004). 
In addition to antibacterial activity, lactoferrin has demonstrated potent antiparasitic activity, 
towards a broad spectrum of species. It is also considered to be an important host defense 
molecule during infant development (Jenssen & Hancock 2009). Many other functions have been 
ascribed to this cationic protein, including the inhibiting action toward bacterial adhesion and 
invasion of target host cells. Different physicochemical properties of the molecule, which include 
the iron-binding capability, the binding to anionic cell surfaces and molecules, and serine 
protease activity (Valenti et al. 2004) are responsible for different lactoferrin functions. Besides 
scavenging free iron in fluids and effected areas of the body, Lf is a microbicidal protein that 
interacts with and damages components of the microbial surface (Farnaud & Evans 2003; Shi, 
Kong & Nakayama 2000; Viejo-Díaz, Andrés & Fierro 2004) and also inhibits bacterial biofilm 
development, a major medical problem (Singh et al. 2002). Lf and its peptides have the capacity 
to kill a wide variety of pathogenic microorganisms (Farnaud & Evans 2003; Lönnerdal & Iyer 
1995; Orsi 2004). Lf acts synergistically in vitro with antibiotics against bacteria and fungi and 
in bacterial strains that have developed resistance to antibiotics (Diarra, Petitclerc & Lacasse 
2002; Kuipers et al. 1999; van der Strate et al. 2003). Metronidazole resistance had been found in 
cultures of Entamoeba histolytica (Upcroft et al. 1999a), as well as strains of Trichomonas 
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vaginalis a common sexually transmitted protozoan and Giardia lamblia, an important cause of 
childhood diarrhea in developing countries. This resistance has been found to be associated with 
increased expression of iron-containing superoxide dismutase and reduction of peroxiredoxin 
(Wassmann et al. 1999). Since iron is important for virulence in many bacteria and parasites, 
lactoferrin could be a natural molecule that could be an effective antimicrobial by itself or may 
potentiate their effect of classical antimicrobials in resistant infections. One of the major 
advantages of lactoferrin as a potential antimicrobial would be that this molecule is in use in milk 
formulations and if found effective, it could be used safely without detailed toxicity studies as 
this is already in use. 
 
2.4.1 Regulation of iron absorption 
Lactoferrin’s most striking physiochemical feature includes a great iron-binding affinity. It can 
retain this metal over a wide range of pH values thus helping in resistance to proteolysis. Two 
Fe+3 ions are bound with two synergistically bound Co32- ions. Lf helps in iron absorption by 
binding to it and maintenance of cellular iron levels in the body. The structural features of Lf 
provide an additional function of Fe+3 homeostasis. 
 
2.4.2 Antimicrobial activity 
Lactoferrin exhibits anti-microbial activity against a broad spectrum of bacteria, parasites, fungi, 
yeasts and viruses (García-Montoya et al. 2012; Yamauchi et al. 2006). It has been extensively 
used in the treatment of infectious diseases. The wide range of applications of lactoferrin has 
been the driving force in Lf research and its antimicrobial activity has been particularly useful. 
 
Mechanism: This antimicrobial protein has physiological capabilities of host defense and its 
mechanism of action involves iron sequestration at the sites of infection, causing a bacteriostatic 
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effect by iron sequestration in such sites. Other mechanisms include direct interaction of 
lactoferrin with molecular and cellular components of both hosts and pathogens (Farnaud & 
Evans 2003; Valenti & Antonini 2005). A cationic domain located in the N-terminus of 
lactoferrin, lactoferricin was found to show direct bactericidal activity (Wakabayashi, Takase & 
Tomita 2003).  Mechanism of action of lactoferrin against gram-positive bacteria is based on 
binding to negatively charged molecules on the bacterial surface such as lipoteichoic acid, 
causing reduction of negative charge on the cell membrane and allowing the contact between 
lyzozyme and underlying peptidoglycan. In case of gram negative bacteria Lf damages their 
external membrane by binding with lipopolysaccharide (LPS) and liberating it from the cell wall, 
increase in membrane's permeability and damage to bacteria (Fig. 2.2).This interaction of Lf and 
LPS may further cause the secretion of antibacterial such as lyzozyme from the mucosa  
(González-Chávez, Arévalo-Gallegos & Rascón-Cruz 2009).   
 
Antibacterial activity: Lactoferrin has been found to exhibit bacteriostatic and bactericidal 
activities against a number of Gram-positive and Gram-negative bacteria (Table 2.2), its function 
is mainly because of the direct interaction with the bacterial surfaces as mentioned above (Fig. 
2.2). Its role as an antimicrobial agent has attracted more attention because it has been proven 
effective in case of resistant strains of Staphylococcus aureus, Listeria monocytognes, methicillin 
resistant Klebsiella pneumoniae and Mycobacterium tuberculosis and among other microbes like 
Haemophillus influenza that were inhibited by an iron dependent interaction with the cell surface 
(Arnold et al. 1981; Qiu et al. 1998; Wakabayashi, Takase & Tomita 2003). A group of 
researchers demonstrated that Lf could prevent the formation of biofilms in Pseudomonas 
auruginosa in vitro (Singh et al. 2002).   
 
Lf has shown to prevent adhesion and/or internalisation of bacteria and viruses to tissue culture 
cells (Francesca et al. 2004; Ochoa et al. 2003). Serine protease activity was also shown by Lf 
that specifically inactivated Haemophilus influenza IgA1 protease and Hap adhesion putative 
colonization proteins (Qiu et al. 1998). 
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Lactoferrin was found to exhibit bacteriostatic and bactericidal activity against a number of gram 
positive and gram-negative bacteria (Bullen 1976; Murdock et al. 2007). A study by Mosquito et 
al. reports the protective role of bLf against the Salmonella infection, reducing the severity, 
mortality and the degree of inflammation of this infection in mice (Mosquito et al. 2010). Some 
researchers (Drago-Serrano et al. 2010) were also successful in explaining that the efficacy of 
bLf against S. typhimurium in mice might be the result of its modulatory effect on 
immunocompetent cells (from intestinal and peripheral organs) involved in antibody production. 
Some studies (Fischer et al. 2007; Worley et al. 2006) have demonstrated the antibacterial effects 
through oral administration of bLf in case of S. typhimurium infection in the liver and spleen of 
mice.  
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Figure 2.2 Mechanism of antibacterial action of lactoferrin (Lf). (A) Gram-positive bacteria: 
LF is bound to anionic molecules of the cell membrane such as lipoteichoic acid, neutralizing 
wall charge and favoring contact between lyzozyme and the underlying peptidoglycan over 
which it exerts an enzymatic effect.  
(B) Gram-negative bacteria: LF can bind to lipid A of lipopolysaccharide, causing release of this 
lipid with consequent damage to the cell membrane, also potentiating the action of lysozyme. 
(González-Chávez, Arévalo-Gallegos & Rascón-Cruz 2009).  
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Table 2.2 Bacteria against which lactoferrin has a reported effect: 
 Target Mode of action Reference 
Gram-
positive 
Bacillus stearothermophilus Iron sequestering (Oliver et al. 1984) 
Bacillus subtilis Iron-dependent 
interaction with 
bacterial surface 
(Oram & Reiter 
1968) 
Klebsiella pneumonia Iron-dependent 
interaction with 
bacterial surface 
(Qiu et al. 1998) 
Listeria monocytogenes Altering bacterial 
surface 
(Bellamy et al. 1992; 
Lee et al. 2005) 
Staphylococcus aureus Iron sequestering (Bhimani, Vendrov 
& Furmanski 2001; 
Hammerschmidt et 
al. 1999) 
Streptococcus mutans Iron independent 
interaction with cell 
surface 
(Arnold et al. 1981; 
Dalmastri et al. 1988; 
Francesca et al. 
2004) 
Streptococcus parasanguinis Altering bacterial 
growth 
(van der Kraan et al. 
2005) 
Actinobacillus Proteolytic activity (Roseanu et al. 
2010a) 
S. epidermis Interaction with 
lipoteichoic acid on 
bacterial surface 
(Roseanu et al. 
2010a) 
S. epidermis Prevents biofilm 
formation-through 
iron sequestering 
(Roseanu et al. 
2010a) 
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Gram-
negative 
Clamydophila psittaci Interference with cell 
adhesion 
(Beeckman et al. 
2007) 
Haemophilus influenzae Altering bacteria 
virulence-degrading 
IgA 1 and Hap  
(Qiu et al. 1998) 
E. coli enteropathogenic (EPEC) Proteolytic activity of 
invasive mechanism 
(Ochoa et al. 2003) 
E. coli enteropathogenic (EAEC) Inhibit adherence of 
diffusely adherent 
(Nascimento de 
Araújo & Giugliano 
2000) 
E. coli (DAEC) Inhibit aggregative 
proliferation 
(Nascimento de 
Araújo & Giugliano 
2000) 
Helicobacter felis Prevention of matrix 
interaction cell-host 
(Dial et al. 2000) 
Helicobacter pylori Iron-independent 
mechanism of 
inhibition 
(Husson et al. 1993; 
Wang et al. 2001) 
Legionella pneumophila Prevent intracellular 
proliferation 
(Goldoni et al. 2000) 
Pseudomonas aeruginosa  Prevents biofilm 
formation 
(Berlutti et al. 2005) 
Shigella flexneri Disrupt bacterial type 
III secretion system-
degrading IpaB and 
IpaC  
(Willer, de L Lima & 
Giugliano 2004) 
Vibrio cholera Iron-independent 
mechanism of 
inhibition 
(Hendrixson et al. 
2003) 
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Mycobacterium tuberculosis  Augment cellular 
immunity 
(Hwang, Kruzel & 
Actor 2005; Schaible 
et al. 2002)  
Mycoplasma bovis Prevents biofilm 
formation 
(García-Montoya et 
al. 2012) 
Porphyromonas gingivalis Disrupt biofilm 
formation-cell 
membrane 
permeabilization 
(Wakabayashi et al. 
2010) 
Salmonella enteridis Interferes with 
polysaccharide cell 
content 
(García-Montoya et 
al. 2012) 
 Salmonella typhimurium Cation chelators, 
Interaction with the 
bacterial surface, 
damaging the 
bacterial membrane, 
altering the outer 
membrane 
permeability, 
resulting in a release 
of LPS 
(Bessler, de Oliveira 
& Giugliano 2006; 
Ellison, Giehl & 
LaForce 1988; 
Ellison et al. 1990) 
B. cenocepacia Prevents biofilm 
formation through 
iron sequestering 
(Berlutti et al. 2005) 
B. cepacia Prevents biofilm 
formation-probably 
through iron 
sequestering  
(Caraher et al. 2007) 
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Antiparasitic activity: The majority of the studies carried out so far have been on the 
antibacterial and anti-viral potency of lactoferrin. There is paucity of literature on the anti-
parasitic effects of lactoferrin, probably due to the fact that for in vitro studies, both parasites and 
viruses are not easy to maintain and study. Here, we would like to summarize the data that is 
available for anti-parasitic effects of lactoferrin and the future research that can be done (Table 
2.3). Lactoferrin’s microbicidal activity has been described in the protozoan Giardia lamblia and 
Toxoplasma gondii, in which the effect is due to Lf’s capacity to bind to the parasite membrane 
(Tanaka et al. 1997; Turchany et al. 1997). Besides lactoferrin (Gillin, Reiner & Wang 1983a; 
Ochoa et al. 2008), its N-terminal peptides (Lfpep’s) generated by gastric pepsin cleavage of 
human Lf (residues 18 to 40 of the native molecule), have also shown giardicidal activity 
(Turchany et al. 1997). It has been suggested that lactoferrin shows antiparasitic activity towards 
Pneumocystis carinii through iron sequestration (Weinberg 1994). A similar mechanism is also 
observed in Entamoeba histolytica. Both human and bovine lactoferrin have demonstrated the 
ability to kill this amoeba in a concentration-dependent manner. The antimicrobial activity was 
inhibited by both Fe2+ and Fe3+ and other divalent cations like Mg2+ and Ca2+ (Beaumont, Maggs 
& Clarke 2003). Growth of the intra-erythrocytic form of P. falciparum can be inhibited by Fe3+-
free [apo] Lf (apo-Lf) and Fe3+-bound [holo] Lf (holo-Lf) (Fritsch et al. 1987). This is thought to 
result from the generation of oxygen-free radicals by the Lf/Fe3+ complex, which damages 
membranes of erythrocytes and protozoans (Fritsch et al. 1987). It was shown that growth of B. 
caballi was inhibited only by apo-Lf (Ikadai et al. 2005). Therefore, it is suggested that the 
mechanism of action of Lf in B. caballi differs from that in P. falciparum. The inhibitory effect 
of apo-Lf on B.caballi appears to be related to inactivation or inhibition of a growth factor in the 
culture medium (Ikadai et al. 2005). By contrast holo-Lf can be used by some parasites as an iron 
source for growth (Britigan et al. 1998; León-Sicairos et al. 2005; Weinberg 1999). Lf may serve 
as an iron source for Trichomonas vaginalis (Tachezy et al. 1996) and Leishmania chagasi 
(Wilson et al. 1994). A recent study has shown that transferring could improve the growth of 
Leishmania donovani while chelation of iron could inhibit this action (Das et al. 2009). This 
would indicate that different formulations of lactoferrin could have varied effects on the growth 
of parasites. Therefore, there is a need to study the molecular mechanisms involved in the 
interaction of lactoferrins with various parasites. 
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Table 2.3 Metal binding protein lactoferrin and its potential as an anti-parasitic activity in 
different isolates from humans: 
 
Parasite Activity/action References 
Entamoeba histolytica Iron sequestration, Membrane 
disruption 
(Leon-Sicairos et al. 2006b) 
Toxoplasma gondii Direct interaction by binding the 
surface membrane of parasite 
(Tanaka et al. 1997) 
Babesia caballi Interference with Fe+3  uptake by 
pathogen, Direct interaction  
(Farnaud & Evans 2003) 
Giardia lamblia Direct interaction by binding the 
surface membrane of parasite 
(Turchany et al. 1997) 
Pneumocystis  carinii Iron sequestration (Weinberg 1994) 
Plasmodium falciparum Blocking of the receptor heparin 
sulphate of host to which the 
parasite was to bound, membrane 
disruption of infected erythrocytes 
and parasite 
(Sinnis et al. 1996) 
Trypanosoma cruzi Stimulation of phagocytosis and 
killing by blood monocytes 
(Turchany, Aley & Gillin 1995) 
Eimeria   stiedai Effect of basic peptides on 
parasite membrane integrity and 
interaction with host tissues 
(Omata et al. 2001) 
Trichomonas  vaginalis Decreased adhesion to host 
epithelial cells and an increase in 
CP30-induced apoptosis in 
response to low iron 
(Kummer et al. 2008) 
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Antiviral activity: The antiviral activity of lactoferrin has been documented in the past against a 
broad range of RNA and DNA viruses that infect humans and animals (Van der Strate et al. 
2001). It was found to inhibit virus host interaction in enveloped viruses such as herpes simplex 
virus (HSV) (Andersen et al. 2004); inhibition of intracellular virus trafficking in the hepatitis B 
virus (HBV) (Hara et al. 2002) and human cytomegalovirus (HCMV) (Andersen et al. 2001) and 
direct binding of Lf to the viral particle in the hepatitis C virus (HCV) (Ikeda et al. 2000), feline 
herpes virus (FHV-1) (Sato et al. 2000) and hepatitis G virus (HGV) (Beaumont, Maggs & 
Clarke 2003). Lf also exerts a strong activity against human immunodeficiency virus (HIV) by 
inhibiting viral replication in the host cell (Swart et al. 1996). Human respiratory syncytial virus 
is inhibited by Lf too in addition to non-enveloped viruses such as adenoviruses and 
enteroviruses (Seganti et al. 2004). Lf exhibits antiviral activity against viruses that infect 
animals, like Friend virus complex, which causes erythroleukemia in rodents (Hangoc et al. 
1987) and feline calcivirus (Addie et al. 2003). 
 
Antifungal activity: Through various mechanisms like sequestering iron, altering the 
permeability of the cell membrane, Lf has been found to exhibit antifungal activity on several 
Candida species, some of which were pathogenic to humans too (ViejoǦDíaz, Andrés & Fierro 
2004). Lf has been shown to be fungicidal to Cryptococcus neoformans and C. albicans via 
cytoplasmic and mitochondrial membrane permeabilization (Kondori et al. 2011). In a study 
Apo-Lf was found to be fungicidal to Aspergillus fumigatus due to iron sequestration (Zarember 
et al. 2007). 
 
2.4.3 Anticancer Activity 
The use of lactoferrin as a potential therapeutic for wide range of cancers of colon, lung, 
pancreas, bladder, esophagus and liver has been highly considered (Kanwar et al. 2012b). It was 
found that when administered orally, bLf reduced chemically induced tumorigenesis in rodents 
(Bezault et al. 1994). This protein has been found to show antimetastatic activity and inhibition 
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of growth of transplanted tumours (Tsuda et al. 2002). In animal models colorectal cancer was 
inhibited by bLf (Nakajima et al. 2011). Also human Lf reduced the risk of colon carcinogenesis 
as observed in a clinical study (Nakajima et al. 2011) and feeding of bLf prevented the rats from 
colon cancer (Sekine et al. 1997). Lf was able to limit the growth of breast cancer cells and the 
addition of exogenous Lf to the culture of breast cancer cell lines, (MDA-MB-231) induced cell 
cycle arrest at the G1/S transition (Damiens et al. 1999). Also, it has been demonstrated that 
bovine Lfcin induced apoptosis in THP-1 human monocytic leukemic cells (Yoo et al. 1997). 
Oral administration of rhLf to mice implanted with head and neck squamous tumours suppressed 
growth by 75% and 20-fold increase in lymphocytes (Wolf et al. 2007). This study also 
suggested that lactoferrin has the potential to induce G1 -G0 growth arrest and also prevent the 
production of pro-inflammatory and pro-metastatic cytokines, increasing the activity of immune 
system. LF’s anticancer effect was observed through the immunoexpression of LF in human 
renal cell carcinomas and in adjacent healthy tissue (Giuffrè et al. 2007). Iigo et al. (Iigo et al. 
2009) demonstrated that oral administration of bLF inhibits carcinogenesis in the colon and other 
organs in rats, and lung metastasis in mice by enhancement of apoptosis. Lf defense against 
tumorigenesis was also reported by Bezault et al. (Bezault et al. 1994) where intraperitoneal 
administration of hLF to the mice inhibited the growth of solid tumors and prevented lung 
metastasis of murine melanoma cells. It increased the activation of natural killer (NK) cells and 
lymphokine-activated killer (LAK) cells, increased neutrophil activity and enhanced macrophage 
cytotoxicity by upregulating the production of cytokines and reactive oxygen species (ROS).  
 
Beneficial effects of administration of bovine lactoferrin have also been reported in a 
randomized placebo-controlled clinical trial setting in blocking the growth of polyps that are 
often thought to lead to colon cancer (Kozu et al. 2009). Norrby and coworkers assessed the 
effect of orally administered iron-unsaturated bLf on angiogenesis induced by VEGF165 and IL-
1-α in adult rats (Norrby et al. 2000), it inhibited angiogenesis via vascular endothelial growth 
factor (VEGF) blocking. A study reported the antitumour activity of the peptide analogs, derived 
from the N-terminal alpha-helical region of lactoferricin activity against Meth A, HT-29 and 
MT-1 cell lines (Artym, Zimecki & Kruzel 2003). Lactoferricin B has been found to show 
cytotoxic effects against Meth A fibrosarcoma, BI6F10 melanoma and C26 colon carcinoma in 
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vitro by membrane disruption and in vivo by extensive hemorrhagic necrosis (Artym et al. 2003). 
Oral administration of Lf, Lf hydrolyzate and lactoferricin to mice bearing subcutaneous 
implants of highly metastatic colon carcinoma 26 [Co26Lu], inhibited lung metastases (Togawa 
et al. 2002). Zimecki et al. demonstrated the role of NK cells in the control of colonization of 
lungs by BI6-F10 melanoma cells in syngeneic mice (Zimecki et al. 2003). Bovine apolactoferrin 
and lactoferricin B were shown to inhibit tumor metastasis when studies using BI6-BL6 
melanoma and L5178Y-ML25 lymphoma cells were carried out (Hayashida, Takeuchi & Harada 
2004). 
 
In an interesting study by Kanwar et al. (Kanwar et al. 2008) it was shown that iron-saturated 
lactoferrin augmented the chemotherapy to eradicate tumours that are otherwise resistant. It was 
reported that 100% iron saturated bLf given to mice infected with EL-4 lymphoma completely 
hindered tumour growth as compared to native lactoferrin (~15% iron saturated) which showed 
only 13-33% efficacy. This effect was due to the significant increase in the numbers of immune 
subsets of CD4+, CD8+ T cells, dendritic cells and NK cells in the spleen, as well as in the 
mucosal sites in mice, indicating that immune cells including NK cells have a role in tumour 
rejection due to antitumour immunity in the mice. Fe-Lf had to be fed to mice for more than two 
weeks prior to chemotherapy to be wholly effective in eradicating tumours from all mice, 
suggesting it acts as a competence factor. Fe-Lf significantly reduced tumour vascularity and 
blood flow, increased antitumour cytotoxicity, tumour apoptosis, and the infiltration of tumours 
by leukocytes. Importantly, it restored both red and white peripheral blood cell numbers depleted 
by chemotherapy, potentially fortifying the mice against cancer. 
 
2.5 Lactoferrin and immunity 
Lactoferrin bridges innate and adaptive immune function in mammals (Legrand et al. 2006b). 
Besides anti-cancer, anti-inflammatory and antimicrobial activities the protective effects of 
lactoferrin include immune modulator activities.  
Recurring infections have been observed in people with congenital or acquired Lf deficiency 
(Breton-Gorius et al. 1980). Oral administration of bLf seems to influence mucosal and systemic 
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immune responses in mice (Sfeir et al. 2004). Lf can moderate both specific and non-specific 
expression of antimicrobial proteins, pattern recognition receptors and lymphocyte movement 
related proteins (Wakabayashi et al. 2006). Also the source of Lf in external fluids are the 
neutrophils which are rapidly recruited to sites of microbial challenge during the initial acute 
phase of infection leading to activation and degranulation of Lf rich secondary granules provides 
an additional source to this protein to aid in the innate immune response against microbial 
infection at the mucosal surface (Masson, Heremans & Schonne 1969). Lf plays a role in 
regulating innate immune responses working as a first line host defense mechanism against 
invading pathogens, monitoring both acute and chronic inflammation (Fig. 2.3) (Kruzel et al. 
2006; Legrand et al. 2005). It also induces mediators from innate immune cells that subsequently 
impact adaptive immune cell function. Lf's positive charge allows it to bind to negatively 
charged molecules on the surface of various cells of the immune system (Baker & Baker 2005), 
and this association can trigger signaling pathways leading to cellular responses such as 
activation, differentiation and proliferation. Lf can be transported into the nucleus, where it can 
bind DNA (Swart et al. 1996) and activate different signaling pathways (Öztafl & Özgünefl 
2005). In addition to inducing systemic immunity, Lf can promote skin immunity and inhibit 
allergic responses. It activates the immune system against skin allergens, causing dose-dependent 
inhibition of Langerhans cell migration and the accumulation of dendritic cells in lymph nodes 
(Van der Strate et al. 2001). Leukocytes exposed to Lf modulate their cytokine production; 
proinflammatory cytokines, TNF-α, IL-6, and IL-1β can be modulated by Lf to increase 
(Sorimachi et al. 1997) or decrease (Machnicki, Zimecki & Zagulski 1993) (Kruzel et al. 2006) 
(Zimecki et al. 2003; Zimecki et al. 1999). Also increased production of IL-10 has been reported 
in many cases (MansourEl-Loly & Mahfouz 2011). Production of these factors is dependent 
upon the type of signal recognized by the immune system. 
 
At the cellular level, Lf increases the number of natural killer (NK) and adaptive (T strain CD4+ 
and CD8+) cells (Haversen et al. 2002), boosts the recruitment of polymorphonuclear cells 
(PMNs) in the blood (Shimizu et al. 1996), induces phagocytosis (Kurose et al. 1994), and can 
modulate the myelopoietic process (Szuster-Ciesielska, Kamińska & Kandefer-Szerszeń 1995). 
It is well documented that IL-12 plays an important role in driving development of helper T-cell 
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type 1 immunity (Trinchieri, Pflanz & Kastelein 2003). Therefore, the role of Lf in the regulation 
of proinflammatory cytokines and IL-12 clearly demonstrates communication between innate 
and adaptive immune responses. 
 
Proteolysis of Lf leads to release of two fragments N- and C-terminal lobes. Treatment with the 
enzyme pepsin produced a low molecular weight peptide with antibacterial properties against a 
number of Gram-positive and Gram-negative bacteria, in addition to fungi. It was found that 
lactoferricin (Lfc-B) had a region of amino acids at the N-terminus which was shown to exhibit 
greater antimicrobial activity than Lf (Bellamy et al. 1992). Thus minimal variations in the 
amino acid sequence change the antimicrobial activity of the peptide, Lfampin 268-284 and 
Lfampin 265-284 fragments of bLf differ in only three amino acids (265Asp-Leu267-Ile268) but 
exhibit different strengths of antimicrobial activity (Van der Kraan et al. 2006). Proteolysis of 
iron-free Lf could release Lf-derived active peptides in biological fluid (Gifford, Hunter & Vogel 
2005).     
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Figure 2.3 Regulation of the inflammatory response by Lf. Physiological processes, 
biological responses induced by infection aggression, and down regulation induced by the 
release of lactoferrin upon inflammatory process (Burrow et al. 2011; Legrand et al. 2005) 
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2.6 Rationale for using iron saturated lactoferrin 
Delivering Lf by oral route is a big challenge due to the physical and biochemical barriers of the 
digestive system which is designed to break down protein into small fragments prior to absorption. 
Delivery approaches for Lf are mainly focused on maintaining the stability against GI degradation of 
Lf, enhancing its absorption and oral bioavailability (Yao et al. 2012). Using its nanoformulation and 
saturating Lf by iron is a very efficient approach to solve these issues. 
 
As mentioned earlier saturated Lf/Fe-Lf is more stable and resistant to proteolysis than native 
lactoferrin which is 15-20% saturated and always has the capacity to bind iron. The study was planned 
by taking the Fe saturated Lf so as to examine its effect on the microbes and to see whether there was 
any acquisition of iron from Lf or if there was inhibition of these parasites. In a study (Kanwar et al. 
2008) oral administration of 100% saturated bLf (Fe-bLf) was significantly more effective at 
potentiating cancer chemotherapy than apo-bLf, natural bLf (native) and 50% iron-saturated bLf. The 
exact mechanism by which Fe-Lf exerts increased antimicrobial activity remains is not known yet. It 
is hypothesized that Fe-Lf is more bioavailable and resistant to degradation and proteolysis than 
natural bLf as it moves through the digestive tract. Thus, several studies have reported that the degree 
of iron saturation of Lf affects the gastric digestion of Lf, where 20% iron-saturated Lf is more easily 
digested than 100% iron-saturated Lf. A further possibility is that delivery of iron by Fe-Lf directly to 
lymphocytes, as reflected by the preferential uptake of Lf+ into Peyer’s patch lymphocytes, may 
endow lymphocytes with enhanced immune function. 
 
2.7 Nanoformulated lactoferrin 
Nanotechnology has gained significant momentum in recent years. It offers its advantages in the 
form of nanoparticles. Nanoparticles have the potential as novel intracellular probes for both 
diagnostic and therapeutic purposes and are expected to generate innovations and play a critical 
role in nanomedicine. They have a long shelf life and can encapsulate a great range of 
therapeutics. Drug targeting by nanoparticles offers multiple benefits such as sustained release, 
reduced dosage, lower side effects, non-toxicity, ease of delivery, improved efficiency, 
protection against degradation and enhancement of drug stability. Besides drug delivery the 
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nanoparticles exhibit a wide range of applications; they are useful in the detection of microbes 
(Edelstein et al. 2000), detection of proteins (Thaxton et al. 2009) and tissue engineering (Ma et 
al. 2003). 
 
Nanoparticles can serve as an efficacious antibacterial (Ma et al. 2007), anti-parasitic (Durand et 
al. 1997; Kirthi et al. 2011), anti-viral (Andersen et al. 2004) and anti-fungal (Eweis, Elkholy & 
Elsabee 2006) preparation. Thus there are wide arrays of nanoformulations that have played 
major roles as antimicrobial agents (Ma et al. 2007; Zhang et al. 2010). In addition for the 
treatment of cancer, there is progress in the development of polymeric nanocarriers, liposomes, 
dendrimers, carbon nanotubes and inorganic nanoparticles.  
 
In a study by Kanwar et. al., nanotechnology and RNA-carrying cationic cell-penetrating 
peptides were used for the treatment of colon cancer, for better protection from the enzymatic 
digestion and enhanced cellular internalization of these biomolecules (Kanwar, Mahidhara & 
Kanwar 2011). No work has been carried out to use the Lf nanoparticles to encapsulate and 
deliver bioactive ingredients other than by Kanwar and his co-workers (Kanwar, Mahidhara & 
Kanwar 2012). These researchers used alginate gel-encapsulated ceramic nanocarriers loaded 
with Fe-saturated bovine lactoferrin (AEC-CP-bLf NPs) for the first time for human colon 
cancer therapy and obtained excellent results.  
 
Nowadays, there is a rapid growing interest in nanotechnological approaches in microbiology as 
in all fields of the science, considering that nanoparticles will be able to be used in the treatment 
of various diseases in the future (Allahverdiyev et al. 2011). Due to the limitations of the existing 
drugs, more attention is focused on natural active components from plants, animals, and other 
organisms for the treatment of various infectious diseases. A great array of insects and their 
products are used as drugs in traditional medicines (Gunbilig & Boland 2009). Insects are a large 
and unexplored source of potentially useful compounds for modern medicine (Pemberton 1999).  
Chitin and chitosan having an animal origin, have been investigated as an antimicrobial material 
against many bacteria and fungi (Goy, de Britto & Assis 2009). Recently a study by Akhtar et al. 
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has shown that binding of curcumin to chitosan nanoparticles cured Plasmodium yoelii infection 
in mice (Akhtar, Rizvi & Kar 2012). Many types of drug delivery nanosystems have been 
developed.  
 
2.7.1 Liposomes     
Liposomes, discovered more than 40 years ago, are the ideal models for biological membranes. 
They basically consist of phospholipids and are found to be efficient carriers for drugs, vaccines 
and nutrients (Bangham 1993; Kingsley et al. 2006). The development of technical advances 
such as remote drug loading, long-circulating (PEGylated) liposomes, triggered release 
liposomes, liposomes containing nucleic acid polymers, ligand-targeted liposomes and liposomes 
containing combinations of drugs have led to numerous clinical trials in such diverse areas as the 
delivery of anti-cancer, anti-fungal and antibiotic drugs, the delivery of gene medicines, and the 
delivery of anesthetics and anti-inflammatory drugs (Allen & Cullis 2012).  
 
In a study it was found that liposomes were found to cure visceral leishmaniasis in hamsters 
(Alving et al. 1978). Yih et al. confirmed the potential of liposomal systems by demonstrating 
that liposome-encapsulated antimonials were 700 times more active than the unencapsulated 
drug (Yih & AlǦFandi 2006). Some modifications of liposomes like sugar bearing liposomes, 
were targeted at infected macrophages surfaces that contains the receptors for galactose, 
mannose and glucose yield of glycosides (Owais et al. 1995); others like positively charged 
liposomes have been found to be very good at delivering DNA to the target cells. Also, there are 
reports which specify better uptake of drugs by macrophages coupled with improved delivery to 
liver and spleen when entrapped in positively charged liposomes than that of negatively charged 
or neutral liposomes (Miller et al. 1998). Tufstin, a macrophage activating peptide, has been 
employed for improving the targeting of anti-leishmanial drugs due to their property of 
preferential binding to cells of the mononuclear phagocyte system (MPS) (Agrawal & Gupta 
2000). Immunoliposomes have also helped in combating leishmaniasis. The surface of 
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macrophages possesses Fc receptors that bind to the Fc portion of antibodies like 
immunoglobulins (Ig) (Kole, Das & Das 1999). 
 
Arsonoliposomes are the type of liposomes which are vesicular carriers composed of 
arsenolipids and other commonly used liposomal ingredients while the Arsenolipids are 
analogues of neutral lipids, like monoglycerides, glycolipids, phospho-lipids and also 
phosphonolipids that contain covalently linked arsenic (Fatouros et al. 2001). Drugs like 
artesunate liposomes (1.5mg of artesunate/ml suspension encapsulated into liposomes) have been 
shown to be efficacious against malaria (Gabriels & Plaizier-Vercammen 2003). Arteether 
encapsulated in dipalmitoylphosphatidylcholine, dibehynoylphophatidylcholine, cholesterol 
liposomes were shown to have significant effects on New Zealand rabbits (Bayomi et al. 1998). 
Researchers studied the chloroquine-encapsulated liposomes and evaluated their efficacy in 
chloroquine-resistant Plasmodium berghei infection in mice, and found that the tagged antibody 
against infected erythrocytes on these liposomes was specific to P. berghei and choloroquine 
encapsulation eradicated both susceptible and resistant P. berghei infections significantly curing 
the mice from infection by 90% (Owais et al. 1995). Liposomes have been used in 
trypanosomiasis but with a much lower success rate. The arsenic containing lipids, 
arsonoliposomes have been used against T. brucei in some in vitro studies (Antimisiaris, Ioannou 
& Loiseau 2003).  
 
Various other liposomal formulations like ampicillin encapsulated liposomes were targeted at 
Salmonella typhimurium and Listeria monocytogenes (Fattal et al. 1991) or Helicobacter pylori 
(Bardonnet et al. 2008), polymyxin B loaded liposomes in the treatment against Gram –negative 
bacterial strains and P. aeruginosa (Alipour et al. 2008) and liposomal benzyl penicillin activity 
against S. aureus have also been reported (Kim & Jones 2004). AmBisome, a small unilamellar 
formulation of amphotericin B, differs from several other lipid formulations of Amphotericin B 
in that it forms true liposomes with uniform, stable, spherical single membrane vesicles. 
AmBisome administered to febrile neutropenic patients in this study was well tolerated, and was 
effective in preventing breakthrough fungal infections (Walsh et al. 1998). 
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2.7.2 Polymeric Nanoparticles   
Over the past few decades, researchers have had considerable interest in developing 
biodegradable nanoparticles as a drug- delivery system. Most polymeric nanoparticless are 
biodegradable and biocompatible (Panyam & Labhasetwar 2012; Sahoo & Labhasetwar 2003). 
Besides this other important properties of these nanoparticles are structural stability, particle size, 
zeta potential, drug release action and their surface property that can be modified with the target 
ligand or the drug attached (Zhang et al. 2010) thus making them ideal candidates for cancer 
therapy, delivery of vaccines, contraceptives and delivery of targeted antibiotics.   
 
Polymeric nanoparticles have been extensively studied in exhibiting antimicrobial activity. 
Antibacterial activity of alginate or PLG nanoparticle loaded Rifampicin has been reported 
against Myobacterium tuberculosis, M. avium and Staphylococcus aureus (Ahmad et al. 2006; 
Skidan et al. 2003). In a study ODNs were combined with the biodegradable polymer chitosan to 
form solid nanoparticles and were found to inhibit the growth of Plasmodium falciparum K1 
strain in vitro. They proved to be effective antimalarial agents (Föger et al. 2006). When the 
efficacy of primaquine-loaded polyisohexylcyanoacrylate (PIHCA) nanoparticles was evaluated 
using J774G8 macrophage-like cells infected with Leishmania donovani, as an in vitro model of 
visceral leishmaniasis, the antileishmanial activity of primaquine-loaded nanoparticles showed a 
21-fold increase in ED50 compared with free primaquine (Gaspar et al. 1992). In a study by 
Durand et al. when the activity of pentamidine-loaded nanoparticles was compared with that of 
free pentamidine in a BALB/c mice model of visceral leishmaniasis induced by Leishmania 
infantum, bound pentamidine was found to be more potent than the free drug (Durand et al. 
1997). The in vitro study on T. cruzi showed the efficacy of nifurtimox-loaded 
polyethylcyanoacrylate (PECA) nanoparticles against the parasite (Gonzalez-Chavez, Arevalo-
Gallegos & Rascon-Cruz 2009; Sanchez et al. 2001a). Duanomycin nanoparticles have been used 
for the treatment against T. bruce. Nanoparticles were conjugated with transferrin antibodies 
aimed at targeting the transferrin receptors present on the surface of the parasites. It was 
observed that the targeted nanoparticles induce trypanocidal activity (Flaig et al. 2005).   
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Chitosan (CS) a biopolymer, derived by deacetylation of chitin (Qi et al. 2004), has a wide scope 
of applications. Eweis and coworkers showed the biological activities of chitosan obtained from 
exoskeletons of crustaceans, such as shrimps, crabs and squids (Eweis, Elkholy & Elsabee 2006). 
A few studies have also reported the biological activity of this polymer in the larvae of housefly 
(Ding et al. 2006; Jing et al. 2007). It has also shown killing activity against Gram-positive and 
Gram-negative bacteria but lower toxicity toward mammalian cells (Franklin & Snow 1981). 
Chitosan nanoparticles were used as a new delivery system for many antiparasitic drugs, used for 
the treatment of Leishmania, P. falciparum, and Cryptosporidia (Föger et al. 2006; Kayser 2001; 
Pujals et al. 2008). In the case of Plasmodium berghei-infected mice, they helped in improving 
the efficacy and bioavailability of curcumin (Akhtar, Rizvi & Kar 2012). 
 
2.7.3 Nanocrystals 
Nanocrystals are the moieties that are produced by combining a large number of drug particles 
together to form a single crystal. A nanocrystal can consist of about a hundred drug molecules 
which when combined are coated with a surfactant coating to protect the drug molecule (Kanwar 
et al. 2012a). 
 
Some researchers have reported that nanocrystals are rapidly taken up by the mononuclear 
phagocytic system to allow regional specific delivery. It is also known that these nanoparticles 
act very quickly when pathogens persist intracellularly, e.g., in targeting antimycobacterial, 
fungal or leishmanicidal active macrophages (Kayser, Lemke & Hernandez-Trejo 2005). A study 
on Carbon-60 nanocrystals reported that incubation of E.coli and B.subtilis with these crystals at 
a concentration of 0.4mg/L showed no growth of bacteria even after 24 hours (Fortner et al. 
2005). Bacteriocide properties of nanocrystalline zinc oxide (ZnO) (Perelshtein et al. 2008) or 
magnesium oxide (MgO) particles (Makhluf et al. 2005) were also reported in some studies and 
were shown to have a significant effect on bacterial growth. 
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2.7.4 Nanoemulsions 
Nanoemulsions have various advantages as they are biodegradable, biocompatible and are easy 
to produce. They can be used as carriers for lipophilic drugs that are prone to hydrolysis and 
exhibit excellent drug release profile due to their very large interfacial area (Brüsewitz et al. 
2007). 
 
Nanoemulsions have been used in the treatment of malaria in which they were mixed with 
antimalarial drugs such as Primaquine for targeting hepatocytes and exhibited good inhibitory 
activity against the parasite (Dierling & Cui 2005). Various studies have shown the antimicrobial 
activity of nanoemulsions across a wide spectrum of bacteria such as E.coli, Streptococcus 
mutans, S. aureus, S. mutans, Influenza, Gonorrhoeae, Propionibacterium acnes and Salmonella, 
fungi such as Candida albicans, Trichophyton mentagrophytes, T. rubrum, and Microsporum spp 
and viruses like Herpes simplex and HIV (Hamouda et al. 2001; Hemmila et al. 2010; 
Karthikeyan et al. 2011; Pannu et al. 2009; Pannu et al. 2011). 
 
2.7.5 Metal nanoparticles 
Metal nanoparticles can be synthesized in very small sizes of around 50 nm. This provides them 
with the ability to carry a higher dose of drugs due to their large surface area (Parveen, Misra & 
Sahoo 2012). Nanoparticles play an important role in drug delivery, diagnostics, imaging, 
sensing, gene delivery, artificial implants, and tissue engineering (Morones et al. 2005). 
 
Due to the exceptional properties of silver nanoparticles (nAg), including antibacterial activity, 
high resistance to oxidation, and high thermal conductivity they have been used in a many 
medical and chemical applications (Choi et al. 2007; Feng et al. 2006; Soni & Prakash 2012). 
Antiplasmodial activity has been shown by silver nanoparticles made from the leaves of the plant 
Andrographis paniculata (Paneerselvam, Ponarulselvam & Murugan 2011). The antileishmanial 
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effect of silver nanoparticles was determined through the production of free radicals  
(Allahverdiyev et al. 2011).     
The bacterial strains, E. coli, S. aures and Bacillus subtiliss and P. aeruginosa were found to be 
sensitive to the silver and copper nanoparticles. The bacillus species showed highest sensitivity 
to copper nanoparticles as compared to other microbes (Ruparelia et al. 2008). There are also 
some reports of fungus Fusarium oxysporum used in the production of silver as well as gold 
nanoparticles and have shown to inhibit many gram negative bacteria (Mukherjee et al. 2002). 
Kirthi et al. studied the acaricidal, pediculocidal and larvicidal activity of synthesized ZnO 
nanoparticles (Kirthi et al. 2011). Antiparasitic activity of ZnO nanoparticles was reported, with 
100% mortality within 12 hours. In another study gold nanospheres were tagged with an 
antibody specific to T. gondii and were shown to be specific to the parasite and induced death of 
microbes (Pissuwan et al. 2009). A study was done by Marimuthu et al. to check the antiparasitic 
activities and to determine the efficacies of synthesized silver nanoparticles (AgNPs) using 
aqueous leaf extract of Mimosa pudica Gaertn (Mimosaceae) against the larvae of the malaria 
vector, filariasis vector  Ixodidae etc. (Marimuthu et al. 2011).  In a search for new anti-giardial 
agents, the antiparasitic potential of silver, chitosan and curcumin nanoparticles was evaluated in 
a study by Said and coworkers (Said, Elsamad & Gohar 2012). The best effect in the treatment of 
giardiasis was observed with the combinations of nano-silver and nano-chitosan but complete 
cure was obtained by combining the three nano-forms.  
2.7.6 Lactoferrin (Lf) for nanotherapy 
There are only a few studies on the use of Lf in nanoformulations. Although Lf is a 
multifunctional protein, most of the work is primarily focused on various cancers (Kanwar et al. 
2008; Roseanu et al. 2010b) and brain diseases (Huang et al. 2010) and not much work has been 
reported on its actions as an antimicrobial agent. Choe and coworkers studied that Lf increased 
transfection about 3 fold with cationic liposomes targeted at Hela cells (cervical cancer cells) 
(Choe, Park & Hong 1998). It was investigated that intragastrically infused enteric-formulated 
bLF (EF-bLF) was more efficiently absorbed than bLF from the intestine in adult rats (Takeuchi 
et al. 2006). These studies showed an increased uptake by Hela or intestinal cells and modifying 
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the protein protected it from gastric digestions. In a study lactoferrin-conjugated biodegradable 
polymersome holding doxorubicin and tetrandrine (Lf-PO-Dox/Tet), was designed and it was 
found that Lf-PO-Dox/Tet could have therapeutic potential for gliomas (Pang et al. 2010).  
 
Kanwar et al. (Kanwar et al. 2008) investigated that 100% iron saturated bovine Lf (Fe-bLf) acts as a 
natural adjuvant by augmenting chemotherapy to destroy tumours that are found to be resistant to 
treatment. It was reported that Fe-bLf completely eradicated EL-4 lymphoma, lung carcinoma and 
melanoma tumours. Fe-bLf encapsulated in various nanoplatforms including liposomes (Trif et al. 
2001), PLGA (Hu et al. 2009), chitosan and super paramagnetic iron oxide nanoparticles (SPION) 
were observed to have significant anti-cancer activity (Xie et al. 2011). The particles were tagged with 
LNA-nucleolin-modified DNA aptamer and LNA-EpCAM-RNA aptamer and tested on colon, breast 
and normal intestinal and mammary cells. The LNA Fe-bLf nanoparticles induced enhanced 
cytotoxicity and apoptosis on the cancer cells while refraining from harming the normal cells. It is 
suggested that these LNA-aptamer Fe-bLf nanoparticles are able to specifically kill cancerous cells 
while avoiding harm to the normal cells. Recently, Fe-bLf loaded biodegradable, non-toxic polymeric 
nanoparticles were examined in vivo on colon cancer mouse models. Fe-bLf nanoparticels fed orally 
showed no signs of systemic toxicity, inhibited tumour growth and enhanced iron and calcium 
absorption (Kanwar, Mahidhara & Kanwar 2012) 
 
2.7.7 Nanoformulations against parasitic infection-giardiasis 
Only one study has reported the antigiardial activity by the combination therapy of curcumin, 
chitosan and silver nanoparticles (Said, Elsamad & Gohar 2012) and was found to be successful 
in the complete cure of the disease. No other study has been reported to date on the use of 
nanoparticles or the nanoformulated lactoferrin against Giardia. 
2.7.8 Nanoformulations against bacterial infection-salmonellosis 
In a study (Fierer et al. 1990) enhanced gentamycin accumulation in Salmonella infected liver 
and spleen in mouse models proved that nanocarriers improved biodistribution of drugs in the 
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target organ when they were encapsulated. Martínez-Gutierrez et al. found that the combination 
of silver nanoparticles with antibiotics, ampicillin, erythromycin, kanamycin and 
chloramphenicol against E. coli and Salmonella typhi, increased the antibacterial effect of silver 
nanoparticles (Martínez-Gutierrez et al. 2012). Thus, nanomedicine approach can limit the 
distribution of drugs to target organs of infection (Lecaroz, Gamazo & Blanco-Prieto 2006). A 
nanotechnology-driven approach uses anti-salmonella, antibody-conjugated, oval-shaped gold 
nanoparticles to selectively target and destroy pathogenic bacteria, for the label-free detection of 
S. typhimurium (Wang et al. 2010). It can also be used in treatment of infectious bacterial 
pathogens.  
 
So far there are no reports on the use of nanoformulated lactoferrin for the treatment of infections 
like salmonellosis and giardiasis. The currently used pharmaceutical agents in the market cause 
adverse side effects and detrimental effects on organs. There is a necessity to discover a better 
treatment that can fight infectious diseases as microbes have developed resistance to 
conventional drugs. Hence, with the recent advances in nanotechnology, nanoparticles may 
provide opportunities as effective agents in eradicating these diseases (Kanwar et al. 2012b). The 
development of safe and effective nanoformulations is urgently needed as therapies. In this study 
Fe-bLf was incorporated into the nanoparticles (AEC-CP-Fe-bLf) to improve oral 
bioavailability. 
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Chapter 3: Materials and Methods 
3.1 Purification of lactoferrin 
All glassware was washed with analytic grade nitric acid and thoroughly rinsed with distilled, 
deionized water before use. Only reagents low in metal ions were used to minimize the 
possibility of iron or other metal ions binding to the protein. Lactoferrin was purified using a 
cation exchange chromatography on SP-Sepharose. 
 
3.1.1 Colostrum fractionation 
Frozen colostrum was thawed with running tap water at room temperature, diluted 9:1 (v:v) with 
4.0 M NaCl, 0.1 M phosphate buffer (68.5 mM NaH2PO4, 31.5 mM Na2HPO4), adjusted to pH 
4.6 with 0.1 M glacial acetic acid (Merck, Germany), and  gently agitated for 1 hour at 4 ºC. 
After centrifugation at 56,000Xg for 30 min. at 4 ºC, three clearly separated layers were 
obtained: fats in the top layer and casein plus cellular debris at the bottom. The middle whey-
containing layer was carefully collected and immediately adjusted to pH 6.5 with 0.1 M NaOH. 
Whey was further clarified by serial ultrafiltration using a glass fibre prefilter on top and three 
nitrocellulose membrane filters of 0.8, 0.45 and 0.2 μm pore-sizes placed on each other with 
polyester separators between them, as recommended by the manufacturer for difficult-to-filter 
liquids. The final whey was conveniently aliquoted in glass containers and stored at –20 ºC until 
use. 
 
3.1.2 Chromatography 
A column was packed with 100 mL of a strong cationic exchanger (SP Sepharose BB) and rinsed 
with 10 volumes of distilled water (Conesa et al. 2008). Then it was equilibrated with 10 
volumes of 0.4 M NaCl, 0.01 M phosphate buffer (pH 6.5, flow rate 1ml/min). One volume of 
clarified whey was mixed with 3 volumes of the above equilibration buffer and passed through 
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the column at a linear flow rate of 0.5ml/min.  Five volumes of binding buffer (0.4 M NaCl, 0.01 
M phosphate buffer, pH 6.5) were passed through the column to elute unbound proteins (flow 
rate of 0.5ml/min). Bound lactoferrin was eluted in a single peak with 0.8 M NaCl, 0.01 M 
phosphate buffer (pH 6.5) when 3 volumes of it was passed through the column (flow rate of 
0.5ml/min). The various fractions obtained after elution were centrifuged in Amicon 
ultrafiltration tubes of molecular weight cut off of 30kDa. Then the fractions were checked with 
SDS-PAGE, and those with a single band were pooled thereafter. These final pooled fractions 
were concentrated against 0.01 M phosphate buffer (pH 6.5) and desalted to 0.15 M NaCl with 
the help of a mini dialysis kit of 8kDa cut off (G.E. Healthcare). This was further centrifuged in 
Amicon ultrafiltration tubes. Protein estimation was done to find out the concentration of protein 
obtained and the protein sample was stored at ‒20 ºC for further use. 
 
3.2 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) 
The protein preparations (both before and after affinity chromatography) were electrophoresed 
according to the method of Laemmli (Laemmli 1970) with Bio-Rad Protean apparatus. Protein 
samples were denatured before electrophoresis for 5 min at 100ᵒC in a sample buffer (0.6MTris-
HCl (pH6.8), glycerol 10%, SDS 10%, β-mercaptoethanol 5% and bromophenol blue 0.05%). 
Samples containing 5-10μg of total protein and molecular mass standard were loaded on to a 
discontinuous acrylamide gel (12%) (See Appendix). Electrophoresis was done at 80 V for 2h 
and the gel was stained with Coomassie blue. 
 
3.2.1 Visualizing the proteins on SDS-PAGE Staining with Coomassie brilliant blue (R250) 
When electrophoresis was over, the gel was removed from the plates and transferred to 15 times 
the gel volume of staining solution (0.25% w/v Coomassie brilliant blue R-250). The gel was 
incubated and gently shaken for 4 hours overnight at room temperature to obtain optimum 
staining of proteins. 
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3.2.2 Destaining the gel 
The gel was transferred from the staining solution to an excess volume of destaining solution 
(See Appendix) and kept at RT with shaking. Two to three changes of destaining solution were 
made so that protein bands became clearly visible with no background stain. 
 
3.3 Protein Estimation 
Lowry method: Different dilutions of BSA solutions were prepared by mixing stock BSA 
solution (1 mg/ ml) and water in the test tube.  The BSA range was 0.05 to 1 mg/ ml. From these 
different dilutions, 0.2 ml protein solution was added to different test tubes and 2 ml of alkaline 
copper sulphate reagent (analytical reagent) was added. The solutions were mixed well. This 
solution was incubated at room temperature for 10 mins. Then 0.2 ml of reagent Folin Ciocalteau 
solution (reagent solutions) was added to each tube and incubated for 30 min. The colorimeter 
was set to zero with blank and the optical density (measure the absorbance) was taken at 660 nm. 
The absorbance was plotted against protein concentration to get a standard calibration curve.  
The absorbance of unknown sample was checked and the concentration of the unknown sample 
was determined using the standard curve plotted above. 
 
3.4 Preparation of different forms of lactoferrin 
3.4.1 Preparation Iron free (apo) bovine lactoferrin (apo-bLf) 
Apo-bLf was prepared by dissolving Australian health grade bLf capsules (200 mg each) in 
Milli-Q water (pH 5.8) to make a final concentration of 80 mg/mL. The pH of the solution was 
carefully adjusted to 2.06 by the addition of 6 M HCL. During this process the solution changed 
from a murky red color to ivory white, indicating the non-iron form of bLf.  
 
To remove unligated metal ions and protein fragments, the sample was extensively dialyzed 
against 0.1 M citric acid using Spectra/Pro dialysis tubing with MWCO at 50 kDa (Pacific 
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Laboratory, Nunawading, Victoria, Australia). This was kept overnight on a magnetic stirrer at 4 
oC and the dialysis buffer was changed twice more over a 48 h period. Following dialysis, the 
sample was removed from the stock solution and aliquoted into protein low-bind Eppendorf 
tubes (Eppendorf South pacific, West Heidelberg, NSW, Australia) for storage at -20oC until 
required for further sample analysis.  
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4.2 Iron saturation of bovine lactoferrin (Fe-bLf) 
Ferric Nitrilotriacetate (Fe-NTA) was prepared immediately prior to use. Ferric nonahydrate at a 
molar concentration of 300mM was mixed with 600mM of nitrilo-triacetate (NTA) disodium salt 
in a 1:2 ratio, giving a molar ratio of 1:4. The pH was adjusted to 7.4 with the careful addition of 
sodium carbonate (Toyokuni, Hakomori & Singhal 1994).  
 
Solid sodium bicarbonate was added to Apo-bLf making a final concentration of 0.1 M. The pH 
of the sample was then adjusted to 8.0 with the careful addition of 6 M NaOH. Fe-NTA solution 
Dissolve parental bLf in 
Milli-Q   
Final conc 
80mg/ml   
Add 6 M HCL (ph 2.06)  
Dialysis in 0.1M citric 
acid  
Aliquote samples 
(-20 oC)   
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was slowly added drop-wise to the apo-bLf sample and mixed on a magnetic stirrer for 1 h at 
room temperature. Following addition, the pH of the solution was readjusted to 8.0 with the 
careful addition of 6 M NaOH. To ensure complete metal binding, the solution was further 
stirred for 1 hour at room temperature. The sample was extensively dialyzed against sterile Milli 
Q using Spectra/Pro dialysis tubing with MWCO at 50 kDa. Dialysis was performed over a 48 
hour period at 4 oC on a magnetic stirrer. The dialysis buffer was changed twice more over the 
48 h period. The aliquot sample was put into Eppendorf tubes and stored at -20 oC. The color of 
the sample was noted as maroon red, indicating the iron bound form of the protein. 
 
Ferric nonahydrate (300Mm)       NTA 
(600mM) 
 
 
 
 
 
 
 
 
 
 
48 hr at 
4 oC 
Add drop-wise  
Mix in 1:2 ratio immediately   
before use 
Fe-NTA 
Apo-bLf 
Add NaCO3 
(0.1M) 
Add 6 M NaOH  
Apo-bLf (pH 8.0)  
 
Mix in magnetic 
stirrer  
Dialysis in Mili-
Q  
1 hr in RT 
Aliquote samples 
(-20 oC)   
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3.5 Iron estimation 
Briefly, to 1 mL of Fe-bLf, iron standard (see below) and Milli-Q water (blank), 50 μL of 
ascorbic acid was added and mixed well. The solutions were allowed to stand for 5 mins 
followed by the addition of 100 μL of 65 % tricholoroacetic acid into each tube. The tubes were 
immediately covered with parafilm and shaken vigorously for 30 secs and allowed to stand for 
10 mins. The tubes were then centrifuged at 10000 rpm for 20 mins. Following centrifugation, 
500 μL of supernatant from each sample, iron standards and blank, were added into new 
Eppendrof tubes containing 100 μL of alkaline acetate solution followed by the addition of 75 
μL of tripyridyl solution. The samples were mixed well and allowed to stand for a further 10 
mins. 200 μL of each solution was then transferred into an optically clear 96-well flat-bottom 
micro plate and the absorbance read at 550 nm with an Asys Expert Plus microplate reader. Iron 
concentration was determined by substituting the resulting absorbance values into the following 
equation: 
 
 Iron (μg/mL) =          x concentration of standard 
 
 
 
Stock solution - Dissolve 0.0216 g of ferric ammonium sulphate in 200 μL Milli-Q. Add 50 
μL of concentrated HCl and make up to 500 μL with Milli -Q. 
Working iron standards: Dilute 200 μL and 400 μL of stock solution to 1 mL to give a 
final concentration of 1 μg and 2 μg per 1 mL respectively 
 
Alkaline acetate Saturate 500 μL N-NaOH with 0.25 g sodium acetate. 
 
Ascorbic acid  Mix 25 μL ascorbic acid in 275 μL of N-HCl prepared fresh 
immediately before use. 
Tripyridyl Dissolve 6.7 μL of ascorbic acid in 500 μL of Milli-Q and add   0.6 g 
of tripyridyl.  
   Test – Blank 
Standard - Blank 
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65 % Trichloroacetic    Dissolve 0.325 g trichloroacetic acid in 500 μL of Milli-Q 
acid  
4 % Paraformaldehyde Mix 4 g of paraformaldehyde in 0.1 M PBS had heat to 60 oC while 
stirring. Add a few drops of 2N NaOH until stir unitl solution becomes 
clear. Cool at room temperature and set pH to 7.2. 
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30 secs   
Add 100 μL of 65 % 
tricholoroacetic   
Fe-bLf (1ml)   Iron standard 
(1ml)   
Milli-Q (1ml)   
Cover & shake vigorously   
Let stand for 10 mins   
Centrifuge - 10000 rpm 20 
mins 
Remove 500 μL of 
supernatant 
Add to 100 μL alkaline 
acetate 
Add to 75 μL of 
tripyridyl 
Mix well and stand for 
10 mins 
Read absorbance at 
550 nm 
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3.6 Preparation of endotoxin free Fe-bLf and enzyme sensitivity studies 
Endotoxin-free bLf was prepared from Australian bovine milk. Endotoxin was tested with 
Genscript ToxinSensor, Chromogenic Limulus Amebocyte Lysate (LAL) Endotoxin Assay Kit 
(Genscript ToxinSensor, NJ, USA). Fe-bLf was prepared from the bLf according to the 
previously described method developed by Kanwar et al. (Kanwar et al. 2008).  In brief, bLf, 
after – treatment with mild acidic solution (pH-2.6) was dialyzed for a period of 48 hrs in 0.1M 
citric acid to get rid of the bound metal ions. It was then saturated with ferric [Fe (III)] 
nonahydrate to form bLf- Fe3+coordinate complexes for the development of deep red coloured 
Fe-bLf. The obtained Fe-bLf was loaded on to the C-CP NCs and covered with alginate to test its 
size and effects against the parasite.  
 
3.7 Synthesis of ZnXFe3-XO4 nanoparticles 
ZnXFe3-XO4 nanoparticles were prepared according to methods with modifications (Arulmurugan 
et al. 2006; Girgis et al. 2011; Sato Turtelli et al. 2008; Varma et al. 2008). Briefly, Fe3O4 nano-
particles were prepared by chemical co-precipitation technique and magnetic zinc ferrite 
(ZnXFe3-xO4) nanoparticles were prepared using ferric chloride (FeCl3.6H2O), ferrous chloride 
(FeCl2.4H2O) and sodium hydroxide (NaOH). 0.125M of FeCl3.6H2O, FeCl2.4H2O and ZnCl2 
salts were dissolved in 80ml deionised water to obtain an aqueous solution of Fe3+ and Fe2+ ions, 
respectively. The aqueous solution was constantly stirred at 200 rpm and maintained at 30°C 
followed by drop wise addition of 30ml 1M NaOH, resulting in the formation of black 
precipitates which gradually settled down on withdrawing stirring. The precipitated material was 
transferred to an autoclave and maintained at 150°C for 12 hours. The particles obtained were 
washed several times followed by magnetic decantation. Subsequently, these particles were 
freeze dried for 26 hours. SEM, TEM, XRD and magnetization tests showed that ZnXFe3-XO4 
particles size milled 14 hour was the range between 20±3nm and the solid spherical morphology 
with high magnetization product. 
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3.8 Preparation of ZnXFe3-XO4– bovine lactoferrin (ZnXFe3-XO4–bLf): 
The fabrication of ZnXFe3-XO4–bLf was carried out according to our earlier research studies and 
previous methods with modifications. Briefly, 1:3 ratio of the 300mM superparamagnetic 
ZnXFe3-XO4 nanoparticles (described above) and 600mM of nitrilotriacetate acid disodium salt 
(NTA) (MW = 235.10) were dissolved in sterile water. Further, pH was adjusted to 7. Later, 
solution of apo bLf (iron free bovine lactoferrin) was substituted with 0.1M solid sodium 
bicarbonate.  Later, pH was adjusted to 8. Now the freshly prepared ZnXFe3-XO4–NTA solution 
was added drop wise to prepared apo bLf solution in a 1:3 ratio, while magnetically stirring the 
solution. In the presence of carbonate ions, structural confirmation of lactoferrin molecule 
possessing iron binding pockets initiates the uptake of iron molecules. The ZnXFe3-XO4–NTA 
solution was added to the protein solution until a blackish red colour solution is formed. This 
colour formation signifies the saturation of lactoferrin with ZnXFe3-XO4. Further, the obtained 
mixture is subjected to overnight magnetic stirring at 40C in order to stabilise the ZnXFe3-XO4–
bLf nanocomplexation. Later on the ZnXFe3-XO4 –bLf solution was separated by magnetic and 
centrifugation techniques.  
 
3.9 Preparation of Alginate/EUDRAGIT® S 100 enclosed guar gum conjugated-ceramic 
(calcium-phosphate)-ZnXFe3-XO4–bLf nanocarriers (AEC-CP-Fe-bLf NCs): 
AEC-CP-Fe-bLf NCs were prepared by a combination of nano precipitation and ionic gelation 
methods by Kanwar and coworkers (Kanwar, Mahidhara & Kanwar 2012) with modifications. 
Calcium phosphate was prepared from its constituents as follows: disodium hydrogen 
orthophosphate (Na2HPO4) in a molar ratio of 4:1 was added to calcium chloride (CaCl2) in a 
drop-wise manner, with continuous stirring. The obtained suspension was sonicated at 4°C to 
ensure a white precipitate of calcium phosphate was obtained. Acquired calcium phosphate (1% 
w/v) suspension was incubated for 24 h with 10% w/w Fe-bLf with constant stirring at 4°C, 
under a pH ≤8.0, the isoelectric pH of Lf, in order to adsorb Fe-bLf on to the NCs. After the 
electrostatic interaction of Fe-bLf on to the calcium phosphate (ceramic core), the obtained 
suspension was centrifuged and washed several times to remove traces of unbound protein and 
freeze-dried. Fe-bLf protein or anti-parasitic drug (MZ) loaded NCs were coated with a 
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dispersion of guar gum (0.02% w/w) in ethanol/water (20% v/v). Fe-bLf was then conjugated to 
the guar gum nanocores as described in previous reports with slight modifications (Chen et al. 
2007). Briefly, 150 μl EDC/NHS solution was used to initiate the cross linking reactions. Fe-
bLf/EDC/NHS in a weight ratio of 1:1.84:0.23 were added to NCs suspension at pH 5.5 and 
conjugated by stirring for 72h at 4°C. NCs then under constant stirring and 0.01% of cross 
linking agent, sodium tri polyphosphate (STPP) was added drop wise. Constant stirring at 6000 
rpm for 12 h was done to ensure that the nanoformulation obtained the size of 200 ± 40 nm, 
followed by freeze drying the sample to make sure that the sample has obtained spherical shape. 
These nano cores were then coated with alginate gel by using 2% w/v EUDRAGIT® S 
100/alginate solution and calcium chloride, with 0.6% mass ratio of calcium alginate. The finally 
obtained nanocarriers were washed and lyophilized for further characterization. All these 
experiments were done at 40C as to protect the polymeric and protein components in the 
formulation.  
 
3.10 Estimation of lactoferrin loaded onto AEC-CP-nanocarriers (ACNs) 
Encapsulation efficacy of the nanoparticles was calculated using the ratio between bound and 
total protein added to the formulation. The formula used was: 
Encapsulation efficacy (%) = (total protein loaded-total unbound protein)/total protein loaded x 
100. 
 
3.11 Characterization of nanoparticles 
Dynamic light scattering was done using a zetasizer, after 500-fold dilution with autoclaved 
milliQ water to determine the average size of the prepared NCs following various steps of their 
preparation viz, calcium phosphate core, chitosan formulation and alginate enclosed NCs. 
Surface morphology of these particles was determined by scanning electron microscopy (SEM), 
at an accelerating voltage of 5-10 kV (Zeiss Supra). For SEM visualization, different 
preparations including C-CP NCs, C-CP-Fe-bLf NCs, and AEC-CP-Fe-bLf NCs were fixed on 
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the stub by a double sticky tape and then coated with a gold layer by a SC7620 sputter coater 
(Quorum technologies, UK) for 60 s. 
3.12 Control release and pH sensitivity studies of AEC-CP Fe-bLf NCs 
In order to obtain the control release studies of the oral drug delivery system, in vitro release 
profile of the NCs entrapped Fe-bLf was carried out in PBS (pH 7.2). AE-C-CP-Fe-bLf NCs (1 
% w/v) were suspended into phosphate buffer saline under constant stirring maintained at a 
temperature of 37 °C. At various time intervals starting from 1 h to 24 h, each sample was 
centrifuged, supernatant was collected and the pellets were dispersed in fresh solution. 
Supernatants were analyzed for protein concentration. To estimate the protein concentration the 
Better Bradford assay (Pierce) was performed, with Fe-bLf protein standards. For 
immunoblotting, 15μg of Fe-bLf, NCs were separated by SDS-PAGE, by using 10% gel. The 
separated proteins then were transferred to a PVDF membrane for 90 min at 0.35mA and 100V 
(The mini PROTEAN 3 apparatus, BioRad, Gladesville, NSW, Australia). Following transfer, 
the membrane was removed, rinsed with TBS and incubated overnight in 1: 500 dilution of goat 
anti bLf antibody, and later with anti-goat HRP conjugated IgG at 1: 60,000 dilution. The bands 
were developed with ECL chemiluminescent detection kit. 
 
3.13 In vivo stability of Fe-bLf and AEC-CP-Fe-bLf NCs 
In vivo stability of Fe-bLf and rhodamine loaded AEC-CP-Fe-bLf NCs nanoparticles in mouse 
plasma after feeding was carried out according to the existing methodology (Hu et al. 2011; 
Wang et al. 1997) and by confocal microscopy. Fe-bLf and AEC-CP-Fe-bLf NCs were 
administered orally to two groups of mice at a dose fixed at 100 mg/kg body weight. The blood 
was harvested from the animal for a time period starting from 15min to 10D i.e. 15min, 30min, 
1h, 2h, 3h, 6h, 8h, 10h, 12h, 24h, 36h, 72h, 5D, 8D, 10D, into heparinized microcentrifuge tubes 
(containing 20 μl of 1000 IU heparin/ml of blood). Plasma was immediately prepared by 
centrifugation at 1000 g for 15 min at 4°C. A thin smear of plasma samples was examined under 
confocal laser microscopy. 
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3.14 Pharmacokinetic studies after oral administration of Fe-bLf and AEC-CP-Fe-bLf NCs 
Female nude mice (age, 6 weeks), were randomly divided into two groups. The first group 
comprised the control animals and was given Fe-bLf only (Fe-bLf group). The second group was 
given AEC-CP-Fe-bLf NCs labelled with rhodamine/coumarin-6 as an oral administration. Fe-
bLf dose in both cases was fixed at 100 mg/kg body weight. Prior to and 30 min, 60 min, 1 h, 2 
h, 3 h, 6 h, 8 h, 10 h, 12 h, 24 h, 36 h, 72 h, 5 D, 7 D and 10 days after administration, blood was 
harvested from the tail vein into heparinized microcentrifuge tubes (containing 20 μl of 1000 IU 
heparin/ml of blood). After each sampling, 0.25 ml of dextrose-normal saline was administered 
to prevent changes in the central compartment volume and electrolyte plasma was immediately 
prepared by centrifugation at 1000 g for 15 min at 4 °C and stored at −80 °C until use. The 
plasma samples (100 μL) were then acidified to pH 3.0 using 6 N HCl and Fe-bLf was extracted 
from it using twice the volume of a mixture of ethyl acetate and isopropanol (9:1; v/v) by 
shaking the mixture for 6 min. The samples were centrifuged at 5000 g for 20 min, and the upper 
ethyl acetate layer was removed. The extraction procedure was repeated twice. The combined 
extractions were evaporated to dryness in vacuum, and the residue was dissolved. An aliquot of 
this solution was analyzed for the content of Fe-bLf by HPLC. Blood was collected from the 
heart and serum was separated. Heparinized blood was used for RBC count. 
 
3.15 Estimation of intracellular iron by calorimetric method 
The procedure for measuring iron saturation in the tissues was modified from the method 
described (Young & Hicks 1965). Briefly, to 1 ml of serum sample or to the Fe-bLf, 50 μl of 
ascorbic acid was added and mixed well to maintain iron in a reduced state. A sample without 
protein was taken as control and a series of standards were made with ferric nonahydrate. 100 μl 
of 65% tricholoroacetic acid was added into each tube after 5 min to digest the bound proteins. 
The tubes were immediately covered with parafilm and shaken vigorously for 30 sec and allowed 
to stand for 10 min and centrifuged at 10,000 rpm for 20 min. Following centrifugation, 500 μl 
of supernatant from each sample, iron standards and blank, were added into new eppendrof tubes 
containing 100 μL of alkaline acetate solution followed by the addition of 75 μl of tripyridyl 
solution, to obtain a coloured product. The samples were mixed well and allowed to stand for a 
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further 10 min. Absorbance was read at 550 nm with an Asys Expert Plus microplate reader 
(Asys Hitech, Cambridge, UK). Iron concentration was determined by comparing the resulting 
absorbance values taken with the iron standards. 
 
3.16 Measurement of intracellular calcium [Ca+2] 
Fura-2/acetoxymethyl ester (AM) was used to measure calcium concentration as previously 
described with modifications (Kanwar et al. 1995). The serum samples were incubated with 
3mM Fura-2/AM for 30 min at 37 0C in the dark and washed with Krebs/HEPES buffer (143.3 
mM Na+, 4.7 mM K+, 2.5 mM Ca+2, 1.3 mM Mg+2, 125.6 mM Cl-, 25 mM HCO-3, 1.3 mM 
H2PO-4, 1.2 mM SO4-2, 11.7 mM glucose and 10 mM HEPES, pH 7.4) to remove extracellular 
Fura-2/AM. The loaded serum samples were further incubated at the room temperature for de-
esterification of the Fura-2/AM. Excitation wavelength of 510 nm and an emission at 340 and 
380 nm were recorded. The [Ca+2]i was calculated by ratio of fluorescence at 340/380 nm using 
Grynkiewicz method as represented below 
[Ca+2] = Kd x [(R-Rmin) / (Rmax-R)] x Q 
Here Kd is the Ca+2 binding constant (with Fura-2/AM at 370C). R is the ratio of 340/380 during 
the experiment, Rmax and Rmin are the ratio of 340/380 under Ca+2 saturation conditions and Ca+2 
free conditions and Q is the ratio of Fmin/Fmax at 380nm.the calibration values were determined in 
the presence of 1mM of  Ca+2 or 10mM EGTA (Rmin). 
 
3.17 Biodistribution of tissues 
Normal and lactoferrin treated specimens (small intestine, spleen, liver, large intestine, brain, 
kidney and mesenteric lymph nodes, ovary, eye, lung, heart, stomach, spinal cord, leg muscles, 
arm muscles) and blood were removed and were frozen in liquid nitrogen immediately after 
surgical removal and stored at -80ºC until use. 
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3.18 Western blotting analysis 
Approximately 200 mg of tissue samples was powdered in liquid nitrogen and then homogenized 
in lysis buffer (150 mmol/liter NaCl, 10 mmol/liter Tris-HCl, pH 7.5) supplemented with 
protease inhibitor cocktail (Roche Diagnostics) (Appendix). The lysate was collected and 
centrifuged at 4ºC for 30 min at 14,000 rpm to remove the insoluble material. The protein 
concentration of the supernatant was measured by spectrophotometry using the BCA protein 
assay (Pierce; Rockford, IL). Protein extracts were subjected to 12% SDS-PAGE. After 
electrophoresis, proteins were transferred to nitrocellulose filters. For immunoblotting, 
unspecific binding was blocked with 5–10% non-fat milk and the membranes were incubated 
with the primary antibodies at room temperature (RT) for 1 hr. Then the filters were washed in 
TBST buffer (5% non-fat milk in 20 mM Tris-HCl, 150 mM NaCl, 0.1% Tween-20) and 
incubated with a horseradish peroxidase conjugated anti-goat anti-bovine lactoferrin antibody at 
RT for 30 min. After washing in TBST buffer, the signal was detected using the enhanced 
chemiluminescence (ECL) method. The intensity of the radiographic bands for each normal and 
lactoferrin treated sample was quantified by video densitometry (Berberat et al. 2001). 
 
3.19 ELISA of cytokine and nitrite production in the small intestine 
Cytokine levels in the supernatants of homogenates of the small intestine were determined using 
a ‘sandwich’ ELISA kit (Endogen, Woburn, MA, USA) (Kanwar et al. 2008). They were 
detected within standard curve ranges of 15–375 pg/ml for IL-4, 0–2450 pg/ml for IL-5-IL-17, 
15–1000 pg/ml for TNF-α, 0–3000 pg/ml for IFN-γ, 37–3000 pg/ml for IL-10, 31.3–2000 pg/ml 
for IL-12 and 31.3–2000 pg/ml for IL-18, respectively. Quantification of nitrite, indicative of NO 
production, was carried out by the Griess reaction (Sigma) (Appendix). The results are expressed 
as the mean nitrite concentration (μM) ±SEM. 
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Chapter 4: Antimicrobial activity of buffalo lactoferrin against Giardia lamblia 
4.1 Introduction 
Giardiasis is a common cosmopolitan protozoal infection of the intestinal tract resulting from 
infestation with the human parasite Giardia lamblia (syn. Giardia intestinalis, Giardia 
duodenalis), a flagellated diplomonad that causes extensive morbidity worldwide. The giardiasis 
disease exists in both epidemic and endemic form, and is mainly transmitted through 
contaminated food and water with the parasite mostly colonizing the proximal small intestine 
(Fig. 4.1). Symptomatic infection is characterized by diarrhoea, epigastric pain, nausea, 
vomiting, and weight loss, yet many infections are asymptomatic. In the developing world about 
1.25% to 73.5% of the population is infected and in developed countries such as United 
Kingdom, USA, Canada and Australia the prevalence rate is between 2% to 7% in adults and 2% 
of children are infected at least once (Tian, Chen & Wen 2010). One billion cases have been 
reported of giardiasis at one time could be found and 2.5 million deaths occur annually from the 
diarrheal disease (Rossignol 2010). 200 million symptomatic infections are found in Asia, Africa 
and Latin America alone. Due to its increasingly common transmission route and zoonotic 
potential, giardiasis is recognized as the re-emerging infectious disease. In addition, Giardia 
infection is a common cause of diarrheal disease in domestic animals (e.g. dairy calves, dogs, 
and cats) associated with substantial economic losses (Thompson, Hopkins & Homan 2000). 
Thus, this disease represents a significant global burden, poses a great challenge for drug 
discovery and delivery, and is included in the World Health Organisation’s (WHO) “Neglected 
Disease Initiative” from 2004 (Savioli, Smith & Thompson 2006). 
 
Inappropriate use of antibiotics has led to development of resistant strains of pathogens. The 
infection is self-limiting in the majority of cases provided that individuals are healthy, designing 
of new and safe therapeutics is urgently needed.  Metronidazole and tinidazole are used to treat 
infections by the anaerobic protozoa Trichomonas vaginalis, Giardia duodenalis and Entamoeba 
histolytica (Upcroft & Upcroft 2001). Albendazole due to its pleasant taste and efficacy is an 
alternative for the treatment of giardiasis, with 62 to 95% reported efficacy compared with 97% 
for metronidazole (Hall & Nahar 1993). Soon after metronidazole was introduced in the 1960s, 
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drug failures in trichomoniasis treatment appeared (Upcroft & Upcroft 2001). Resistance has 
recently been confirmed among clinical isolates of Giardia via difficult in vivo assays (Lemee et 
al. 2000). Currently, there are no Giardia vaccines available for humans, and due to the 
disadvantages and limitations of existing drugs, search for new anti-giardial compounds must 
continue. Experimental studies on bacitracin zinc, chloroquine, DLpropranolol, propolis, and 
ozonized sunflower oil have shown some promising results (Escobedo & Cimerman 2007), and 
the protein disulphide isomerases PD12 and PD14, as well as GINR-1 nitroreductase, have been 
reported as promising targets for new drugs (Muller et al. 2007). Additionally, in vitro studies 
have revealed that some HIV-protease inhibitors, mainly ritonavir, inhibit Giardia growth at 
therapeutic plasma concentrations (Dunn et al. 2007). 
 
Multiple in vitro and animal studies have shown a protective effect of lactoferrin on infections 
with enteric microorganisms, including Giardia. Lactoferrin, an approximately 80 kDa iron 
binding glycoprotein initially purified from milk, is an important component of the innate 
immune system. It is a multifunctional protein, a potent antimicrobial and antiviral agent and is 
found in exocrine secretions, e.g., tears, nasal exudate, saliva, bronchial mucus, gastrointestinal 
fluids, etc. Human lactoferrin, bovine lactoferrin and its derived N terminal peptides have been 
demonstrated to have giardicidal activity and to cause ultrastructural changes in Giardia 
trophozoites, suggesting that lactoferrin may be an important non-immune component of host 
mucosal defense against Giardia. Lactoferrin, especially in the form of the N-terminal peptides 
(Lfpep’s) generated by gastric pepsin cleavage of human Lf (residues 18 to 40 of the native 
molecule), showed giardicidal activity (Turchany et al. 1997). 
 
Lactoferrin bridges innate and adaptive immune function in mammals (Legrand et al. 2006a). 
Besides anti-ancancer, anti-inflammatory and antimicrobial activities the protective effects of 
lactoferrin include immune modulator activities. Machnicki and coworkers (Machnicki, Zimecki 
& Zagulski 1993) and Haversen et al. (Haversen et al. 2002) have reported that the protective 
effect of Lf is manifested in a reduced production of some pro-imflammatory cytokines such as 
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tumour necrosis factor (TNF-α) or interleukins IL-1β and IL-6. Increased amount of anti-
inflammatory interleukin-10 has also been reported in several cases (MansourEl-Loly & 
Mahfouz 2011). 
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Figure 4.1 Life cycle of Giardia lamblia. It has a simple life cycle consisting of an infective cyst 
(resting form) and a vegetative trophozoite (feeding or proliferative form). Infection of a host is 
initiated when a cyst is ingested with contaminated water or less commonly, food or through 
direct fecal oral contact. After exposure to the acidic environment of the host stomach, cysts 
excyst into trophozoites in the proximal small intestine. The trophozoite divides by binary fission 
in the small intestine. The environmental changes cause the trophozoites to encyst and are passed 
in the feces, allowing completion of the transmission cycle by infecting a new host (From 
Wikipedia). 
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The amino acid sequence of buffalo Lf consists of a single polypeptide chain of 689 residues. 
The overall folding of buffalo Lf is similar to human Lf, mare Lf and bovine lactoferrin 
(Karthikeyan et al. 2000b). This lactoferrin was used in the current research, as many studies 
have taken bovine lactoferrin but there is a lack of information regarding the buffalo lactoferrin. 
In addition, in Northern India the majority of population drinks buffalo milk, which is more 
nutritious than cow milk. Therefore the study was planned to see the effect of buffalo Lf on the 
inhibition of Giardia lamblia. 
 
Though a number of antiparasitic effects of lactoferrin have been reported, the role of lactoferrin 
as an antiparasitic molecule remained ill defined, and mechanisms tended to be parasite specific. 
The in vitro and in vivo experiments carried out in this study have been successful in explaining 
the mode of action of buffalo lactoferrin in the treatment of Giardia infection. Histopathological 
changes in the host tissue after infection by Giardia lamblia and treatment by buffalo lactoferrin 
confirmed the results of efficacy of the protein in clearing up infection. The immune response to 
infection in infected and drug treated groups of mice was tested by analysis of cytokines. 
 
4.2 Materials and Methods  
 
4.2.1 Maintenance of culture of parasites and in vitro study: 
The standard strain of Giardia lamblia, Portland 1 was maintained axenically in TYI-S-33 
medium (Department of Parasitology, PGIMER, Chandigarh). The trophozoites were 
subcultured every 48-72 hours as mentioned in Appendix. 
 
4.2.2 Preparation of buffalo lactoferrin: 
Purification of lactoferrin: 
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As mentioned in Section 3.1, buffalo lactoferrin was purified using a cation exchange 
chromatography on SP-Sepharose. 
 
4.2.3 Drug Susceptibility Assay: 
Stock solution of lactoferrin was made by dissolving 6.4mg of Lf in 1ml of PBS. The various 
drug concentrations used were 3200, 1600, 800, 400 and 200 μg/ml of the protein. 2 Negative 
Controls one with PBS and another without drug were taken. For comparison of results negative 
controls of culture without lactoferrin and positive controls with metronidazole were used. All 
the experiments were performed in triplicate. Various effective concentrations of lactoferrin were 
obtained at which percentage non-viability of the parasites were obtained. 
 
4.2.4 Animals 
Animal experiments were performed using female BALB/c mice, aged 4 weeks, obtained from 
Central Animal House, PGIMER, Chandigarh after getting the approval of Institutional Animal 
Ethics Committee (IAEC no. 50/IAEC/240). All the guidelines of the committee were followed 
for the care and use of animals accordingly. Mice had free access to tap water and rodent chow 
and were made to undergo acclimatization for one week before any intervention. Stool 
specimens of all the animals were examined for three consecutive days to verify absence of any 
protozoan infections. Stool samples were collected by keeping single mouse in a single cage for 
2 hrs and processed by standard method. Only parasite free, mice were used for further 
experiments. 
 
4.2.5 Inoculation and development of infection of parasites in mice:  
Cultured trophozoites of parasites maintained and harvested during log phase from G. lamblia, 
were tested for infectivity in various groups (Table 4.1) of suckling BALB/c mice (20-22g) after 
1 week of post inoculation. Trophozoites were detected in mice 7 days after they had been 
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exposed to the infection in the test group and treated with diet prepared with buffalo lactoferrin 
(8mg/kg body weight), and the reference drug Metronidazole (20mg/kg body weight of mice) 
(Benere et al. 2011) and the results analyzed. Control mice were given the standard diet. 
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Experimental design 
Table 4.1 The animals were divided into the following groups: 
 
Group I (n=20) : Control 
mice 
These mice were fed orally 
with single dose of 0.1 ml 
TYI-S-33 medium using a 
blunt tip canula. 
 
 
Group II (n=20) : Normal 
mice 
 
 
Group III (n=60): Giardia 
infected mice 
These mice were fed orally 
with a single dose of 
1x107/0.1ml Giardia 
trophozoites 
(Tantawiwattananon et al. 
2006). 
IIIa: 20 mice were not given any drug 
treatment. 
 
IIIb: 20 mice were fed with buffalo lactoferrin 
for 4 days post infection. 
IIIc: 20 mice were fed with Metronidazole for 7 
days post infection. 
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4.2.6 Enumeration of Giardia cysts in stool 
Stool specimens were taken from the animals of the Giardia infected group as mentioned in the 
Table 4.1 in order to verify the presence of Giardia lamblia cysts. Cysts were counted by the 
standard method (Vinayak, Sharma & Naik 1979). Briefly, one gram of freshly passed fecal 
samples was dissolved in 10 ml saline, homogenized using a pestal and morter. Cysts were 
counted in hemocytometer at higher magnification in Lugo’s iodine stained preparation. The 
cysts count was performed on every alternate day for 27 days. 
 
4.2.7 Enumeration of Giardia trophozoites in small intestine  
The tropozoites were counted in intestinal perfusate of the mice according to the method of 
Ganguly et al. (Ganguly et al. 1982). Mice were sacrificed via retro orbital route. The entire 
small intestine was removed and flushed with a fixed amount of ice cold normal saline. The 
material was centrifuged at 500 xg for 10 min. Giardia tropozoites were counted from the 
sediment using hemocytometer and results expressed as tropozoites per ml. 
 
4.2.8 Histopathological studies 
Tissue sample preparation: mice were sacrificed under euthanasia by cervical dislocation and the 
upper part (jejunum) of the small intestine was removed, fixed in 10% buffered formalin and 
processed for histological examination (Shukla & Sidhu 2011). After eosin and hematoxylin 
staining slides were coded without reference to prior treatment and examined in a blinded 
fashion by a pathologist as a combined score of inflammatory cell infilteration, tissue damage 
and presence of no. of parasites in infected tissues in tissue sections. The location of the parasite, 
changes in the brush border, presence or absence of ulceration and inflammatory changes in the 
lamina propria were examined. 
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4.2.9 Biodistribution of tissues 
The methodology for finding the biodistribution of lactoferrin, specimens (small intestine, 
spleen, liver, large intestine, brain, kidney and mesenteric lymph nodes, ovary, eye, lung, heart, 
stomach, spinal cord, leg muscles, arm muscles) and blood were processed as discussed in 
section 3.17. Western Blotting of the samples was described in section 3.18. 
 
4.2.10 Clinical score 
A disease scoring was done according to the method described earlier, with slight modification 
by Seigmund (Siegmund 2004). In brief, experimental each animal was examined to determine 
the degree of clinical impairment by assessing the variations in parameters like appearance of 
diarrhea, skin coat and weight besides the trophozoite and cyst count in mice (Table 4.2).  
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Table 4.2 Clinical assessments of all the above-mentioned five groups of mice 
 
Parameter Score 
Fecal consistency 0 = Well-formed pellets 
1 = Pasty/semi formed stools 
2 = loose stools/watery diarrhea 
Skin Coat 0 = Normal hair coat with healthy skin 
1 = Rough hair coat 
2 = Very rough hair with loose skin 
Weight of mice 0 = Normal mice with no weight reduction 
1 = Mice with less than 15% reduction in 
weight 
2 = Mice with more than 15% reduction in 
weight, underweight 
 
 
The total scores given for fecal consistency, skin coat and weight of mice were added and 
divided by 3 for a maximal disease score of 3. 
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4.2.11 ELISA of cytokine and nitrite production in the small intestine 
Cytokine levels in the supernatants of homogenates of the small intestine were determined using 
the methodology described in section 3.19. 
 
4.2.12 Statistical Analysis: 
Comparisons between groups, efficacy of lactoferrin in comparison with the negative controls 
(with only the PBS or media), between themselves and with the positive control Metronidazole 
against the parasite in in vitro study were undertaken using paired t-test. Results are expressed as 
Mean ± Standard Deviation (SD). Significant differences at various levels were thus investigated 
and analysis was carried out using the SPSS 16 Software. 
 
4.3 Results 
4.3.1 Purification of lactoferrin 
Lactoferrin was isolated from whey fraction of buffalo colostrum by Cation exchange 
chromatography. Clear bands of molecular weight of 80kDa were detected by SDS-PAGE, 
confirming lactoferrin. Peak of lactoferrin was observed in the second eluted fraction of 
chromatography after whey sample was passed through the column (Fig. 4.2). Amicon ultra 
filtration was done to concentrate the protein, followed by desalting through dialysis membrane 
and protein estimation and lyophilisation and stored as a stock in -80ºC to carry out further in 
vitro and in vivo experiments.  
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Figure 4.2 SDS PAGE of the pooled fractions after Cation Exchange Chromatography for 
the isolation of purified buffalo lactoferrin from whey and its antiparasitic activity in vitro.  
Electrophoretic seperation of first fraction of Indian buffalo Lf (lane 1), second fraction of Indian 
buffalo Lf (lane 2), crude sample/ colostrum from buffalo (lane 3) and Molecular weight Marker 
(lane M) after Coomassie Blue staining in 12.5% SDS PAGE. Estimated molecular weights (kD) 
are shown on the left side. 
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4.3.2 Giardicidal activity of Buffalo Lf in vitro 
The inhibitory activity of various concentrations of buffalo lactoferrin was checked against 
Giardia lamblia. This was also found to be concentration-dependent and significant differences 
(P <0.001) were noted in the efficacy of the lactoferrin and the reference drug metronidazole as 
compared to the negative controls with only PBS and media alone.  
 
When the giardicidal activity of Lf was compared to the reference drug, the activity of 
Metronidazole was significantly similar to that of Lf at all its concentrations, ranging from 200-
3200 μg/ml. This suggested that the test drug Lf is similar in efficacy to the effective dose of Mz 
used in this study, at the lowest concentration 200 μg/ml bLf (Fig. 4.3). At 200 μg/ml, Lf showed 
90% of inhibition as compared to metronidazole which showed IC90 at 16 times the same 
concentration i.e. 40μM ( 3200 μg/ml) (Table 4.3). 
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Figure 4.3 Comparison of Effect of Indian buffalo Lf on Giardia lamblia (Portland-1 strain) 
with the conventional drug metronidazole after 12 h incubation. Indian buffalo Lf showed 
more inhibitory effect against the trophozoites of G. lamblia as compared to Metronidazole (Mz) 
as observed from the non-viability percentage values of the parasite. At 200μg/ml of 
concentration, Lf showed around 90% significant inhibition against parasites. Metronidazole was 
used as the reference drug. In all cases non-viability was estimated using PI staining. 
Experiments were done in triplicate; mean ± SD values were calculated. Paired, two-tailed t-test 
was used. ** P < 0.001 versus both Negative controls (C), PBS and Media only was considered 
to be highly significant. Raw P value is used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
[Type text] 
 
71 
 
 
Table 4.3 Minimum Inhibitory Concentration (MIC) values of different drugs 
 
Drugs *IC90 
Metronidazole (reference drug) 40 μM 
Buffalo Lf 200 μg/ml 
 
*IC90 is the 90% inhibitory concentration of various drugs for treatment of Giardia lamblia 
Results are representative of 3 experiments in triplicate. 
[Type text] 
 
72 
 
4.3.3 Rise in parasitemia and drug treatment in mice 
Inoculation of 107 trophozoites of Giardia lamblia (Portland 1) to suckling BALB/c mice 
resulted in infection in all the animals. The maximum trophozoite and cyst counts were obtained 
on day 7 post-infection and thereafter the counts started declining. By day 27 infection was 
cleared in most of the animals; however few trophozoite and cysts could still be detected in few 
animals.    
 
Animals of the control group did not eliminate cysts or trophozoites during the experimental 
period. 
 
a) Enumeration of Giardia Cysts in Feces 
The cyst load was least from the beginning, i.e., day 3 onwards, in mice (Giardia-infected). 
Excretion of cysts in feces (Fig. 4.4) increased gradually on day 7 post inoculation, in all the 
groups of mice. The period of maximum cyst release was between days 7 and 11 of infection and 
after day 11 a decline in the number of cysts was observed in the infected group. Mice became 
Giardia free by day 11 p.i or after 4 days of treatment with buffalo Lf but in the case of the 
metronidazole treated group the number of cysts declined only after 13 days post infection or 6 
days of treatment with the drug showing a delay of 2 days in cyst elimination as compared to Lf 
treatment. The infectivity period was much more prolonged and cyst count was much higher 
from the beginning, however in the Giardia-infected group.  
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Figure 4.4 Cyst counts in the small intestine of mice belonging to different groups. In the 
infected group of mice the cyst count reached peak after 7 days of infection with 1x107/0.1ml 
trophozoites of Giardia lamblia. The infection resolves thereafter 27 days post infection. But 
when buffalo lactoferrin was administered to the infected mice, the cyst count diminished within 
4 days of treatment or 11 days post infection. Values are represented as mean ± SD. 
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b) Enumeration of Giardia trophozoites in small intestine of mice 
Oral inoculation of mice with Giardia trophozoites resulted in the establishment of infection as 
assessed by the number of trophozoites counted in jejunum and cysts count in feces after 7 days. 
The number of trophozoites increased following Giardia infection in Giardia-infected mice as 
compared to the drug treated group of mice (Fig. 4.5) at all the studied time points. Only a few 
trophozoites were found in mice after 11 days post infection or 4 days of treatment with buffalo 
Lf and the infection had almost cleared up by the 14th day p.i./7 days of treatment with the same 
drug. But in the case of Metronidazole treatment some parasites could also be seen on the 14th 
day post infection /7 days of treatment. 
 
Thus no trophozoites or cysts were recovered from the mice after 4 days of treatment with 
buffalo Lf as compared to the metronidazole-treated mice and the infected group, where 
infection persisted. 
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Figure 4.5 Trophozoite count in the mice belonging to different groups. The trophozoites 
were found in the infected (inoculated with 1x107/0.1ml of trophozoites of Giardia lamblia) 
group of mice 7 days post infection and their maximum numbers were found on the same day. 
When the test drug buffalo Lf was administered to mice trophozoites were eliminated within 7 
days of treatment or 14 days of infection with the parasite. But in the infected group the infection 
resolved only after 27 days post infection. Values are presented as mean ± SD. 
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4.3.4 Histopathology results of treatment  
By comparing the infection rate (Table 4.4) in the Giardia-infected group with normal mice and 
the drug-treated group, a maximum histopathological score of +1 was observed in the infected 
group on 7th, and +3 on 9th and +4 on 14th day post-infection. The score declined in the buffalo Lf 
treated group. The results of histopathological examination of the intestinal tissue sections of 
infected mice suggest that Giardia lamblia can alter the architecture of the intestinal mucosa 
through hyperplasia of the crypts and atrophy of the villi. Swollen ileum and edematous villous 
was observed along with slight reduction in height of villi. A small number of 
lymphomononuclear cells were found and a few trophozoites of Giardia lamblia could be seen in 
the infected intestinal tissues of mice  
 
Infected animals demonstrated impaired weight gain and reduced jejunal villus:crypt ratio (V:C). 
Reduction in V:C ratio was maximal between 7 and 9 days of post infection. The mid jejunum 
contained the highest trophozoite counts and significant pathological abnormalities (Fig. 4.6B-
E). As compared to normal mice in the control group ileum showed normal villi and normal 
brush border cells and goblet cells (Fig.4.6A). The morphology of intestine became normal after 
4 days of treatment of infected mice with the buffalo Lf (Fig. 4.6F) and completely normal in 7 
days of treatment with this drug after elimination of the parasites.  
 
After 21 days (Fig. 4.6D, E) post infection there was also no recurrence of infection in the mice 
due to Giardia was observed and the small intestinal tissues of mice showed a normal 
pathological profile. Regular villus with a low population of lymphomononuclear cells was 
observed and lining cells appeared longer. The crypts showed paneth cell hyperplasia, ileum 
showed villi of equal height with some budding. 
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Figure 4.6 Photomicrographs of the histopathological analysis of small intestinal tissues of 
mice belonging to different groups. (A) Photomicrograph of the small intestine of normal mice 
(H and E, 100X) in the control group, showing normal morphology, ileum shows normal villi 
and normal brush border cells and goblet cells. (B) Photomicrograph of the small intestine of 
Giardia infected mice (H and E, 40X) after 7 days post infection, ileum swollen, edematous 
villous, slightly reduced in height. The numbers of LMN cells are small, parasites are seen (panel 
b). (C) Photomicrograph of the small intestine of Giardia infected mice (H and E) 200X after 7 
days post infection. (D) Photomicrograph of the small intestine of Giardia infected mice (H and 
E, 40X), after 21 days post infection. Cross section of ileum showing villi of equal height with 
some budding. (E) Photomicrograph of the higher magnification of small intestine of Giardia 
infected mice (H and E, 200X) after 21 days post infection. Higher magnification shows regular 
villi with low population of LMN cells. The lining cells also appear longer. The crypts show 
paneth cell hyperplasia. (F) Photomicrograph of the small intestine of buffalo Lf treated mice 
after 4 days of drug treatment or 11 days of post infection with trophozoites of Giardia lamblia. 
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Table 4.4Histopathological analysis of small intestinal tissues of mice, after each dissection: 
 
Giardia 
infection 
group 
Infection rate 
(Days post infection) 
 
07 days post 
infection. 
09 days post 
infection. 
(i.e. two days 
after start of 
drug treatment) 
14 days post 
infection. 
27 days post 
infection. 
Normal mice 
(no infection) 
0 0 0 0 
Mice (with 
infection), but 
not treated 
1+ 3+ 4+ 0 
Mice with 
treatment 
Drug 
administered 
0 0 0 
 
Scoring: Indicates the quantum of infection by Giardia lamblia in the mice. A pathologist 
performed the score in a blinded manner. 
 
 
 
Table 4.5 Results of histopathological study showing the infilteration of cells are 
summarized in the following table: 
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Animals Lymphomononuclear 
Cells 
Epithelial Cells Parasites 
Control 20 Average - 
Infected group 40 Average + 
Drug treated group 
(2 days of drug 
treatment) 
40 Normal - 
Drug treated group 
(7 days of drug 
treatment) 
10-20 Normal - 
  
−Sign indicates absence of parasites 
+Sign indicates presence of parasites 
 
 
 
 
 
 
4.3.5 Clinical response in Giardia infected mice and treated groups 
In the series of in vivo experiments we determined the extent of clinical involvement in BALB/c 
mice using a grading scale that we developed for this study. It can be seen that the severity of 
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clinical impairment was much higher in Giardia-infected BALB/c mice than the treated mice. 
Thus the mice treated with buffalo Lf were more clinically improved as compared to infected 
groups (Fig. 4.7). The cyst and trophozoite score was maximum in the Giardia infected group on 
day 7 p.i and declined more rapidly in the buffalo Lf treated group (Fig. 4.4, 4.5) within 4 days 
of treatment, but in the metronidazole treated group the trophozoite and cyst score declined only 
after 7 days of treatment or 14 days post infection and persisted in the infected group with no 
drug treatment. 
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Figure 4.7 Clinical score of different groups of mice. Clinical score was awarded by taking the 
mean values of the scores of the parameters: appearance of diarrhea (fecal consistency), skin coat 
and weight of mice and comparison was done in the (a) Giardia infected and (b) Buffalo 
lactoferrin treated groups (c) Normal mice. The score was less in the Buffalo Lf treated group of 
mice as compared to Giardia infected group as is observed clearly from the graph. 
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4.3.6 Biodistribution of buffalo lactoferrin in the tissue lysates in mice:  
After 4 days of treatment of the infected mice with buLf the concentration of lactoferrin in the 
tissue lysates was studied. The concentration of buLf was found more in the mice even after 11 
days of treatment, in the vital tissues small intestine, liver, spleen and blood (Fig. 4.8).     
 
0
400
800
1200
1600
2000
O
v
a
r
y
M
u
s
c
le
B
o
n
e
E
y
e
B
lo
o
d
L
iv
e
r
S
p
le
e
n
K
id
n
e
y
L
u
n
g
H
e
a
r
t
B
r
a
in
S
to
m
a
c
h
S
m
a
ll
 i
n
te
s
ti
n
e
L
a
r
g
e
 i
n
te
s
ti
n
e
S
p
in
a
l 
c
o
r
d
L
e
g
 m
u
s
c
le
s
A
r
m
 m
u
s
c
le
s
M
L
N
C
o
n
c
e
n
tr
a
ti
o
n
 o
f 
F
e
-b
L
f 
in
 
ti
s
s
u
e
 l
y
s
a
te
s
 (
n
g
/m
l) buLf-4D
buLf-11D
 
 
 
[Type text] 
 
87 
 
Figure 4.8 Biodistributtion study of lactoferrin in tissue lysates of mice after oral 
administration in diet. When the concentration of buffalo lactoferrin in the tissue lysates was 
studied in the Giardia infected tissues of mice after 4 days of treatment with this drug, maximum 
concentration of Lf was observed in the tissues even after 11 days of treatment showing the 
sustainability of the drug. 
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4.3.7 Cytokine response by mice tissues (small intestine) 
The ability of oral bLf to affect the intestinal expression of a panel of Th1 (IL-1β, IL-2, IL-6, IL-
18, TNF-α and IFN-γ) and Th2 (IL-4, IL-5, Il-6 and IL-10, TGF-β) was examined in the mice to 
compare the local profile of the Th response in the untreated and the buLf treated animals. The 
roles of various cytokines were assessed in the innate and adaptive immune defenses and other 
cytokines related to haematopoiesis and Th17 differentiation and activation (Tables 4.6-4.9).   
 
In case of adaptive immune response of the cytokines, up regulation of IL-2, IL-4, IL-5, IL-17 
and IFN-γ was observed. The level of IL-2 showed a drastic significant increase of about 10 fold 
in case of buLf treated group and IL-4, IL-5, IL-17, IFN-γ increased significantly to 1.7, 2.6, 3.3, 
2.5 fold respectively as compared to control group of mice with no drug treatment. IL-5 also 
showed up regulation in case of metronidazole treated group to 1.8 fold as compared to control 
group of mice. Almost same levels of IL-4 were observed in both the buLf treated group and 
metronidazole treated group of mice (Table 4.7).  
 
The cytokines of haemopoiesis are IL-3, IL-7, IL-9, IL-11, Granulocyte-Colony Stimulating 
Factor (G-CSF), Monocyte-Colony Stimulating Factor (M-CSF) and Granulocyte Monocyte 
Colony-Stimulating factor (GM-CSF). In comparison to the control group of mice without any 
drug treatment, IL-3, IL-9, G-CSF and M-CSF showed 1.3, 3.3, 4.6, and 1.2 fold significant 
increase respectively in the buLf treated group of mice as compared to control. GM-CSF showed 
decrease in the level to 1.2 fold when the control group was compared to the buLf treated group. 
The levels of the cytokines of haemopoiesis decreased in the metronidazole treatment group of 
mice except the in case of IL-9, where 1.4 fold increase was observed as compared to control 
(Table 4.8). 
 
[Type text] 
 
89 
 
The cytokines of the Th17 differentiation and activation of immune cells like IL-21, IL-22, TGF-
β, IL-17A, IL-17F, TNF-α showed a significant increase in the levels.   IL-21, IL-22, TGF-β and 
TNF-α increased to 2.1, 3.2, 1.6 and 1.4 fold respectively buLf treated group of mice as 
compared to control. IL-22 and IL-17A showed down regulation in case of metronidazole 
treatment to 1.6 fold and 3.2 fold respectively as compared to the control (Table 4.9).  
 
Other cytokine like IL-26 was up regulated to 1.9 fold in the buLf treated group of mice as 
compared to control. The levels of NO production declined to 3 fold in the buLf treated group 
(Table 4.9). The CD4+ and CD8+ cells from intestine proliferated in the buLf treated mice to 
about 4 and 2.7 fold respectively as compared to control. Significant increase in levels of  IFN-γ 
(2.6 fold) was observed after 11 days of treatment in the buLf treated group as compared to 
control group of mice. NK cell activity increased to 3.5 times in the treated group. TH17+ 
production was also observed in the buLf treated groups when compared to normal mice (Fig. 
4.9). 
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Figure 4.9 The levels of cytokines in the small intestine of mice after treatment of Giardia 
infected mice by buffalo Lf as compared to the control diet. Results are expressed as mean 
concentration (micromolar) for the cytokines. 
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4.3.8 Cytokine response by spleen 
Our results suggest that T cell responses are required for elimination of infection. IFN-γ was the 
dominant cytokine produced by splenocytes in response to infection. Considering the essential 
roles of CD4+ cells in resolving the infection we found that they were the major cytokine 
secreting cells and produced predominantly in the Lf treated group of mice. Activation of 
dendritic cells was observed. The level of IFN-γ increased significantly to 4.3 fold and 6.3 fold 
and that of Th17 cells to 3.7 and 4.7 respectively after 4 and 11 days of treatment in the Lf 
treated group as compared to the control (Fig. 4.10).    
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Figure 4.10 The levels of cytokines in the spleen of mice after treatment of Giardia infected 
mice by buffalo Lf as compared to the control diet. Results are expressed as mean 
concentration (micromolar) for the cytokines. The mean of the representative experiment was 
calculated and presented as mean ± standard error of the mean values. 
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Table 4.6 The cytokines of innate immunity. 
Cytokines (μM) buLf Control Metronidazole 
IL-1beta 32±6 10±2 7±4 
IL-6 385±58 300±25 300±42 
IL-18 58±31 50±24 250±80 
IL-12 650±120 250±20 100±10 
IL-23 21±3 8±2 15±5 
IL-10 345±35 234±21 241±67 
IL-15 25±5 42±5 5±2 
IFN-1α 25±5 25±5 5±2 
IFN-1β 16±5 16±5 5±2 
IFN-III 20±5 25±5 5±2 
IL-27 25±5 16±5 5±2 
 
Table 4.7 The cytokines of adaptive immunity 
Cytokines (μM) buLf Control Metronidazole 
IL-2 125±15 20±5 15±5 
IL-4 24±6 14±6 25±5 
IL-5 22±6 8±3 15±7 
IL-17 10±3 3±1 2±1 
IL-13 15±5 15±5 5±2 
IFN-γ 5±2 2±2 2±1 
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Table 4.8 The cytokines of haemopoiesis 
Cytokines (μM) buLf Control Metronidazole 
M-CSF 10±4 8±3 5±2 
G-CSF 23±5 5±2 6±2 
IL-9 40±2 12±5 16±5 
GM-CSF 22±5 26±5 5±2 
IL-7 17±5 16±5 5±2 
IL-11 10±5 10±5 5±2 
IL-3 15±5 12±5 5±2 
 
 
Table 4.9 Other cytokines and cytokines of TH17 differentiation and activation of immune 
cells for immune responses and inflammation. 
 
Cytokines (μM) buLf Control Metronidazole 
IL-35 5±2 4±2 5±2 
TGF-beta 25±2 15±4 16±5 
TNF-alpha 22±7 15±4 10±5 
NO 3±2 9±3 12±4 
IL-17A 5±2 5±2 16±5 
IL-17F 24±4 22±5 24±6 
IL-22 32±5 10±2 16±5 
1L-26 23±5 12±5 16±5 
IL-21 17±5 8±2 5±2 
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Chapter 5: Antimicrobial activity of nanoformulated lactoferrin against Giardia lamblia 
5.1 Introduction 
As mentioned in previous chapter 4, Giardia lamblia (syn. G. duodenalis or G. intestinalis), the 
causative agent of giardiasis, is one of the most common causes of worldwide intestinal 
infections in humans and responsible for multiple outbreaks. The disease is mainly transmitted 
through contaminated food and water and the parasite mostly colonizes the proximal small 
intestine, causing abdominal pain, nausea, vomiting, acute or chronic diarrhea and weight loss. In 
developing countries the prevalence of giardiasis is 40% (Nkrumah & Nguah 2011) while in the 
industrialized world it is 2-7% (Pereira, Atwill & Barbosa 2007). One billion cases of giardiasis 
can be found at any one time and 2.5 million deaths are reported annually from the diarrheal 
disease (Rossignol 2010). 200 million symptomatic infections are found in Asia, Africa and 
Latin America alone. Due to its increasingly common transmission route and zoonotic potential, 
giardiasis is recognized as the re-emerging infectious disease. In addition, Giardia infection is a 
common cause of diarrheal disease in domestic animals (e.g. dairy calves, dogs, and cats) 
associated with substantial economic losses (Thompson, Hopkins & Homan 2000). Thus, this 
disease represents a significant global burden, poses a great challenge to drug discovery and 
delivery, and as a result has been included in the World Health Organisation’s (WHO) 
“Neglected Disease Initiative” from 2004 (Savioli, Smith & Thompson 2006). 
 
In spite of the high efficiency of metronidazole treatment for giardiasis, the incidence of this 
disease is still very high. Various other drugs like tinidazole, furazolidone, paramomycin and 
nitazoxanide have been available for several decades but none of them is entirely satisfactory 
(Adagu et al. 2002; Davila-Gutierrez et al. 2002; Morrone et al. 2004). Resistance of many 
strains of parasite to the existing drugs, as well as the multiple side effects of these drugs, and 
their action in destroying normal flora and their potential carcinogenicity (Ellis et al. 1993; 
Upcroft et al. 1999b) has encouraged the development of new antigiardial agents that could 
replace them. 
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Currently most attention is focussed on identification of natural compounds with antiparasitic 
activity. Lactoferrin, a multifunctional protein present in mammalian milk and in most exocrine 
secretions has been shown to initiate microbicidal activity against Giardia lamblia (Gillin, 
Reiner & Wang 1983a; Ochoa et al. 2008). It has also been shown to inhibit the growth of other 
protozoan parasites such as Toxoplasma gondii (Tanaka et al. 1996), Plasmodium falciparum 
(Fritsch et al. 1987), Trypanosoma cruzi (Lima & Kierszenbaum 1985) and Entamoeba 
histolytica (Leon-Sicairos et al. 2006a; Leon-Sicairos et al. 2006b). Lactoferrin, especially in the 
form of the N-terminal peptides (Lfpep’s) generated by gastric pepsin cleavage of human Lf 
(residues 18 to 40 of the native molecule), has also shown giardicidal activity (Turchany et al. 
1997). 
 
For the past few decades various formulations of nanoparticles have been used for drug delivery 
research to increase therapeutic benefit. Lactoferrin has been used as a potential antimicrobial in 
coatings but the cations including Na+, Ca2, and Mg2 interfere with its activity (Al-Nabulsi & 
Holley 2005; Franklin, Cooksey & Getty 2004). To avoid this microencapsulation and controlled 
release paste-like microcapsules were incorporated by some researchers in edible whey protein 
isolates (WPI) packaging film to test the antimicrobial activity of LF against the meat spoilage 
organism Carnobacterium viridans. The growth of C. viridans was delayed at both temperatures 
and microencapsulated Lf was found to have greater antimicrobial activity than when 
unencapsulated (Al-Nabulsi & Holley 2006). A number of antiparasitic effects of lactoferrin 
have been reported, though the role of lactoferrin as an antiparasitic molecule remains ill defined, 
and mechanisms tend to be parasite specific. For the current study the in vitro and in vivo 
experiments were carried out in this study have been successful in explaining the mode of action 
of alginate gel-encapsulated ceramic nanocarriers loaded Fe- bovine Lf (AEC-CP-Fe-bLf NPs) 
preparations in the treatment of Giardia infection. Analysis of cytokine production by mice small 
intestinal tissues and spleen cells has also been done in infected and drug treated groups to check 
the host immune response on infection. In this study for the first time the efficacy of 
encapsulated Fe-Lf+ on alginate gel-encapsulated ceramic nanocarriers (AEC-CP-Fe-bLf NPs) 
as an antimicrobial agent was assessed, especially in case of giardiasis. Histopathological 
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changes in the host tissue alongwith ultrastructural studies by transmission electron microscopy 
(TEM) after infection by Giardia lamblia and treatment by various drug formulations further 
confirmed the results of efficacy of the nanoformulated drug.  
 
5.2 Materials and Methods 
5.2.1 Maintenance of culture of parasites and in vitro study: 
Trophozoites of the standard strain of Giardia lamblia, Portland 1 were maintained axenically in 
TYI-S-33 medium (Department of Parasitology, PGIMER, Chandigarh). Bovine lactoferrin in 
various forms such as native form, iron saturated (Fe-bLf), apo form (iron-depleted), was 
obtained after being prepared at Deakin University, Victoria, Australia. 
 
Trophozoites were grown axenically in TYI-S-33 medium supplemented with horse serum. After 
chilling the tubes with 48 hour growth of trophozoites, tubes were centrifuged at 500Xg for 5 
mins and washed with PBS. Then 1X107/ml trophozoites were suspended in medium without 
lactoferrin or with various forms of lactoferrin separately in different wells of a 96-well plate so 
as to get a final concentration of 200 and 400, 800, 1600, 3200 μg/ml of lactoferrin (from stock 
solution in PBS). Parasites were incubated for about 12 hours and the viability was checked by 
exclusion of Propidium iodide using Fluoroscence Microscopy. 
 
5.2.2 Preparation of endotoxin free Fe-bLf and enzyme sensitivity studies 
Endotoxin free bLf was prepared as described in Section 3.6. 
 
5.2.3 Drug Susceptibility Assay: 
Dissolving 6.4mg of Lf in 1ml of PBS made stock solution of Lf. 
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Table 5.1 Concentrations of various forms of lactoferrin used in drug susceptibility assay: 
  
 Australian bLf 
(native form) μg/ml 
Apo-bLf (μg/ml) Fe-saturated bLf 
(μg/ml) 
Different 
concentrations of Lf 
3200 3200 3200 
1600 1600 1600 
800 800 800 
400 400 400 
200 200 200 
 
 
Two Negative Controls, one with PBS and another without the drug were taken. For comparison 
of results, negative controls of culture without lactoferrin and positive controls with 
metronidazole were used. All the experiments were performed in triplicate. Various effective 
concentrations of different forms of lactoferrin were obtained at which percentage non-viability 
of the parasites were obtained. 
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5.2.4 Preparation and Characterization of alginate enclosed chitosan-calcium phosphate-
loaded Fe-bLf nanocarriers 
AEC-CP-Fe-bLf NCs were prepared by a combination of nano precipitation and ionic gelation 
methods by Kanwar and coworkers (Kanwar, Mahidhara & Kanwar 2012). The methodology for 
the same is described in section 3.7-3.16.  
 
5.2.5 Animals 
Animal experiments were performed using female BALB/c mice, aged 4 weeks, obtained from 
Central Animal House, PGIMER, Chandigarh after getting the approval of Institutional Animal 
Ethics Committee (IAEC no. 50/IAEC/240). All the guidelines of the committee were followed 
for the care and use of animals accordingly. Mice had free access to tap water and rodent chow 
and were made to undergo acclimatization for one week before any intervention. Stool 
specimens of all the animals were examined for three consecutive days to verify absence of any 
protozoan infections. Stool samples were collected by keeping single mouse in a single cage for 
2 hrs and processed by standard method. Only parasite free, mice were used for further 
experiments. 
 
5.2.6 Inoculation and development of infection of parasites in mice:  
ACNs encapsulated Fe-saturated Lf (AEC-CP-Fe-bLf NPs) form of Australian bovine Lf was 
prepared and transported by Deakin University, Australia for experiments. Cultured trophozoites 
of parasites maintained and harvested during log phase from G. lamblia, were tested for 
infectivity in various groups (Table 5.2) of suckling BALB/c mice (20-22g) after 1 week of 
postinoculation. Trophozoites were detected in 7 days of post culture mice in the test group and 
treated with diet prepared with alginate gel-encapsulated ceramic nanocarriers loaded Fe- bovine 
Lf (AEC-CP-Fe-bLf NPs) (supplemented at 1.2% w/w of the diet), bovine lactoferrin (8mg/kg 
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body weight), and the reference drug Metronidazole (20mg/kg body weight of mice) (Benere et 
al. 2011) and the results analyzed. Control mice were given the standard diet. 
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Experimental Design: 
Table 5.2 The animals were divided into groups as follows: 
Group I (n=20) : Control mice 
These mice were fed orally with 
single dose of 0.1 ml TYI-S-33 
medium using a blunt tip canula. 
 
 
Group II (n=20) : Normal mice 
 
 
Group III (n=80): Giardia 
infected mice 
These mice were fed orally with 
a single dose of 1x107/0.1ml 
Giardia trophozoites 
(Tantawiwattananon et al. 
2006). 
IIIa: 20 mice were not given any drug 
treatment. 
 
IIIb: 20 mice were fed with AEC-CP-Lf 
NPs preparations (Drug treatment group) 
 
IIIc: 20 mice were fed with bovine 
lactoferrin 
 
IIId: 20 mice were fed with 
Metronidazole 
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Table 5.3 The plan of experimental animal work according to number of days: 
 
p.i. days Infected 
group 
 
 
Group 1 
Mice fed 
with Lf 
Np’s diet 
 
Group 2 
Mice fed with 
Oral bovine 
Lf 
 
Group 3 
Mice fed with 
antibiotic 
(positive 
control: 
metronidazole) 
Group 4 
Control 
(Normal mice) 
 
 
Group 5 
7th day 5 mice 
sacrificed 
(tissues of 3 
for counting 
trophozoites, 2 
for 
Histopathology
) 
Drug 
administere
d 
Drug 
administered 
Drug 
administered 
5 mice 
sacrificed 
(tissues of 3 
for counting 
trophozoites, 2 
for 
Histopathology
) 
9th  ,, 5 mice 
sacrificed 
(tissues of 3 
for counting  
trophozoites
, 2 for 
Histopathol
ogy) 
5 mice 
sacrificed 
(tissues of 3 
for counting  
trophozoites, 2 
for 
Histopathology
) 
5 mice 
sacrificed 
(tissues of 3 for 
counting  
trophozoites, 2 
for 
Histopathology) 
,, 
14th  ,, ,, ,, ,, ,, 
Last day 
of their 
survival or 
27th day 
,, ,, ,, ,, ,, 
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5.2.7 Giardia cysts collection from stool 
Fresh stool specimens were taken from the animals of the Giardia-infected group as mentioned 
in the Table 5.3 in order to verify the presence of G. lamblia cysts. Cysts were counted by 
standard method (Vinayak, Sharma & Naik 1979). Briefly, one gram of freshly passed fecal 
samples was dissolved in 10 ml saline, homogenized using pestal morter. Cysts were counted in 
hemocytometer at higher magnification in Lugo’s iodine stained preparation. The cysts count 
was performed on every alternate day for 27 days. 
 
5.2.8 Enumeration of Giardia tropozoites in small intestine  
The tropozoites were counted in intestinal perfusate of the mice according to the method of 
Ganguly et al. (Ganguly et al. 1982). Mice were sacrificed via the retro orbital route. The entire 
small intestine was removed and flushed with a fixed amount of ice-cold normal saline. The 
material was centrifuged at 500 xg for 10 min. Giardia tropozoites were counted from the 
sediment using hemocytometer and results expressed as tropozoites per ml. 
 
5.2.9 Histopathological studies 
Tissue sample preparation: mice were sacrificed under euthanasia by cervical dislocation and 
upper part (jejunum) of small intestine was removed, fixed in 10% buffered formalin and 
processed for histological examination following the method of Shukla and Sidhu (Shukla & 
Sidhu 2011). After eosin and hematoxylin staining slides were coded without reference to prior 
treatment and examined in a blinded fashion by a pathologist as a combined score of 
inflammatory cell infiltration, tissue damage and presence of no. of parasites in infected tissues 
in tissue sections. The location of the parasite, changes in the brush border, presence or absence 
of ulceration and inflammatory changes in the lamina propria were examined. 
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5.2.10 Transmission Electron microscopy 
A part of the small intestine from each animal was collected and cut into small pieces and fixed 
in 3% glutaraldehyde with sodium cacodylate for ultrastructural study. Two hours later the 
collected intestines were transferred to 2% osmium tetraoxide, dehydrated with ascending 
concentration of alcohol and embedded in epoxy resin according to the technique of Grimaud et 
al. (Grimaud et al. 1980). Semi and ultra thin sections were cut with a leika ulta microtome. 
These sections were stained with uranyl acetate and lead citrate and examined under TEM. 
 
5.2.11 Clinical score 
A disease scoring was done according to method described earlier with slight modification 
Seigmund (Siegmund 2004). In brief, each experimental animal was examined to determine the 
degree of clinical impairment by assessing the variations in parameters like appearance of 
diarrhea, skin coat and weight besides the trophozoite and cyst count in mice (Table 5.4).  
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Table 5.4 Clinical assessments of all the above-mentioned five groups of mice. 
Parameter Score 
Fecal consistency 0 = Well-formed pellets 
1 = Pasty/semiformed stools 
2 = loose stools/watery diarrhea 
Skin Coat 0 = Normal hair coat with healthy skin 
1 = Rough hair coat 
2 = Very rough hair with loose skin 
Weight of mice 0 = Normal mice with no weight reduction 
1 = Mice with less than 15% reduction in 
weight 
2 = Mice with more than 15% reduction in 
weight (underweight) 
 
The total scores given for fecal consistency, Skin coat and Weight of mice were added and 
divided by 3 for a maximal disease score of 3. 
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5.2.12 Biodistribution of tissues 
Biodistribution and western blotting of tissues was done as per the methodology described in 
Section 3.17. 
 
5.2.13 ELISA of cytokine and nitrite production in the small intestine 
Cytokine levels in the supernatants of homogenates of the small intestine were determined using 
a a method described in section 3.19. 
 
5.2.14 Statistical Analysis 
Comparisons between groups, efficacy of the two forms of lactoferrin: native bLf and Apo-bLf 
with the negative controls (with only the PBS or media), between themselves and with the 
positive control Metronidazole against the parasite in in vitro study were undertaken using paired 
t-test. Results are expressed as Mean ± Standard Deviation (SD). Significant differences at 
various levels were thus investigated and analysis was carried out using the SPSS 16 Software. 
 
5.3 Results 
5.3.1 Giardicidal activity of Apo-Lf in vitro 
When inhibitory activities of the native and apo forms of lactoferrin were checked against 
Giardia lamblia, they were also found to be concentration dependent. Significant differences 
were also obtained in the efficacy of the two forms of lactoferrin and the reference drug 
metronidazole as compared to the negative controls with only PBS and media alone. In contrast, 
apo-bLf showed significantly higher (P <0.0005) inhibitory activity at all the concentrations 
ranging from 200 μg/ml to 3200 μg/ml as compared to native bLf (P <0.0005), which showed 
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more significant inhibition only at the highest drug concentration of 3200 μg/ml.  The 
concentration of Mz, 40μM, also significantly (P <0.0005) inhibited the parasite (Fig. 5.1). 
When the giardicidal activity of Apo-bLf and native bLf was compared to the reference drug, the 
activity of Metronidazole was significantly similar to that of Apo-bLf at 800, 1600 and 3200 
μg/ml and 1600 and 3200 μg/ml of Native-bLf. This suggests that our test drug Lf is similar in 
efficacy to the effective dose of Mz used in this study, at the lowest concentration 800 μg/ml of 
Apo-bLf. At 3200 μg/ml apo-bLf showed 92% of inhibition and native lf 90%, as compared to 
metronidazole, which also showed IC90 at the same concentration (Table 5.5). 
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Table 5.5 Minimum Inhibitory Concentration (MIC) values of different drugs: 
 
Drugs *IC50 *IC90 
Metronidazole (reference drug)    N.D 40 μM 
Apo-bLf 200 μg/ml 3200 μg/ml 
Native bLf 1600-3200 μg/ml 3200 μg/ml 
 
 
* IC50 is the 50% and IC90 is the 90% inhibitory concentration of various drugs for treatment of 
Giardia lamblia 
Results are representative of 3 experiments in triplicate 
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Figure 5.1 Comparison of Effect of Australian Native and Apo-blf on Giardia lamblia 
(Portland-1 strain) after 12 h incubation.  
 Apo Lf showed more inhibitory effect against the trophozoites of Giardia lamblia as compared 
to native Lf as observed from the non-viability %age values of the parasite. At 200μg/ml of 
concentration, native Lf showed around 20% inhibition while Apo-Lf showed around 80% 
inhibition of the parasites. Metronidazole was used as the reference drug. In all cases non-
viability was estimated using PI staining. 
 Experiments were done in triplicate; mean ± SD values were calculated. Paired, two tailed t-test 
and raw P values are used. 
** P < 0.0005 versus both Negative controls, PBS and Media only were considered to be highly 
significant. 
* P < 0.005 versus both Negative controls, PBS and Media only were considered to be 
significant. 
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5.3.2 Giardicidal activity of Fe-bLf: 
The efficacy of Fe-bLf was compared to the two negative controls with only PBS and media 
alone. Significant difference (P <0.05) was obtained only at the concentration of 200, 400 and 
800 μg/ml of Lf as compared to the negative control with PBS and at 200, 400, 800 and 1600 
μg/ml of Lf. However, at higher concentrations of the drug Lf, no significant inhibition (P <0.05) 
was observed, indicating that parasites were at their confluence at 3200 μg/ml of Fe-Lf. Fe might 
be used for growth of the parasite at this drug concentration.  As compared to the positive control 
Mz no significant difference was observed in the viability percentage values of different 
concentrations of Lf, showing that the old drug has more efficacy than Fe-Lf in killing the 
parasites (Fig. 5.2).     
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Figure 5.2 Effect of Australian Fe-blf on Giardia lamblia  (Portland-1 strain). Values are 
taken as mean ± SD.  Significant differences between the two negative controls and viability 
percentage values of two drugs were determined by using Student’s t test (P <0.05 is considered 
to be significant).  * P <0.005 versus both Negative controls, PBS and Media only were 
considered to be significant. Paired, two tailed t-test and raw P values are used. The experiments 
were done in triplicate. 
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Figure 5.3 Propidium iodide staining of the non-viable trophozoites. The non-viable 
trophozoites of G.lamblia took orange red colour when stained with propidium iodide after 12 h 
of incubation with various drugs-Apo-bLf, Native bLf and Metronidazole seen under 
Fluorescence Microscope (40X). The 2 nuclei (arrows) of the parasites are clearly observed due 
to the stain also showing the fluorescent orange colour. 
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Figure 5.4 Cysts in the feces of mice after 3 days of infection with G. lamblia observed 
under Light Microscope (40X). The ovoid shaped cysts (arrows) were clearly observed as they 
were stained yellow by iodine staining.  
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5.3.4 Preparation and characterization of AEC-CP-Fe-bLf NCs 
Dynamic light scattering (DLS) spectrometric results indicate an increase in the hydrodynamic 
size of NCs after coating with chitosan and further encapsulation using alginate. Size of the NCs 
was increased from 207 ± 39.1 nm for C-CP-Fe-bLf NCs to 344 ± 50.4 nm after complete 
formation of AEC-CP-Fe-bLf NCs. SEM results further supported the DLS data and it also 
determined the spherical morphology of NCs, which conveys the advantage in transporting the 
anticancer protein to the cancer tissue via mucosal, gastric and subsequent systemic circulation. 
These results are taken from the previous study by Kanwar and coworkers (Kanwar, Mahidhara 
& Kanwar 2012).    
   
5.3.5 In vitro cellular uptake of bLf loaded on AEC-CP-Fe-bLf NCs 
When the stability of AEC-CP-Fe-bLf NCs after treatment with HCl pH 1.2 and with PBS at pH 
7.4, for different time intervals from 1 to 6 h, was investigated it was found that the percentage 
cumulative release of bLf was low in acidic buffer whereas the amount of protein released from 
the NC’s in the alkaline pH was increased (Fig. 5.5). These calorimetrical results had been 
proved by SDS-PAGE and western blotting where more intense bands were observed from 4h of 
incubation time in alkaline medium representing the release of C-CP-Fe-bLf NCs by dissolution 
of outer alginate covering compared with acidic pH where no Fe-bLf-specific bands were 
observed until 6h of incubation time.     
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Figure 5.5  In vitro release profile of bLf and in vivo stability of Fe-bLf and AEC-CP-Fe-
bLf NCs: (A) Release profiles of Fe-bLf in various buffers at (i) low pH 1.5 (as observed in the 
stomach) to (ii) pH 8 (as in the intestine) were analyzed. Percentage cumulative release of bLf 
was low in acidic buffer whereas the amount of protein released from the NCs in the alkaline pH 
was increased. Data represents mean ± SEM Experiments were repeated 3times independently 
with similar results. 
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5.3.6 Availability of AEC-CP-Fe-bLf NCs in plasma upon oral feeding 
In vivo stability of Fe-bLf and rhodamine loaded AEC-CP-Fe-bLf NCs nanoparticles in mouse 
plasma after feeding was carried out.  Blood samples were found to be positive for rhodamine 
fluorescence in AEC-CP-Fe-bLf treated mice as compared with control suggesting that AEC-CP-
Fe-bLf NCs could enter the blood circulation without effecting the gut epithelial cell layer 
(Kanwar, Mahidhara & Kanwar 2012).    
 
5.3.7 Pharmacokinetic study after oral administration of Fe-bLf and AEC-CP-Fe-bLf NCs: 
The feasibility of using AEC-CP-Fe-bLf NCs as an efficient carrier, to improve the 
bioavailability of Fe-bLf when delivered orally, was investigated. As shown in the Table 5.6 on 
oral feeding of Fe-bLf at a dose of 100mg/kg body weight to mice the maximum concentration 
of Fe-bLf (Cmax ) could be detected in the blood at 3 h post feeding. In contrast when the same 
amount of Fe-bLf bound to chitosan NPs was fed to animals the Cmax was detected in the blood at 
8h. Figure 5.6 shows the mean Fe-bLf concentration in plasma at different time-points after oral 
administration. Oral delivery through chitosan nanoparticals ensured a sustain release of Fe-bLf 
over 10 days post feeding, whereas in case of Fe-bLf alone the levels declined after 3h and were 
not detectable beyond 12h.  
 
Table 5.6 Pharmacokinetic parameters of Fe-bLf and AEC-CP-Fe-bLf NCs 
 
Formulation Fe-bLf Dose (mg/Kg body Wt 
of mice) 
Cmax (ng/ml) Tmax (h) 
Fe-bLf 100 560 ± 40 3 
AEC-CCo-CP-Fe-
bLf NCs 
100 1200 ± 80 8 
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Figure 5.6 In vivo stability of Fe-bLf and rhodamine loaded AEC-CP-Fe-bLf NCs 
nanoparticles in mouse plasma after feeding was carried out. Chitosan nanoparticles showed 
a sustained release of Fe-blf for 10 days when mice were fed orally while in case of Fe-bLf alone 
the levels declined after 3h and were not detectable beyond 12h. 
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5.3.8 Rise in parasitemia and drug treatment in mice 
Inoculation of 107 trophozoites of Giardia lamblia (Portland 1) to suckling BALB/c mice 
resulted in infection in all the animals. The maximum trophozoite and cyst counts were obtained 
on day 7 post infection and thereafter the counts started declining. By day 27 infection had 
cleared up in most of the animals, however a few trophozoites and cysts could still be detected in 
some animals.    
Animals of the control group did not eliminate cysts or trophozoites during the experimental 
period. 
 
a) Enumeration of Giardia cysts in feces 
The cyst load was least from the beginning, i.e., from day 3 onwards, in mice (Giardia-infected). 
Excretion of cysts in feces (Fig. 5.4) increased gradually on day 7 post inoculation in all the 
groups of mice. The period of maximum cyst release was between days 7 and 11 of infection and 
after day 11 declines in number of cysts was observed in the infected group. Mice became 
Giardia free by day 9-post infection or after 2 days of treatment with the drug (AEC-CP-Fe-bLf 
NPs preparations) whereas the infectivity period was much more prolonged (Fig. 5.7) and cyst 
count was much higher from the beginning in the Giardia-infected group.  
 
 
Whereas when the bovine lactoferrin treated group and metronidazole treated group was 
observed for the presence of cysts, there were few numbers till 11th day of infection or 4 days of 
drug treatment and no cysts were seen thereafter.  
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Figure 5.7 Cyst counts in the small intestine of mice belonging to different groups. The cyst 
count reached peak after 7 days of infection with 1x107/0.1ml trophozoites of Giardia lamblia in 
the infected group. The infection resolves thereafter 27 days post infection. With the treatment of 
nanoformulated Lf, mice became Giardia free within 2 days or 9 days p.i. but when bovine 
lactoferrin was administered to the infected mice, the cyst count diminished within 4 days of 
treatment or 11 days post infection. Values are represented as mean ± SD.  
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b) Enumeration of Giardia trophozoites in small intestine of mice 
Oral inoculation of mice with Giardia trophozoites resulted in the establishment of infection as 
assessed by the number of trophozoites counted in jejunum and cysts count in feces after 7 days. 
The number of trophozoites increased following Giardia infection in Giardia-infected mice as 
compared to the drug treated group of mice (Fig.5.8) at all the studied time points. 
 
Thus no trophozoites or cysts were recovered from the mice after 2 days of treatment with 
nanoformulated Lf as compared to bLf and metronidazole. 
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Figure 5.8 Trophozoite counts in the small intestine of mice belonging to different groups. 
The trophozoites were found in the infected (inoculated with 1x107/0.1ml of trophozoites of 
Giardia lamblia) group of mice 7 days post infection and their maximum numbers were found 
on the same day. The mice fed with nanoformulated lactoferrin diet were cleared of infection 
after 2 days of administration of the drug. When the test drugs, bovine Lf and metronidazole 
were administered to mice trophozoites were eliminated within 4 days of treatment or 11 days of 
infection with the parasite. But in the infected group the infection resolved only after 27 days 
post infection. Values are presented as mean ± SD. 
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5.3.9 Histopathology results of treatment (with Australian bovine Lf loaded on NPs)  
By comparing the infection rate (Table 5.7) in the Giardia infected group with normal mice and 
the drug treated group, a maximum histopathological score of +1 was observed in the infected 
group on 7th, and +3 on 9th and 13th day post infection. The score declined in the nanoformulated 
Lf treated group. The results of the histopathological examination of the intestinal tissue sections 
of infected mice suggest that Giardia lamblia can alter the architecture of the intestinal mucosa 
through hyperplasia of the crypts and atrophy of the villi. Mild infiltration of 
lymphomononuclear in the lamina propria along with the vacuolated epithelial cells and reduced 
goblet cells is also observed (Table 5.8). Infected animals demonstrated impaired weight gain 
and reduced jejunal villus:crypt ratio. Reduction in v:c ratio was maximal between 7 and 9 days 
of post infection. The mid jejunum contained the highest trophozoite counts and significant 
pathological abnormalities (Fig. 5.9 C-F). As compared to normal mice in control group ileum 
shows normal villi and normal brush border cells and goblet cells (Fig. 5.9 A and B). The 
morphology of intestine became normal after 2 days (Fig. 5.9 E and F) of treatment of infected 
mice with the diet prepared with encapsulated Fe-saturated lactoferrin on alginate gel-
encapsulated ceramic nanocarriers (AEC-CP-bLf NPs) and completely normal in 9 days (Fig. 5.9 
I and J) of treatment with this drug after elimination of the parasites. After 21 days (Fig. 5.9 K 
and L) of drug treatment it was observed that no recurrence of infection had occurred due to 
Giardia, and the small intestinal tissues of mice showed normal pathological profile. 
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Figure 5.9 Photomicrographs of the histopathological analysis  of small imtestinal tissues of 
mice belonging to different groups. (A) Photomicrograph of the small intestine of normal mice 
in the control group (H and E, 40X). (B) Photomicrograph of higher magnification (H and E, 
200X) of the small intestine of normal mice in the control group. The ileum shows long, normal 
villi, lining cells including the brush border and goblet cells are normal. (C) The villi show mild 
excess of LMN cells, occasional villous is swollen, lining cells are normal, some crypts show 
paneth cell hyperplasia, and surface shows presence of parasites (H and E, 40 X). (D) 
Photomicrograph of higher magnification (H and E, 200X) of the small intestine of mice in the 
infected group. (E) Photomicrograph of higher magnification (H and E, 400X) of the small 
intestine of mice in the infected group. Higher magnification highlights the parasites (arrow). (F) 
Photomicrograph of the small intestine of mice of the Giardia infected group after 7days of 
infection. Arrow shows the trophozoites along the brush border of small intestine of infected 
mice (H and E, 400X). (G) Photomicrograph of the small intestine of mice of the 
Nanoformulated Lf treated group after (9days of infection and) 2 days of drug treatment. (H and 
E, 40X). (H) Photomicrograph of higher magnification (H and E 200X) of the small intestine of 
mice of the Nanoformulated Lf treated group after 2 days of drug treatment. Section of ileum, 
long parallel villi show mild LMN cells, the epithelial cells (arrow) appear somewhat vacuolated. 
(I) Photomicrograph of the small intestine of mice of the Giardia infected group after 14 days of 
infection and 7 days of drug treatment. (H and E, 40X). (J) Photomicrograph of higher 
magnification (H and E, 200X) of the small intestine of mice of the Giardia infected group after 
14 days of infection and 7 days of drug treatment. Illeal villi, more or less normal with very few 
cells (arrow) in lamina propria. (K) Photomicrograph of the small intestine of mice of the 
Giardia infected group after 27days of infection and 21 days of drug treatment. (H and E, 40X). 
(L) Photomicrograph of higher magnification (H and E, 200X) of the small intestine of mice of 
the Giardia infected group after 27days of infection and 21 days of drug treatment. 
 
 
Table 5.7 Histopathological analysis  of small intestinal tissues of mice, after each 
dissection: 
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Giardia infected 
group 
Infection rate 
(Days post infection) 
 
07 days post 
infection. 
09 days post 
infection. 
(i.e. two days 
after start of 
drug treatment) 
14 days post 
infection. 
27 days post 
infection. 
Normal mice (no 
infection) 
0 0 0 0 
Mice (with 
infection), but not 
treated 
1+ 3+ 3+ 0 
Mice with 
treatment 
Drug 
administered 
0 0 0 
 
 
 
Scoring: Indicates the quantum of infection by Giardia lamblia in the mice. A pathologist 
performed the score in a blinded manner. 
 
Table 5.8 Results of Histopathological analysis: 
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Animals Lymphomononuclear 
Cells 
Epithelial Cells Parasites 
Control 20 Average - 
Infected group 20-30 Average + 
Drug treated 
group (2 days of 
drug treatment) 
20-30 Average - 
Drug treated 
group (7 days of 
drug treatment) 
10-20  - 
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5.3.9 TEM results of treatment (with Australian bovine Lf loaded on NPs) 
Sections of small intestine of infected mice were processed for ultrastructural alternations. 
Transmission electron microscopy showed the presence of trophozoites of Giardia at higher 
magnification of 27800X (Fig. 5.10) and 36000X (Fig. 5.11) in the Giardia infected group of 
mice. 
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Figure 5.10 Transmission electron micrograph of the small intestine of Giardia infected 
mouse on day 7-post infection showing the presence of trophozoite (arrow). Magnification 
27800X. 
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Figure 5.11 Higher magnification 36000X of Transmission electron micrograph (TEM) of 
the small intestine of Giardia infected mouse on day 7-post infection showing the presence 
of trophozoite (arrow). 
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5.3.10 Clinical response in Giardia infected mice and treated groups 
In the series of in vivo experiments we determined the extent of clinical involvement in BALB/c 
mice using a grading scale that we developed for this study. It can be seen that the severity of 
clinical impairment was much higher in Giardia infected BALB/c mice than the treated mice. 
Thus the mice treated with nanoformulated bLf were more clinically improved as compared to 
bLf treated and metronidazole treated groups (Fig. 5.12). 
 
The cyst and trophozoite score also diminished in the nanoformulated group after 2 days of 
treatment but in the bLf treated and metronidazole treated group the trophozoite and cyst score 
declined only after 7 days of treatment or 14 days post infection and persisted in the infected 
group with no drug treatment. 
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Figure 5.12 Clinical score of mice in different groups. Clinical score was awarded by taking 
the mean values of the scores of the parameters: appearance of diarrhea (fecal consistency), skin 
coat and weight of mice and comparison was done in the (a) Giardia infected and (b) 
Nanoformulated Lf groups (c) Metronidazole treated groups (d) Bovine lactoferrin treated 
groups (e) Normal mice.  
The score was less in the Nanoformulated Lf treated group of mice as compared to 
Metronidazole and bLf treated groups and the Giardia infected group as is observed clearly from 
the graph. 
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5.3.11 Blood Haematological profile, serum iron and serum calcium of mice 
When the serum iron, calcium and blood haematological profile of control and experimental 
mice with nanoformulated and control diets were measured, it was observed that the 
conventional drug Metronidazole caused haematological suppression and anaemia. While the Fe-
bLf and nanoformulated diet completely restored the numbers of RBC’s, Haemoglobin level, 
haemocrit level, reticulocytes, liver and spleen Fe, reticulocyte haemoglobin content, Serum iron 
and calcium such that blood cell numbers were upto 50% greater than those of mice fed with 
control diets (Table 5.9). 
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Table 5.9 Serum iron, serum calcium and blood haematological profile of control and 
experimental mice with nanoformulated diet and control diets. 
Organ/cells       Fe-bLf  Metronidazole AEC-CP-Fe-bLf 
NCs diet 
Control nano 
diet  
Haemoglobin level 
(g/dL) 
15.6r 0.5 10.2r 1.5 20.6r 0.5 15.6r 0.5 
Haematocrit level (%) 52.5r 2.5 31.5r 2.1 59.5r 2.2 52.5r 2.5 
Liver Fe (μg/g) 85r 15 52.6r 8 102r 18 70r 21 
Spleen Fe (μg/g) 182r 21 120r 10 185r 22 157r 15 
RBCs (x106/mm3)a  9.2 r 2.5** 3.1 r 1.5 9.0 r 2.2** 4.5 r 1.5 
Reticulocytes, x 109 
cells/L 
415r22 230r24 428r28 359r18 
Reticulocyte 
Haemoglobin content, 
pg 
24r5 12r5 28r6 15r4 
Serum iron  (μg/g) 172r 28** 95r 15 223r 32** 155r 20 
Serum calcium (mg/dl) 9.9±0.8 5.5±1.5 14.2±1.5** 8.5±1.8 
 
aMean values of red blood cell (RBC) counts were recorded in blood samples collected directly 
from the heart at the time of autopsy.  
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5.3.12 Biodistribution of AEC-CP-Fe-bLf NCs in the tissue lysates in mice 
After 7 days of treatment of the infected mice with nanoformulated diet, the concentration of Fe-
bLf in the tissue lysates was studied. The concentration of Fe-bLf was found more in the mice 
fed with AEC-CP-Fe-bLf NCs as compared to mice fed with only Fe-bLf. These concentrations 
were found in the vital tissues, small intestine, liver, spleen and blood (Fig. 5.13).     
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Figure 5.13 Biodistribution study of lactoferrin in tissue lysates of mice after oral 
administration in diet. When the concentration of AEC-CP-Fe-bLf NCs in the tissue lysates 
was studied in the Giardia infected tissues of mice after 7 days of treatment with this drug as 
compared to Fe-bLf alone, maximum concentration of nanoformulated Lf was observed in the 
tissues, mainly the vital tissues of Giardia colonization i.e. Small intestine, Blood, liver etc. 
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5.3.13 Cytokine response by mice tissues (small intestine) 
Immune system consists of innate and adaptive immunity. The innate response in case of 
Giardia-infected group, Metronidazole-treated group, bLf-treated group and nanoformulated Lf-
treated group was initiated by the production of cytokines (Fig. 5.14), IL-1, IL-6, IL-10, IL-12, 
IL-15, IL-18, IL-23, IL-27, IFN-1α, IFN-1β and IFN-III (Table 5.10). IL-6 showed enhanced 
production to 1.7 and 1.4 fold significantly in case of nanoformulated group and bLf-treated 
group respectively as compared to normal mice and the Giardia-infected mice.  
 
Significant increased levels of IL-12 were also observed in the nanoformulated Lf and bLf-
treated mice to 1.4 and 1.3 fold respectively as compared to normal mice. In contrast the 
Giardia-infected and Mz-treated mice showed significant decrease in the production of this 
cytokine to 2.1 and 2.5 fold respectively as compared to the normal mice.  
 
IL-15 showed almost twice the significant increase in levels in the nanoformulated-Lf and bLf-
treated mice as compared to normal mice, and decrease in levels to 1.4 and 2 fold in the infected 
and Mz treated group. Similarly, significant increase in level of IL-18 was also observed in the 
nanoformulated-Lf and bLf-treated mice while the levels decreased in infected group and Mz 
treated group. Almost twice in increase in the levels of IL-23 were found significantly in 
nanoformulated-Lf, bLf-treated and Mz-treated mice as compared to control mice, while the 
infected group showed a decrease to 1.3 fold.  Similarly the levels of IL-27, IFN-1α and IFN-III  
increased significantly in the nanoformulated-Lf and bLf-treated mice and their levels declined 
in the infected and the Mz-treated group of mice but in case of IFN-1β the level increased in the  
nanoformulated-Lf and bLf-treated groups of mice only. 
 
The cytokines that led to adaptive immunity in mice in various groups were IL-2, IL-4, IL-5, IL-
13, IL-17 and IFN-γ (Table 5.11). There was drastic increase in the level of IL-2 significantly to 
8.75 and 10.1 fold in the nanoformulated-Lf and bLf treated groups as compared to normal mice. 
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In comparison to infected group also enhanced production of IL-2 was observed in the above 
mentioned treatment groups of mice. Similar trend was observed in case of IL-4. 
 
In case of IL-5, increased production was observed significantly in all the groups of mice as 
compared to normal mice. Similar increase in the levels of IL-17 were observed in the all the 
groups of mice except the Mz-treated group as compared to normal mice. In contrast, IL-13 
showed significant increase in level only in the nanoformulated-Lf and bLf treated groups as 
compared to normal mice. So the infected and the Mz treated group of mice showed decrease in 
the level of IL-13.  
 
There was 5, 4 and 1.6-fold significant increase in the levels of  IFN-γ in the nanoformulated-Lf, 
bLf treated and infected group of mice as compared to normal mice but metronidazole treated 
group showed decrease in level of IFN-γ.  
 
The cytokines related to haemopoiesis are IL-3, IL-7, IL-9, IL-11, G-CSF, M-CSF and GM-CSF 
(Table 5.12). IL-3 and IL-7 showed significant increase in their levels in the nanoformulated Lf 
and bLf treated groups of mice as compared to normal mice. In contrast there was decrease in the 
levels of both these cytokines in the infected and metronidazole treated groups of mice.  
 
The level of IL-9 increased significantly in all the groups of mice as compared to normal mice. 
The level of IL-11 increased significantly in the infected group of mice to 1.3 fold and remained 
the same as normal mice in the nanoformulated Lf and bLf treated groups of mice but decreased 
in the metronidazole treated group compared to normal mice. 
 
M-CSF and GM-CSF showed enhanced production significantly in the nanoformulated Lf and 
bLf treated groups of mice as compared to normal mice but their levels declined in the infected 
group and metronidazole treated group of mice. In case of G-CSF slight increase in the levels of 
metronidazole and infected groups of mice was observed while the nanoformulated and bLf 
treated groups showed higher increase in the levels to 9 and 6-fold respectively.  
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Other cytokines and cytokines of Th17 differentiation and activation of immune cells for 
immune responses and inflammation were IL-1β, IL-17A, IL-17F, IL-21, IL-22, IL-26, IL-35, 
TGF-β and TNF-α (Table 5.13). The levels of IL-1β rose to 2.6, 1.8 and 1.2 fold significantly in 
the infected, metronidazole treated and bLf treated group of mice as compared to normal mice 
while its level remained the same in nanoformulated Lf treated mice. 
 
When the level of IL-17A was detected in all the groups of mice, it remained the same in 
infected and metronidazole treated groups but the Nanoformulated Lf treated and bLf treated 
groups showed a significant increase in levels to about 4 times when compared to normal mice. 
In case of IL-17F, inceased levels of cytokines were found significantly in the metronidazole 
treated group, nanoformulated Lf and bLf treated groups of mice as compared to normal mice 
but the level of IL-17F decreased in the infected group as compared to normal mice.            
 
The levels of IL-21 increased significantly almost 2 fold in the nanoformulated Lf and bLf 
treated groups as compared to normal and infected mice and decreased in the metronidazole 
treated group. IL-22 showed significant increase in the level in the nanoformulated Lf, bLf and 
metronidazole treated groups as compared to normal mice and infected group of mice. Increase 
in the levels of IL-26 was observed significantly in all the groups of mice as compared to normal 
mice. The levels of IL-35 decreased significantly in all the treatment groups of mice as compared 
to normal and infected group of mice. 
 
Nanoformulated Lf and bLf treatments in mice decreased the levels of TGF-β while enhanced 
production in the infected group was observed as compared to normal mice. Significant increase 
in the levels of TNF-α was observed in the infected group of mice as compared to control but its 
level decreased on treatment with nanoformulated Lf and bLf, but its level remained high in 
metronidazole treated group. 
 
The level of NO production increased significantly in all the groups 1.3 fold in the Mz and 
infected groups and decreased in the nanoformulated Lf and bLf treated groups of mice as 
compared to normal mice.  
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Enhanced production of  CD4+ cells were also found in the small intestine in all the groups of 
mice except the metronidazole treated group as compared to normal mice (Fig. 5.16). 
Proliferation of CD8+ cells was also observed in the infected groups but reduced levels of these 
cells were observed in the metronidazole and nanoformulated Lf treated groups. NK and 
dendritic cells were increased in the treated groups of mice.     
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Figure 5.14 The levels of cytokines in the small intestine of mice after treatment of Giardia 
infected mice by Fe-bLf, Nanoformulated bLf and Metronidazole as compared to the 
control diet. Results are expressed as mean concentration (pg/ml) for the cytokines. 
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Table 5.10 The cytokines of innate immunity 
Cytokines 
(μM) 
bLf Group Nano Fe-
bLf  
Met-drug 
Group 
Infected 
Group 
Normal diet  
IL-1beta 12±3 10±3 18±4 26±4 10±2 
IL-6 431±58 500±89 300±42 300±42 300±25 
IL-18 70±10 55±8 25±5 20±5 50±5 
IL-12 320±50 353±50 100±10 120±10 250±20 
IL-15 22±5 20±5 5±2 6±2 10±3 
IL-23 15±3 18±6 15±5 5±2 8±2 
IL-27 17±5 16±5 5±2 6±2 10±3 
IL-10 235±35 221±23 341±67 441±67 234±21 
INF-1 alpha 22±5 32±5 5±2 6±2 10±3 
INF-1 beta 14±5 12±5 5±2 6±2 6±2 
INF-III 21±5 22±5 5±2 6±2 8±3 
 
 
Table 5.11 The cytokines of adaptive immunity 
Cytokines 
(μM) 
Fe-bLf 
Group 
Nano Fe-
bLf Group 
Met-drug 
Group 
Infected 
Group 
Normal diet 
Group 
IL-2 210±15 175±12 15±5 15±5 20±5 
IL-4 44±12 45±10 10±3 12±5 14±6 
IL-5 26±6 25±8 15±7 15±7 8±3 
IL-13 17±5 16±5 5±2 6±2 10±3 
IL-17 10±3 10±5 2±1 5±2 3±1 
IFN-gamma 12±2 15±4 2±1 5±3 3±2 
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Table 5.12The cytokines of haemopoiesis 
Cytokines 
(μM) 
Fe-bLf 
Group 
Nano Fe-bLf 
Group 
Met-drug 
Group 
Infected Gp Normal diet 
Group 
IL-3 15±5 12±5 5±2 6±2 10±3 
IL-7 17±5 16±5 5±2 6±2 10±3 
IL-11 10±5 10±5 5±2 13±5 10±3 
GM-CSF 22±5 26±5 5±2 6±2 10±3 
IL-9 40±2 30±6 16±5 16±5 12±5 
M-CSF 25±4 28±6 5±2 5±2 8±3 
G-CSF 30±5 45±5 6±2 6±2 5±2 
 
 
Table 5.13 Other cytokines and cytokines of TH17 differentiation and activation of immune 
cells for immune responses and inflammation 
Cytokines 
(μM) 
Fe-bLf 
Group 
Nano Fe-
bLf Group 
Met-drug 
Group 
Infected 
Group 
Normal diet 
Group 
NO 5±2 5±2 12±4 12±4 9±3 
IL-17A 22±5 22±8 5±2 5±2 5±2 
IL-17F 30±4 47±11 24±6 14±5 22±5 
IL-26 32±5 35±6 16±5 16±5 12±5 
IL-22 30±5 35±6 12±5 8±4 10±2 
IL-21 17±5 16±5 5±2 6±3 8±2 
IL-35 5±2 4±2 5±2 12±2 8±3 
TGF-beta 5±2 5±2 16±5 22±5 15±4 
TNF-alpha 10±3 12±4 25±5 30±6 15±4 
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5.3.14 Cytokine response by spleen 
Our results suggest that T cell responses are required for elimination of infection. IFN-γ was the 
dominant cytokine produced by splenocytes in response to infection. Considering the essential 
roles of CD4+ cells in resolving the infection we found that they were the major cytokine 
secreting cells and produced predominantly in the infected group and three Lf treated -bLf, Fe-
bLf and nanoformulated Lf groups of mice. Activation of dendritic cells was observed. The level 
of IFN-γ increased to 1.7 fold in the Mz treated group, 6 fold in the bLf , 7.3 fold in the Fe-bLf 
treated and 6.7 fold in the nanoformulated treated groups as compared to the controls- mice fed 
with normal diet and mice fed with nano-diet with no previous infection (Fig. 5.15).    
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Figure 5.15 The levels of cytokines in the spleen of mice after treatment of Giardia infected 
mice by Fe-bLf, Nanoformulated bLf and Metronidazole as compared to the control diet. 
Results are expressed as mean concentration (micromolar) for the cytokines and NO. 
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Chapter 6: Antimicrobial activity of nanoformulated lactoferrin against Salmonella 
typhimurium 
6.1 Introduction 
Salmonella typhimurium, a gram negative, rod-shaped facultative anaerobic bacterium, is a major 
food borne pathogen, causes gastroenteritis in humans and animals. It can induce enteric fever in 
mouse models when infected with this bacterium, with symptoms similar to those observed in 
humans after infection with S. typhi. The pathogen S. typhimurium is responsible for causing 
systemic infection in humans, mainly in children younger than 2 years of age (Foley et al. 2006). 
The infection is characterized by enterocolitis, invasion of the liver, the spleen and finally the 
brain (Mosquito et al. 2010; Wickham et al. 2007) (Fig. 6.1). Salmonella infections cause an 
estimated 1.4 million human illnesses and 400 deaths annually in the United States. In 2007, 
there were 9,484 cases of Salmonella infection, a rate of 45 cases per 100,000 population, which 
is a 15% increase over the mean of the previous 5 years. In 2007, the most commonly notified 
Salmonella serotype was S. typhimurium (Liu et al. 2009). 
 
Salmonella strains show resistance to quinolones and some β-lactams (Diridl, Pichler & Wolf 
1986; Pichler, Diridl & Wolf 1986; Piddock 2006). The in vitro antimicrobial properties of 
Ciprofloxacin are promising, so the efficacy of this compound was studied in vivo after mice 
were found to be susceptible to Salmonella. The drug was administered orally in normal and 
immunocompromised mice (Brunner & Zeiler 1988). However research has shown that, despite 
the antimicrobial therapy, the morbidity and mortality due to salmonellosis is high, partially 
because of the ability of the bacteria to develop resistance to virtually all antibiotics. Moreover 
the emergence of multidrug resistant strains (Shinagawa et al. 2005), overuse of drugs, their side 
effects and chronic toxicity (Dundas et al. 1999), damage to normal flora of the host (Rishi et al. 
2009; Rishi, Preet & Kaur 2011) all pose a challenge for modern medicine. Therefore there is 
clearly a need for new strategies to identify and develop the next generation of drugs to control 
bacterial infections.  
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In this context, safe therapeutic agents like a natural compound lactoferrin secreted in most 
mammalian external fluids (Gupta et al. 2009; Kanwar et al. 2009) was explored and found to 
exhibit bacteriostatic and bactericidal activity against a number of gram positive and gram 
negative bacteria (Bullen 1976; Murdock et al. 2007). A recent study supports the protective role 
of bLf against the Salmonella infection, reducing the severity, mortality and the degree of 
inflammation of this infection in mice (Mosquito et al. 2010). The findings by Drago-Serrano et 
al. (Drago-Serrano et al. 2010) suggested that the effect of bLf against the infection by S. 
typhimurium in mice might be the result of an antimicrobial activity linked with its modulatory 
effect on immunocompetent cells (from intestinal and peripheral organs) involved in antibody 
production. In the present study, bLf effectively eliminated bacterial infection due to S. 
typhimurium within 6 days of its administration to BALB/c mice. 
 
Mechanisms of pathogenesis and immunity operating in Salmonella infections need to be 
elucidated for a more rational approach to the treatment of the disease. Several cytokines like 
TNF-α, IL-12 and IFN-γ play a crucial role in the early resistance to salmonellosis in mice 
(Mastroeni et al. 1999). We assessed all the cytokines induced in response to Salmonella, which 
led to early host response and development of resistance to infection. 
 
Recent advantages in the field of nanotechnology have led to the development of new biocidal 
agents. Nowadays, nanotechnology offers the opportunity to fight microbial infections via the 
synthesis of nanoparticles (Ranjan et al. 2012). Moreover, it has been suggested that for 
complete clearance of intracellular bacteria like Salmonella the drug molecules should target the 
subcellular niche where the microbe resides. The application of nanomedicine for antibacterial 
therapy can sustain drug release over time, increase solubility and bioavailability and improve 
efficacy (Ranjan et al. 2012). The advances in nanotechnology were explored to protect the 
active biological conformation and structure of the biomacromolecules in the tough conditions of 
the GI tract (Kanwar, Mahidhara & Kanwar 2012). 
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Figure 6.1 Pathogenesis of Salmonella typhimurium. The invasion of bacteria to the secondary 
organs liver, spleen and lymph nodes occurs after it colonizes the small intestine after ingestion. 
Its persistence in these organs leads to suppresion of immune system. Salmonella modulates 
Dendritic cell (DC) migration in systemic tissues (Monack 2012). 
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Considerable interest has been found in the use of nano-carrier based oral formulation for 
anticancer drug delivery (Benny et al. 2008; Feng et al. 2009; Zhang et al. 2006). In the previous 
study by Kanwar and coworkers (Kanwar, Mahidhara & Kanwar 2012), in vitro and in vivo 
anticancer activities were evaluated and was found that AEC-CP-Fe-bLf NPs obtained spherical 
morphology and showed enhanced endocytosis, transcytosis and anticancer activity in Caco-2 
cells in vitro. When this diet of nanoformulated Lf was fed to mice orally as prevention and 
treatment both, none of the mice developed tumour or showed any signs of toxicity. These 
researchers showed that the AEC-CP-Fe-bLf NPs provided protection on the GI tract against 
degradation because of the alginate coat, further improving the biodegradability of the 
nanoformulation.  
 
Thus our investigation was aimed at examining whether oral administration of alginate gel-
encapsulated ceramic nanocarriers loaded Fe- bovine Lf (bLf) (AEC-CP-Fe-bLf NPs) to BALB/c 
mice, would be effective in completely eradicating the Salmonella infection as compared to old 
drugs like Ciprofloxacin. The present study is the first demonstration reported so far of the 
microbicidal activity of the nanoformulated drug that also correlated well with the biochemical 
and histopathological findings showing the efficacy of this drug. 
 
6.2 Materials and methods: 
6.2.1 Bacterial strain   
Salmonella typhimurium (ATCC-14028, wild strain), a pathogenic strain (Drago-Serrano et al. 
2010; Sofi et al. 2007) was taken from Department of Microbiology, PGIMER, Chandigarh, 
India. Bacteria were checked for their viability by plating them on Mac Conkey Agar plate. The 
strain was confirmed by serotyping. The bacterial colony was identified by slide agglutination 
with the use of commercially available antisera to somatic (O) and flagellum (H) antigens. 
Various biochemical tests were also done to confirm the strain prior to storage and use. 
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6.2.2 In vitro assay for Minimum Inhibitory Concentration (MIC): 
Agar plates for drug susceptibility assay were prepared for Salmonella by dissolving various 
drug concentrations of bovine lactoferrin (bLf) in the agar medium (Mac Conkey Agar) to get 
their final concentrations of 200, 400, 800, 1600 and 3200 μg/ml in triplicate i.e. three plates for 
each drug concentration. Also three plates were taken as positive control with Ciprofloxacin as 
the reference drug and three plates were taken as the negative control without any drug. The 
plates were incubated overnight at 37ºC to check for any bacterial growth. 
 
The next day by following the standardized method for bacterial counting, one colony of 
Salmonella typhimurium was suspended in 5ml of peptone water for 6hrs. and after that O.D. of 
bacterial suspension at 590nm was calculated when they were in the logarithmic phase and 
various dilutions (1/10, 1/102, 1/104, 1/106 , 1/108 , 1/109 , 1/1010 ) per ml of bacteria were made. 
The dilution (1/109) per ml of bacteria at which countable colonies were obtained when they 
were plated on MacConkry agar, was standardized for the drug assay and 20μl of that suspension 
was added to the above agar plates with various drugs and without drug and incubated overnight 
at 37ºC to calculate the MIC values the next day (Shukla, Verma & Sharma 2012).   
 
6.2.3 In vivo assay: 
The experimental animals, 100 female BALB/c mice between 6-8 weeks of age, weight around 
22 and 25g, were obtained from Central Animal House, PGIMER, Chandigarh after getting the 
animal ethics approval from Institutional Animal Ethics Committee (IAEC no. 
47/1999/CPCSEA). All the guidelines of the committee were followed for the care and use of 
animals accordingly. Animals were inoculated with about 200μl of 108 CFU/ml (0.1 OD590, 1 X 
108 CFU/ml) suspension in normal saline of log-growth-phase Salmonella typhimurium orally 
with a gavage needle (Allen et al. 2001; Hohmann, Schmidt & Rowley 1978; Lockman & 
Curtiss 1990; Sharma & Agrewala 2004; Sukupolvi et al. 1997; Zhang et al. 2003). Fecal pellets 
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of mice were weighed, homogenized in 1ml PBS, plated on appropriate agar plates to determine 
CFU/mg of feces to check the infection on first and second day post infection. 
 
As soon as the infection was established on the third day post infection bacterial count in organs 
was done. For this 5 mice were sacrificed. Organs (Spleen, liver, small intestine, brain, kidney, 
and mesenteric lymph nodes) were removed and checked for bacterial load by homogenizing 
them and plating. Cardiac puncture was performed for blood cultures. Tissues of these organs 
were collected for histopathology. Serum was collected from infected mice and growth of 
bacteria was checked by plating them. Biochemical tests and serotyping further confirmed the 
results. 
3 groups of mice were given drug treatment after 3 days of infection (5 mice in each group): 
1st group: 16mg/kg body weight of dose of ciprofloxacin administered to each infected mice. 
(positive control)  
2nd group: 8 mg/kg body weight of dose of Australian bovine Lf administered to each 
infected mice. (positive control) 
3rd group: infected mice fed with nanoformulated Lf. 
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Table 6.1 Experimental design for the division of animals into different groups: 
p.i. 
day
s 
Infected 
group 
 
 
Group 1 
Mice fed 
with Lf Np’s 
diet 
 
Group 2 
Mice fed with 
Oral bovine 
Lf 
 
Group 3 
Mice fed with 
antibiotic 
(positive 
control: 
ciprofloxacin) 
Group 4 
Control (Normal 
mice) 
 
 
Group 5 
3rd 
day 
5 mice 
sacrificed 
(tissues of 3 
for counting 
bacteria, 2 for 
Histopatholog
y) 
Drug 
administered 
Drug 
administered 
Drug 
administered 
5 mice sacrificed 
(tissues of 3 for 
counting bacteria, 
2 for 
Histopathology) 
6th ,, 5 mice 
sacrificed 
(tissues of 3 
for counting 
bacteria, 2 
for 
Histopatholo
gy) 
5 mice 
sacrificed 
(tissues of 3 
for counting 
bacteria, 2 for 
Histopatholog
y) 
5 mice 
sacrificed 
(tissues of 3 
for counting 
bacteria, 2 for 
Histopathology
) 
,, 
10th ,, ,, ,, ,, ,, 
Last 
day 
of 
their 
surv
ival 
,, ,, ,, ,, ,, 
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Nanoformulated Lf (AEC-CP-Fe-bLf NPs) were designed and developed by Dr. Jagat 
Kanwar, Deakin University, Australia and imported to India for our experiments. The size 
distribution, morphology, internalization and release profiles of these nanoparticles had been 
studied as described in section 3.6-3.16.   
 
Normal mice were dissected, taken as negative control and plating of organs to rule out any 
infection was done and organs preserved for histopathology, etc. 
 
On 6th day/2days of drug treatment as well as on 10th day of infection/6 days of drug 
treatment also same procedure was repeated for all 3 above mentioned drug treated groups. 
Spleen, liver, small intestine, blood, brain, kidney and mesenteric lymph nodes were 
removed and checked for bacterial load by homogenising them and plating. Tissues of these 
organs were collected for histopathology. Serum was collected from infected mice and 
growth of bacteria was checked by plating them.  
 
Simultaneously on each alternate day mice were observed for persistence of bacterial 
infection especially in infected group till the period of their survival. Further results of 
histopathology of tissues confirmed the results.  
 
6.2.4 Histopathological studies 
Tissue sample preparation: mice were sacrificed under euthanasia by cervical dislocation and 
upper part (ileum) of small intestine was removed, fixed in 10% buffered formalin and processed 
for histological examination following the method of Mosquito et al. (Mosquito et al. 2010). 
After eosin and hematoxylin staining slides were coded without reference to prior treatment and 
examined in a blinded fashion by a pathologist as a combined score of inflammatory cell 
infiltration, tissue damage and presence of no. of bacteria in infected tissues in tissue sections. 
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The location of the bacteria, changes in the brush border, presence or absence of ulceration and 
inflammatory changes were examined. 
 
6.2.5 ELISA of cytokine and nitrite production in the small intestine 
Cytokine levels in the supernatants of homogenates of the small intestine were determined using 
a method described in section 3.19. 
 
6.2.6 Statistical analysis 
Comparisons between groups, efficacy of the two forms of lactoferrin: native bLf and Apo-bLf 
with the negative controls (with only the PBS or media), between themselves and with the 
positive control Ciprofloxacin against the bacteria in in vitro study were undertaken using paired 
t-test. Also to compare the weights of normal mice with the infected group, nanoformulated 
lactoferrin treated group, bovine lactoferrin treated group and ciprofloxacin treated group paired 
t-test was applied. Results are expressed as Mean ± Standard Deviation (SD). Results are 
expressed as Mean ± Standard Deviation (SD). Significant differences at various levels were 
investigated using paired t-test and analysis was carried out using the SPSS 16 Software. 
 
6.3 Results 
The susceptibility of the bacteria was checked for various drugs to be taken as positive control. It 
was sensitive to gentamycin, amoxycillin, chloramphenicol, ciprofloxacin etc. Ciprofloxacin was 
used as a positive control for the experiments. 
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6.3.1 In vitro study 
MIC values were calculated for the drugs at their respective concentrations as compared to 
control when almost no viable colonies of the bacteria Salmonella typhimurium were found. MIC 
of Apo bLf, native bLf and Ciprofloxacin was found to be 0.2mg/ml, 0.2mg/ml and 0.4mg/ml 
respectively when only few colonies were found with the antibiotic discs i.e. 20.67±1.15 CFU/ml 
in case of Ciprofloxacin and 6-15 CFU/ml with Apo bLf and native bLf as compared to control 
with no drug which showed the presence of 315.33±13.78 CFU/ml (Fig. 6.2). The effects of 
native and Apo bovine lactoferrin on the growth of the pathogen showed inhibition in a dose 
dependent manner. 
 
When the efficacy of Ciprofloxacin was compared to the different concentrations of lactoferrin 
used to kill Salmonella, no statistically significant difference was observed in their inhibitory 
activity. In contrast, the negative control without drug, both lactoferrin and ciprofloxacin showed 
significant difference (P<0.05), showing that the drugs had a significant inhibition against the 
bacteria. 
 
 
 
 
 
 
 
 
 
[Type text] 
 
171 
 
0
50
100
150
200
250
300
350
400
N
o.
 o
f C
fu
/m
l
Concentration of various drugs
Native bLf
Apo bLf
Fe-bLf
# €
** ** ** **
** ** **
** ** **
§
** ****
*****
 
 
 
 
 
 
 
[Type text] 
 
172 
 
Figure 6.2 Comparison of the effect of different concentrations of various forms of 
lactoferrin-native bLF, Apo bLf and Fe-bLf on the growth of Salmonella typhimurium 
(ATCC-14028) with the positive control Ciprofloxacin (400μg/ml) and the negative control 
without any drug in in vitro antibacterial assay. bLf showed an IC90<0.2mg/ml while with 
ciprofloxacin an IC90>0.2mg/ml was obtained. Values are mean ± SD. All the experiments were 
done in triplicate. 
#, § and € vs. *P< 0.05and **P< 0.005 
*P< 0.05 vs Control group considered to be significant and **P< 0.005 vs. Control group 
considered to be highly significant. Paired, two tailed t-test and raw P values are used. 
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Figure 6.3 The susceptibility of the bacteria was checked for various drugs to be taken as 
positive control. It was sensitive to Gentamycin, amoxycillin, chloramphenicol, ciprofloxacin 
etc. Ciprofloxacin was used as a positive control for the experiments. 
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Figure 6.4 Mac Conkey Plate showing different dilutions of bacteria (Salmonella 
typhimurium, ATCC-14028). The count was standardized to  108 CFU/ml. 
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Figure 6.5 Inocculation of bacteria (Salmonella typhimurium, ATCC-14028) on XLD plate 
to standardize the count. The count was standardized to 108 CFU/ml. 
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6.3.2 In vivo study 
Different dilutions of bacteria were taken. The count was standardized to 108 CFU/ml by plating 
various dilutions of bacteria on MacConkey (Fig. 6.4) and XLD plates (Fig. 6.5). The tissues, 
small intestine, liver and spleen of the infected group of mice showed septicaemia (Fig. 6.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 
c 
b 
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Figure 6.6 Tissues of mice infected with Salmonella typhimurium showing septicaemia 
(arrows), a) Small intestine b) Spleen c) Liver. 
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Three days post infection, the small intestine, mesenteric lymph node (MLN), liver, spleen, brain 
and kidney tissues were tested for the presence of the bacteria. The bacteria had colonized the 
small intestine (Fig.6.7), MLN (Fig.6.10) and sera (Fig. 6.11) so various drug treatments with 
nanoformulated lactoferrin, Australian bovine lactoferrin and Ciprofloxacin were given to the 
mice. 
 
When the infected and drug treated mice groups were checked for infection, 6 days post infection 
or after two days of drug treatment, bacterial load was observed in sera, mesenteric lymph nodes, 
small intestine, liver and spleen in infected mice (Fig. 6.7-11). Fecal samples also showed the 
presence of bacteria. Bacterial load was also observed in the small intestine (Fig. 6.7), liver (Fig. 
6.8) and spleen (Fig. 6.9), sera (Fig. 6.10) and MLN (Fig. 6.11) of infected mice in ciprofloxacin 
and Australian bovine Lf treated groups but infection was almost cleared in mice fed with 
nanoformulated Lf diet. Thus nanoformulated lactoferrin exhibited rapid clearance of bacteria in 
the small intestine and MLN of infected mice and inhibited the spread of bacteria to other 
organs. 
 
But after 10 days post infection or after 6 days of drug treatment, bacterial load was observed in 
small intestine (Fig. 6.7), liver (Fig. 6.8) and spleen (Fig. 6.9), sera (Fig. 6.10) and MLN (Fig. 
6.11) and even in the brain in the infected mice and also in the Ciprofloxacin treated group. 
Infection was almost cleared in the other drug-treated groups (nanoformulated lactoferrin treated 
and bovine lactoferrin treated) of mice. 
 
Thus the bacterial load was found to be lower in the small intestine of mice on the third day post 
infection but peaked on day 6 post infection in the infected group (Fig. 6.7). Similar results were 
found in the Ciprofloxacin-treated group but there were lower number of bacteria observed in the 
bLf treated group. Thus it was concluded that the dose of bLf contributed to lower bacterial 
counts compared to the infected and Ciprofloxacin treated groups. In addition, only a few 
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bacteria could be observed in mice after 6 days of infection or two days of drug treatment with 
nanoformulated lactoferrin. However, there was no bacterial elimination in the feces of these 
mice after this day, so it can be concluded that this drug successfully eliminated bacteria from 
mice in 2 days. On the10th day after infection or 6 days of treatment with drugs, bacterial load 
was observed only in the infected group of mice and a low bacterial load was observed in the 
Ciprofloxacin treated group in the small intestinal tissue mice (Fig. 6.7). To broaden the 
evaluation of the antibacterial effect of nanoformulated lactoferrin, systemic translocation of 
Salmonella typhimurium was checked in the main peripheral targets, liver and spleen in all the 
drug treated groups and infected group of mice. The highest level of bacterial load in liver and 
spleen was observed only on the 6th day post infection/ 2 days of drug treatment in mice in the 
infected group, with a similar count in the Ciprofloxacin and bLf treated. No bacterial count was 
found in the nanoformulated treated group of mice in the liver and spleen. On 10th day after post 
infection or 6 days of treatment with drugs, bacterial load was observed only in the liver and 
spleen of the infected group and the Ciprofloxacin treated group mice (Fig. 6.8 and 6.9). 
 
After 20 days of infection of Salmonella typhimurium in mice, infection was almost resolved in 
all drug treated groups except for a few bacteria in the infected group which had disappeared by 
the next day (Fig. 6.7-6.11).  
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Figure 6.7 Bacterial counts in the small intestinal tissue of Salmonella infected mice, after 
treatment with nanoformulated lactoferrin in comparison with the Ciprofloxacin and 
native Australian bovine lactoferrin ion various groups of BALB/c mice. Bacteria had 
invaded the intestine within three days of post infection and high bacterial loads were observed 
in the small intestine of infected mice in all the infected and drug treatment groups. After 6 days 
post infection or two days of drug treatment only nanoformulated lactoferrin showed efficacy in 
clearing the bacterial infection from intestine as compared to other groups. 
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Figure 6.8 Bacterial counts in the tissue of liver of Salmonella infected mice, after treatment 
with nanoformulated lactoferrin in comparison with the Ciprofloxacin and native 
Australian bovine lactoferrin ion various groups of BALB/c mice. When the bacterial 
translocation was evaluated in the liver of mice of drug treatment groups after 2 days, the 
bacterial load was observed only in the Ciprofloxacin and bovine lactoferrin groups and 
nanoformulated lactoferrin was successful in inhibiting spread of bacteria to this organ 
effectively. 
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Figure 6.9 Bacterial counts in the tissue of spleen of infected mice, after treatment with 
nanoformulated lactoferrin in comparison with the Ciprofloxacin and native Australian 
bovine lactoferrin ion various groups of BALB/c mice. Similar to liver, when the bacterial 
translocation was evaluated in the spleen of mice of drug treatment groups after 2 days, the 
bacterial load was observed only in the Ciprofloxacin and bovine lactoferrin groups and 
nanoformulated lactoferrin was effective in inhibiting spread of bacteria to this organ after 6th 
day post infection. 
 
 
 
 
 
 
 
[Type text] 
 
189 
 
0
5000
10000
15000
20000
25000
3 6 10 20
N
o.
 o
f 
C
FU
/g
 M
LN
No. of days post infection with Salmonella typhimurium
Salmonella infected 
group
Nanoformulated Lf group
Ciprofloxacin treated 
group
Bovine Lf treated group
Normal mice
 
 
 
 
 
 
 
 
 
 
[Type text] 
 
190 
 
Figure 6.10 Bacterial counts in the Mesenteric lymph node tissue (MLN) of infected mice, 
after treatment with nanoformulated lactoferrin in comparison with the Ciprofloxacin and 
native Australian bovine lactoferrin in various groups of BALB/c mice. After oral ingestion, 
S typhimurium was found to colonize the small intestine and transported to Mesenteric lymph 
nodes, thus high bacterial loads could be observed within 3 days of post infection of the bacteria 
in all the groups of mice and highest bacterial loads could be observed on the sixth day in the 
infected group and Ciprofloxacin and bLf treated groups but the infection had almost resolved in 
the nanoformulated lactoferrin treated group.    
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Figure 6.11 Bacterial counts in the sera of Salmonella infected mice, after treatment with 
nanoformulated lactoferrin in comparison with the Ciprofloxacin and native Australian 
bovine lactoferrin in various groups of BALB/c mice. The Ciprofloxacin and bovine 
lactoferrin showed the presence of bacteria as in the infected group, whereas only few viable 
bacteria were observed in the nanoformulated lactoferrin group on 6th day post infection. 
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6.3.3 Quantitative assessment of bacterial load in brain. 
After 10 days of infection the invasion of bacteria was observed in the brain section. The 
numbers of bacteria in the infected group of mice on the 10th day were observed to be: 3.2 X 104 
± 0.09 X 104 and in the Ciprofloxacin group: 4.2 X 104 ± 0.07 X 104. In comparison with the 
nanoformulated lactoferrin treated and bLf treated groups, no bacterial infection was found in 
their brain sections i.e. bacteria had failed to colonize these organs in the presence of these two 
drugs. 
 
6.3.4 Histopathological analysis 
Histology of chronically infected tissues was performed to examine the consequences on tissue 
integrity, inflammation and lesion formation. Pathological changes were observed in all the drug 
treated groups of mice and the infected group on the 3rd, 6th and 10th day post infection in the 
sections of small intestine, liver, spleen and brain (Fig. 6.12-6.15). No histopathological 
abnormalities were observed in the control group without any infection and drug treatment 
(Fig.6.12A, 6.13A, 6.14A and 6.15A). 
 
Nanoformulated lactoferrin treated group 
In contrast, the sections of small intestine (Fig. 6.12B), mesenteric lymph nodes, liver (Fig. 
6.13B.), spleen (Fig. 6.14B.) and brain (Fig. 6.15B.) showed normal morphology of the tissues in 
the nanoformulated lactoferrin treated group after 2 days of treatment or six days post infection. 
No histopathological changes were observed in different organs of mice as compared to normal 
mice in the control group even after 6 days of drug treatment or 10 days post infection. 
 
Infected group 
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In the infected group, histopathological analysis on the third day showed infection in the small 
intestine and mesenteric lymph nodes. The mesenteric lymph nodes showed diffuse expansion of 
lymphoid cells in the infected mice. The villi of the ileum showed ileitis and were found swollen 
with lymphocytes (Fig. 6.12C). 
 
On the 6th day post infection large lymphoid masses of MLN were observed around the pancreas 
and in the mesenteric fat. Medullary sinus and reactive histiocytes were also observed at 100X. 
The section of ileum showed ulceration or was observed dissolving out.  Villous ulceration was 
observed at the top at 400X also and paneth cells were found in excess. Focal lobular hepatitis 
and infilteration of lymphocytes in one focus were observed in the section of liver. Typhoid 
nodule was also found in liver tissue (Fig. 6.13C.). The tissue of spleen showed more red pulp 
and reduced white pulp (Fig. 6.14C.). Thus the bacteria disseminated to spleen and liver too after 
6 days of infection which was without any drug treatment. 
 
After 10 days of infection with Salmonella the ileum of infected group of mice showed paneth 
cell hyperplasia, lymphoid follicles, excess of lymphocytes in villi. Diffuse lymphoid excess 
with no follicles were observed in mesenteric lymph nodes. A section of liver showed 3 
granulomas. Spleen showed lymphoid follicles in excess. Focal necrosis of the brain was 
observed (Fig. 6.15C). 
 
Bovine lactoferrin treated group 
The ileum of the mice in the bovine lactoferrin treated group showed mild excess of lymphoid 
cells (Fig. 6.12D.). General hyperplasia of kupffer cells was observed in the liver (Fig. 6.13D.). 
Reduced lymphoid follicle and expanded red pulp was observed in the spleen (Fig. 6.14D.). The 
section of brain showed normal morphology (6.15D). 
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Ciprofloxacin treated group 
When the mice were treated with ciprofloxacin after 3 days of infection, infection still persisted 
in them for two days as is evident from histopathology of tissues. Ileum showed focus of 
lymphocytes excess between the glands. Also excess of paneth cells in the glands were observed 
(Fig. 6.12E.). In the section of liver focal lobular hepatitis, small foci of lymphocytes and 
typhoid nodule were seen. Some liver cells showed fat vacuoles and microvascular fatty change 
(Fig. 6.13E). Excess red pulp, depressed lymphoid cells were observed in the section of spleen 
(Fig. 6.14E.). Treatment with ciprofloxacin was continued and after 6 days of drug treatment or 
10 days post infection ileum showed lymphoid hyperplasia and presence of paneth cells. Edema 
of the brain and spongiosis was observed, as infection had reached the brain (6.15E). 
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Figure 6.12 Photomicrographs (H and E staining) of small intestine of mice after 3 days of 
challenge with 200 μl of 108 CFU of Salmonella typhimurium (ATCC-14028). (A)  Section of 
normal or control mice, 200X, showing long, normal villi, lining cells including the brush border 
and goblet cells are normal. (B) Nanoformulated Lf treated mice, 400X, showing normal 
pathology. (C) Salmonella-infected mice, 400X, showing villous ulceration (filled arrow) and 
paneth cell excess (unfilled arrow) seen. (D) Bovine Lf treated mice, 200X, showing mild excess 
of lymphoid cells. (E) Ciprofloxacin treated mice, 400X, with excess lymphocytes in villi, also 
excess of paneth cells in the glands;  
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Figure 6.13 Photomicrograph (H and E staining) of liver after 3 days of challenge with 200 
μl of 108 CFU of Salmonella typhimurium (ATCC-14028). (A) Normal or control mice, 200X, 
showing normal pathology. (B) Nanoformulated Lf treated mice, 200X, showing normal 
pathology. (C)  Salmonella-infected mice, 400X, showing focal lobular hepatitis, infilteration of 
lymphocytes in one focus, lymphocytes boxed, (typhoid nodule). (D) bovine lf treated mice, 
200X, showing general hyperplasia of kupffer cells (arrows), liver cells show fat vacuoles 
(arrow), microvascular fatty change, focal lobular hepatitis, small foci of lymphocytes (arrow), 
typhoid nodule (boxed area). (E) Ciprofloxacin treated mice, 200X. 
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Figure 6.14 Photomicrographs (H and E staining) of spleen after 3 days of challenge with 
200 μl of 108 CFU of Salmonella typhimurium (ATCC-14028) and weight changes in the 
different groups of experimental animals.  (A) Normal or control mice, 200X, showing normal 
pathology. (B) Nanoformulated Lf treated mice, 100X, also showing normal architecture of 
spleen (C) Salmonella-infected mice, 200X, with more red pulp, reduced white pulp. (D) Bovine 
Lf treated mice, 100X, showing reduced lymphoid follicle, expanded red pulp seen. (E) 
Ciprofloxacin treated mice, 200X, with excess red pulp depressed lymphoid cells.  
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Figure 6.15 Photomicrographs (H and E staining) of brain after 10 days of challenge with 
200 μl of 108 CFU of Salmonella typhimurium (ATCC-14028)/6 days post treatment and 
weight changes in the different groups of experimental animals. (A) Section of brain of 
normal mice, 200X, showing normal pathology. (B) Nanoformulated Lf treated mice, 200X, also 
showing normal morphology of brain. (C) Salmonella-infected mice, 200X, showing focal 
necrosis of brain. (D) Bovine Lf treated mice, 100X, showing normal brain section. (E) 
Ciprofloxacin treated mice, 200X, showing edema and spongiosis in the brain. (F) Comparison 
of weights of mice in different groups of mice - infected group, nanoformulated Lf group, bovine 
lactoferrin group, Ciprofloxacin group as compared to normal mice. Significant differences 
(P<0.05) were found in the weights of mice in all the treatment groups and infected mice as 
compared to normal mice from 3rd day onwards. Values are taken as mean ± SD for 5 mice in 
each group. Significant difference (*P<0.05) was found in the weights of mice that had increased 
in the Nanoformulated lactoferrin and only bLf treated group from 5th day onwards as compared 
to mice in the infected group and the normal mice. No significant difference was found in the 
weights of mice in the Ciprofloxacin treated group as compared to mice in the infected group.  
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6.3.5 Weight changes  
Salmonella infected mice lost significant body weight (P<0.05) as compared to normal mice. 
Infected mice were found susceptible to nanoformulated lactoferrin and bLf as in both these 
treatments mice gained weight but showed resistance to Ciprofloxacin. With this drug 
Ciprofloxacin mice lost weight significantly (P<0.05) as in the infected group (Fig. 6.16). 
 
Salmonella infected mice lost significant body weight (P<0.05) as compared to normal mice. 
Infected mice were found susceptible to nanoformulated lactoferrin and bLf as in both these 
treatments mice gained weight but showed resistance to Ciprofloxacin where the mice lost 
weight significantly (P<0.05) as in the infected group. 
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Figure 6.16 Comparison of weights of mice in different groups of mice - infected group, 
nanoformulated Lf group, bovine lactoferrin group, Ciprofloxacin group as compared to 
normal mice. Significant differences (P<0.05) were found in the weights of mice in all the 
treatment groups and infected mice as compared to normal mice from 3rd day onwards. Values 
are taken as mean ± SD for 5 mice in each group. Significant difference (*P<0.05) was found in 
the weights of mice that had increased in the Nanoformulated lactoferrin and only bLf treated 
group from 5th day onwards as compared to mice in the infected group and the normal mice. No 
significant difference was found in the weights of mice in the Ciprofloxacin treated group as 
compared to mice in the infected group. Paired, two tailed t-test and raw P values are used. The 
experiments were done in triplicate. 
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6.3.6 Immune response in mice 
The cytokines of innate immunity are IL-1β, 6, 10, 12, 15, 18, 23, 27, INF-1α, INF-1β and INF-
III (Table 6.2). The level of IL-β significantly increased to 2.6 fold in the Salmonella-infected 
group when compared to the control mice. In contrast there was a slight increase in this cytokine 
in the ciprofloxacin and nanoformulated treated group to 1.8 and 1.2 fold respectively. The 
proinflammatory cytokine was upregulated to much higher level 1.5 fold in all the drug treated 
groups and was downregulated in the infected group of mice as compared to normal mice. In 
case of IL-10 elevated levels were observed in the infected group and ciprofloxacin treated group 
to 1.8 and 1.4 fold respectively but lower levels in case of nanoformulated Lf grouo as compared 
to control. The level of IL-12 rose to 1.4, 1.3, 1.2 fold in the infected group, nanoformulated Lf 
and bovine lactoferrin treated group but its level decreased to 2.5 fold in the ciprofloxacin treated 
group as compared to control. Upregulation of IL-15 was observed in case of bLf and 
nanoformulated treated groups as compared to ciprofloxacin treated, infected group and normal 
mice. 
 
The level of IL-18 increased significantly to 2.8 and 2.7 fold in the bLf and nanoformulated 
treated group respectively while the levels decreased in the infected and ciprofloxacin treated 
groups. Increase in the level of IL-23 was also observed in all the drug treated groups of mice as 
compared to the infected and normal mice. The levels of INF-1α, INF-1β and INF-III were found 
to increase only in the bLf and nanoformulated Lf treated groups as compared to infected and 
normal mice.  
 
The cytokines IL-2, IL-4, IL-5, IL-13, IL-17 and IFN-γ led to adaptive immune response in mice 
(Table 6.3). The levels of IL-2 and IL-4 increased in the bLf and nanoformulated treated group 
respectively as compared to normal mice. IL-5 was increased to 2.6 and 2.5 fold in the bLf and 
nanoformulated treated group respectively and 1.5 fold in both the infected and ciprofloxacin 
treated groups. IL-13 increased to 1.5 fold in both the bLf and nanoformulated treated group as 
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compared to control mice without any drug treatment. IL-17 increased 4 times in the bLf and 
nanoformulated Lf treated groups. Significant levels of IFN-γ increased in all the groups of mice 
except the ciprofloxacin group as compared to control.  
 
The cytokines of haemopoiesis are IL-3, IL-7, IL-9, IL-11, G-CSF, M-CSF and GM-CSF (Table 
6.4). The levels of IL-3 and IL-7 were found to be elevated in the bLf and nanoformulated 
treated group respectively as compared to infected, ciprofloxacin and normal mice. The level of 
IL-9 was increased in all the drug treated groups of mice as well as the infected group as 
compared to normal mice. Very high levels of G-CSF i.e. 7-fold and 9.6 fold were observed in 
the bLf and nanoformulated treated group respectively as compared to normal mice. Similarly 
significant higher levels of GM-CSF and M-CSF were observed in the above-mentioned drug 
treated groups of mice as compared to normal mice but their levels decreased in the infected and 
ciprofloxacin treated groups.    
 
Other cytokines and cytokines of Th17 differentiation and activation of immune cells for 
immune responses and inflammation are IL-21, IL-22, IL-26, IL-35, IL-17A, IL-17F, TNF-α and 
TGF-β (Table 6.5). IL-21 increased significantly to 2.6 fold in both the bLf and nanoformulated 
groups and decreased in the ciprofloxacin and infected group of mice as compared to normal 
mice. Elevated levels of IL-22 were also observed to 3.2, 3.5 and 1.2 fold in the bLf, 
nanoformulated Lf and ciprofloxacin treated groups respectively and reduced in the infected 
group as compared to normal mice. The levels of IL-26 were increased in all the groups of mice 
as compared to normal mice. Upregulation of IL-35 was observed only in the infected group as 
compared to normal mice. Significant increase in the levels of IL-17A were also observed in the 
bLf and nanoformulated Lf treated groups of mice while level of IL-17F increased in all the drug 
treated groups of mice. Significant levels of TNF-α and TGF-β were observed in the infected 
group as compared to control group. The levels of NO increase to almost 3 fold and 2 fold in the 
infected group and ciprofloxacin treated group as compared to the control.  
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Table 6.2 The cytokines of innate immunity 
Cytokines 
(μM) 
Fe-
bLf 
Group 
Nano 
Fe-bLf 
Group 
Cip-
drug 
Group 
Infect
ed 
Group 
Norm
al diet 
Group 
IL-1beta 12±3 10±3 18±4 26±4 10±2 
IL-18 65±8 62±6 22±5 18±5 23±5 
IL-6 345±5
0 
345±50 245±3
0 
212±3
2 
230±2
0 
IL-12 312±3
2 
334±34 100±1
2 
342±1
0 
250±1
5 
IL-15 25±5 42±5 5±2 6±2 10±3 
IL-23 15±3 18±6 15±5 5±2 8±2 
IL-27 23±5 16±5 5±2 6±2 10±3 
IL-10 241±5
6 
212±65 321±5
0 
412±6
0 
230±3
0 
INF-1 
alpha 
25±5 25±5 5±2 6±2 10±3 
INF-1 
beta 
16±5 16±5 5±2 6±2 6±2 
INF-III 20±5 25±5 5±2 6±2 8±3 
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Table 6.3 The cytokines of adaptive immunity 
Cytokines 
(μM) 
Fe-
bLf 
Group 
Nano 
Fe-bLf 
Group 
Cip-
drug 
Group 
Infect
ed 
Group 
Norm
al diet 
Group 
IL-4 45±12 50±10 12±3 12±5 12±6 
IL-2 168±1
2 
156±1
5 
15±5 15±5 20±5 
IL-13 15±5 15±5 5±2 6±2 10±3 
IL-17 12±3 12±5 2±1 5±2 3±1 
IFN-gama 11±3 17±4 3±1 6±3 4±2 
 
Table 6.4 The cytokines of haemopoiesis 
Cytokines 
(μM) 
Fe-
bLf 
Group 
Nano 
Fe-bLf 
Group 
Cip-
drug 
Group 
Infect
ed 
Group 
Norm
al diet 
Group 
IL-3 15±5 12±5 5±2 6±2 10±3 
IL-7 17±5 16±5 5±2 6±2 10±3 
IL-9 40±2 30±6 16±5 16±5 12±5 
IL-11 10±5 10±5 5±2 13±5 10±3 
G-CSF 35±8 48±6 6±2 6±2 5±2 
M-CSF 25±4 28±6 5±2 5±2 8±3 
GM-CSF 22±5 26±5 5±2 6±2 10±3 
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Table 6.5 Other cytokines and cytokines of TH17 differentiation and activation of immune 
cells for immune responses and inflammation. 
Cytokines 
(μM) 
Fe-
bLf 
Group 
Nano 
Fe-bLf 
Group 
Cip-
drug 
Group 
Infect
ed 
Group 
Norm
al diet 
Group 
IL-35 5±2 4±2 5±2 15±2 10±3 
TGF-beta 5±2 5±2 32±5 35±5 15±4 
TNF-
alpha 
12±3 14±4 25±5 32±4 14±4 
NO 6±2 8±2 15±4 23±4 7±3 
IL-17A 22±5 22±8 5±2 5±2 5±2 
IL-17F 30±4 47±11 24±6 14±5 22±5 
IL-26 53±5 33±6 16±5 21±5 12±5 
IL-22 32±5 35±6 12±5 8±4 10±2 
IL-21 21±5 22±5 5±2 6±3 8±2 
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Chapter 7: Discussion  
 
In the treatment of giardiasis, metronidazole is the drug of choice among other treatments that 
include benzimidazoles, quinacrine, paromomycin, furazolidone and nitazoxanide. But 
metronidazole is now known to be toxic and might be mutagenic when it is used at high doses or 
as long-term treatment in humans, (Bendesky, Menéndez & Ostrosky-Wegman 2002; Dobias et 
al. 1994; Roe 1983) so the side effects and limitations of existing drugs is affecting compliance. 
Resistance to anti-giardial drugs through inappropriate use of antibiotics has also been observed 
in Giardia parasite (Upcroft & Upcroft 1993). For these reasons, new approaches to the 
treatment of giardiasis are urgently needed. Alternative biotherapeutic strategies have included 
natural interventions such as probiotics, plant extracts, and products from bees (Shukla, Devi & 
Sehgal 2008). 
 
Several drugs produced from natural sources now seem to be seen as potential alternative. Milk 
proteins have also been found to be microbicidal to Giardia lamblia (Gillin, Reiner & Wang 
1983b). Lactoferrin is the most valuable biomedical protein present in milk, due to the numerous 
and diverse array of therapeutic properties it exhibits. It is a multifunctional protein that may 
regulate iron absorption in the intestine, promotes intestinal cell growth, protects against 
microbial infection, regulates myelopoiesis, and regulates systemic immune responses (Kanwar, 
Mahidhara & Kanwar 2012; Kanwar et al. 2012b; Krissansen 2007). In an experiment with 
Peruvian children, supplementation with bovine apo-Lf led to a lower prevalence of Giardia 
colonization and better growth among children (Ochoa et al. 2008). As the microbicidal property 
of apo-Lf resides in the N-terminal domain, several peptides from this region have been analyzed 
against bacteria and G. lamblia (Turchany, Aley & Gillin 1995). A synergistic amoebicidal effect 
was found between Mz and human Lf, bovine Lf or bLfcin (Leon-Sicairos et al. 2006a).  Both Lf 
and Lf-peptides are able to kill a wide variety of pathogenic microorganisms such as bacteria, 
fungi, parasites and also enveloped viruses, most probably due to their membrane disturbing 
activities (Bolscher et al. 2009; Haney, Lau & Vogel 2007; Haney et al. 2009; Leon-Sicairos et 
al. 2009; Leon-Sicairos et al. 2006a; Leon-Sicairos et al. 2006b; Marr et al. 2009; van der Kraan 
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et al. 2004; Wakabayashi et al. 1996). Therefore, Lf and Lf-peptides are a promising class of 
antimicrobial compounds to fight pathogenic microbes. 
 
Previous research speculated that activity of buffalo lactoferrin might be due to iron binding and 
release at lower rates of pH than bovine lactoferrin, but at a higher pH than human and mare 
lactoferrin (Sharma et al. 1999). 
 
As has been shown in previous research, the in vitro antimicrobial properties of ciprofloxacin are 
promising, so the efficacy of this compound was studied in vivo after mice were found to be 
susceptible to Salmonella. The drug was administered orally in normal and immunocompromised 
mice (Brunner & Zeiler 1988). Ciprofloxacin, broad spectrum antibiotic exhibits lower MICs 
against gram negative bacteria like S. typhimurium and the drug is found to be readily absorbed 
after oral administration. Ampicillin is used in the empirical treatment of acute diarrhea, whereas 
chloramphenicol is widely administered for enteric fever. Reduced susceptibility to 
antimicrobials like nalidixic acid and ciprofloxacin has led to higher incidences of treatment 
failure in cases of persistent salmonellosis (Al-Mashhadani et al. 2011; Crump et al. 2008; Parry 
et al. 2011). Salmonellosis requires new approaches for chemotherapy to overcome the problems 
of drug resistance and high relapse rates with this illness in different parts of the world. 
 
Lactoferrin has been found to play a significant role in the human host defence system due to its 
localization in polymorphonuclear leucocyte and the mucosal secretions including those from the 
breast, respiratory tract and vagina. It has also been found to have bacteriostatic properties 
(Bullen 1976) and many studies have mentioned its bactericidal activity on enteric pathogens 
(Boesman-Finkelstein & Finkelstein 1985). Lactoferrin’s protective effect has been suggested 
against various enteropathogens like Shigella flexineri and E. coli (Gomez et al. 2002; Ochoa et 
al. 2006). Ellison and Giehl (Ellison & Giehl 1991) have shown lactoferrin’s membrane effect 
due to its permeabilizing activity on the outer membrane of gram negative bacteria V. cholera, S. 
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typhimurium and E. coli, enhanced the antibacterial activity of lysozyme. It inhibits bacterial 
multiplication by sequestering iron that is essential for bacterial growth (Goldoni et al. 2000) or 
by destabilizing the surface membrane of Gram negative bacteria after binding to outer 
membrane proteins (Naidu et al. 1993) and LPS components (Appelmelk et al. 1994). Some in 
vitro studies have shown that Lf decreases the adherence of S. typhimurium to HeLa cells 
(Bessler, de Oliveira & Giugliano 2006). Independent of iron, Lf interacts with these bacteria 
and produces the decrease of the bacterial metabolic rate, increasing the bacteriostasis. 
Immunoregulatory effect of bLf on infected mice in a dose dependent manner was observed with 
the production of IgA, IgG, IgM antibodies in Salmonella infected mice by Drago-Serrano et al. 
(Drago-Serrano et al. 2010). 
 
Fischer et al. (Fischer et al. 2007) and Worley et al. (Worley et al. 2006) have demonstrated that 
the antibacterial effects, following the oral administration of bLf in case of S. typhimurium 
infection in the liver and spleen of mice, may be due to the absorption of bLf in a non-digested 
form in the intestine and then it may remain in this form in the peripheral blood and from there is 
distributed to these two organs. Lf in E. coli enteropathogenic EPEC and S. flexineri blocks actin 
polymerization in epithelial cells by degrading proteins of the type three sectretory system 
(TTSS), the needle complex mechanism by which bacteria can attach to or invade host’s tissues 
(Gomez et al. 2002; Ochoa et al. 2006). Some in vivo studies have shown that Lf protects mice 
from lethal intravenous doses of E. coli (Zagulski et al. 1989) and rabbits from enteritis induced 
by S. flexineri (Gomez et al. 2002).  It is speculated by Mosquito et al. (Mosquito et al. 2010) 
that Lf binds to the LPS of the bacteria with disruption of the TTSS, blockade of actin 
polymerization and stimulation of the immune system. 
 
Bovine Lf has been reported to inhibit carcinogenesis and the growth of tumours. In vivo studies 
show that oral administration of bLf to rodents significantly reduces chemically induced 
tumorogenesis in different organs (breast, oesophagus, tongue, lung, liver, colon and bladder) 
and inhibits angiogenesis (Iigo et al. 2009; Tsuda et al. 2002). In a study (Kanwar et al. 2008) 
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100% saturated bLF (Fe-bLF) was significantly more effective at potentiating cancer 
chemotherapy than apo-bLF, natural bLF (native) and 50% iron-saturated bLF. The mechanism 
by which Fe-Lf exerts increased antimicrobial activity is not known yet. Fe-Lf may be more 
bioavailable and resistant to degradation and proteolysis than natural bLf as it passages through 
the digestive tract. Thus, several studies have reported that the degree of iron saturation of Lf 
affects the gastric digestion of Lf, where 20% iron-saturated Lf is more easily digested than 
100% iron-saturated Lf. A further possibility is that delivery of iron by Fe-Lf directly to 
lymphocytes, as reflected by the preferential uptake of Lf into Peyer’s patch lymphocytes, may 
endow lymphocytes with enhanced immune function. In addition, as mentioned above, no 
toxicity problems in mice from ingesting Lf was found. In our study with buLf even with 12±3 
% iron saturation showed efficacy against the parasite. 
 
7.1 Non-nanoformulated buffalo lactoferrin 
In this study, for the first time Lf was purifiedfrom buffalo colostrum and its antimicrobial 
activity was checked against trophozoites of Giardia lamblia. This work is the first step in the 
study of the giardicidal action of buffalo Lf, which could be considered as an excellent candidate 
to combat the parasite and help in the cure of giardiasis. Buffalo Lf showed inhibitory activity 
against Giardia after 12 hrs of incubation with the drug in vitro. When the effectiveness of 
buffalo Lf was tested in comparison with metronidazole (40 PM), buffalo Lf was found to be 
more effective in killing the parasites. IC90 of buffalo Lf was obtained at a very low 
concentration of 200μg/ml. 
 
The parasite load in suckling BALB/c mice infected with trophozoites of the standard strain, 
Portland 1 strain of Giardia lamblia reached a peak of around 107 trophozoites per mouse at 7 
days of post infection and 105 at 9 days of post infection whereas no trophozoites were found in 
the mice after 4 days of treatment with buffalo Lf or 11 days of post infection and with 
metronidazole after 7 days of treatment. The mice were cleared of Giardia subsequently after 
drug treatment but the infection persisted in mice in the untreated group for 27 days. Maximum 
colonization of the parasite was seen in the middle segment, jejunum of the small intestine. 
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Therefore buffalo Lf showed better response in terms of elimination of cysts and shortening the 
period of infectivity. Moreover no toxic effect of the drug was observed. By comparing the 
clinical score of the Giardia infected and drug treated groups various clinical manifestations of 
the disease like diarrhea, change in skin texture, weight loss etc., were recorded to monitor the 
recovery profile of the mice through various drug treatments. The mice treated with buffalo Lf 
showed reduced level of clinical impairment than all other Giardia infected mice and other drug 
treated mice. Thus, marked and rapid recovery was noticed in the buffalo Lf treated group 
followed by metronidazole treated group. In addition to other signs and symptoms when the 
scoring of trophozoites and cysts were done in all the groups of mice it was found that the cyst 
and trophozoite score was maximum in the Giardia infected group on day 7 p.i and declined 
more rapidly in buffalo Lf treated group showing the efficacy of the drug. 
 
These findings suggest that a synergistic effect of Mz and Lf could be an attractive therapeutic 
option in the future treatment of giardiasis and this would help in reducing the Mz dose 
administered to patients. This is important because cases of toxicity and mutagenicity have been 
found in humans, animals and culture cells (Kapoor et al. 1999; Mudry et al. 1994). Thus the 
action of Lf alone or combined with low doses of metronidazole could be an attractive therapy in 
humans without leading to drug side effects. 
 
In the pathogenesis of giardiasis the parasite secretes enzymes that dissolve the host intestinal 
tissue, killing cells on contact, invading the mucosa and causing dysentery which if not treated 
might lead to fatal outcome. On intestinal mucosa Lf concentration is increased as a result of 
neutrophil secretion and can be used as a parameter to identify inflammatory disorders. Thus the 
histological examination showed that the atrophied microvillus, hyperplasia of the crypts, mild 
inflammation and infiltration of lymphomononuclear cells in the lamina propria and vacuolated 
epithelial cells in the infected mice became normal in the buffalo Lf treated mice with normal 
architecture of microvillous, crypt height and epithelial cells. Clinical score was also improved in 
the buffalo lactoferrin treated group as compared to infected group of mice, proving the efficacy 
of the drug.  
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Any immune response to Giardia will activate of T-lymphocytes (Scott et al. 2000), in such 
cases however granulocytic cell influx into the intestine during the acute phase of giardiasis is 
not always detected. Among the cytokines produced by such activation IFN-γ was the most 
abundant. This result is similar to the previous reported study that anti- IFN-γ treatment in 
C57BL/6 mice resulted in prolonged infections in G.muris (Venkatesan, Finch & Wakelin 1996). 
In a study by Ebert (Ebert 1999) it was observed that peripheral blood lymphocytes from naïve 
individuals produced IFN-γ in response to the trophozoites of Giardia. In another study serum 
from infected adults contained elevated levels of IL-5, IL-6 and IFN-γ (Matowicka-Karna, 
Dymicka-Piekarska & Kemona 2009). Also, Zhou et al. (Zhou et al. 2007) showed that mice 
lacking TNF are delayed in parasite elimination. This study was consistent with a finding in 
which elevated TNF levels were found in the sera of infected children (Bayraktar, Mehmet & 
Durmaz 2005). 
 
In a study (Solaymani-Mohammadi & Singer 2011), it was reported that spleen cells and MLNs 
stimulated ex vivo with Giardia extracts produced IFN-γ, TNF-α, IL-4, IL-10, IL-13, IL-17 and 
IL-22. It was also indicated that CD4+ cells were the likely source of these cytokines. Detectable 
levels of CD4+ cells up to 18 cells/field and 25 cells /field have been produced by intestinal and 
spleen cells in our study in the treatment group. In a study by Saigal et al. (Saigal et al. 2012) 
high parasite positivity was found in patients (HIV/AIDS) with CD4 count ˂ 200μl compared to 
those with CD4 count >500 μl. IL-6 appears to be important in the early control of acute Giardia 
lamblia infection; IL-6 deficient mice are only able to control infection slowly (Bienz et al. 2003; 
Zhou et al. 2003). Thus high expression of IL-4 and IL-6 was shown in buLf treated mice that 
resolved infection indicating the Th2 response. IL-4 and IL-6 are produced by gut epithelial and 
TCD4+ cells (Jones 2005; Wershil & Furuta 2008).  
 
Proliferation of CD4+ T cells with cytokine response such as IFN-γ production was also assessed 
in giardiasis (Ebert 1999). Interestingly, it was found that IFN-γ and IL-4 knockout mice can 
control Giardia infections provided that Th2 cells are sufficient (Singer & Nash 2000).  NO has 
been reported to inhibit proliferation and differentiation of Giardia lamblia via its cytostatic 
action (Li, Zhou & Singer 2006). The results in our study also demonstrate the downregulation 
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of NO, a decrease of 3-fold revealing that buLf decreased the production of NO. In a study by 
Kanwar et al. (Kanwar et al. 2008), where bovine lactoferrin fortified the mice against cancer, it 
was found that Lf increased the production of Th1 and Th2 cytokines within the intestine and 
tumour, including TNF, IFN-γ, as well as nitric oxide that have been reported to sensitize 
tumours to chemotherapy. 
 
IL-10 also plays a role in counterbalancing the inflammatory response (Long et al. 2010). Thus 
increased levels to about 340pg/ml have been detected in the buLf treated group in this study, 
helping in resolve the infection where proinflammatory cytokines may be overexpressed and 
causing tissue damage. Detectable levels of the proinflammatory mediator, IL-1β were also 
found in the buLf treated group as compared to control indicating that this cytokine has an 
influence on immunity to giardiasis in this study.     
 
At the cellular level, Lf increases the number of natural killer (NK) and adaptative (T strain 
CD4+ and CD8+) cells (Haversen et al. 2002), boosts the recruitment of polymorphonuclear 
cells (PMNs) in the blood (Shimizu et al. 1996), induces phagocytosis (Kurose et al. 1994), and 
can modulate the myelopoietic process (Szuster-Ciesielska, Kamińska & Kandefer-Szerszeń 
1995). It is well documented that IL-12 plays an important role in driving development of helper 
T-cell type 1 immunity (D'Andrea et al. 1995; Trinchieri, Pflanz & Kastelein 2003). The 
immunoregulatory property of Lf has been found to be mainly downregulating the inflammatory 
response and restabilishing intestinal homeostasis (Gonzalez-Chavez, Arevalo-Gallegos & 
Rascon-Cruz 2009). Therefore, the role of Lf in the regulation of proinflammatory cytokines and 
IL-12 clearly demonstrates communication between innate and adaptative immune responses.  
 
There was a significant increase in levels of Th17 cells in the splenocytes of mice after 
administration of buLf to them. Yang et al. (Yang et al. 2008) has described that IL-17A, F 
released by TH17 cells is involved in the recruitment, activation and migration of neutrophils 
which help the body in fight against infection with various bacterial and fungal species. Th17 
cells have also been involved in tissue repair functions through their production of cytokine IL-
22 alongwith IL-10 (Dong 2008). Anti-infective and anti-inflammatory roles of IL-22 are 
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associated with its functions in maintaining the integrity of epithelial barriers (Torchinsky et al. 
2009). Th17 cells have been described as proinflammatory, playing a role in autoimmunity and 
chronic inflammation. 
 
Thus this study seeks to investigate a safe potent alternative medicine for the cure of giardiasis.  
 
7.2 Non-nano bovine lactoferrin in treatment of giardiasis 
The research presented in this paper is the first step in the study of the giardicidal action of bLf, 
and its potential to combat the parasite and help towards the cure of giardiasis. Two forms of 
bovine lactoferrin (bLf) -the apo and native forms are shown to have microbicidal effect on the 
parasites in vitro, with the killing action dependent on the concentration of the dose. Apo-bLf 
showed more inhibitory activity against Giardia than native bLf after 12 hrs of incubation with 
the drug. When the effectiveness of bLf was tested in comparison with metronidazole (40 PM), 
bLf was found to be more effective in killing the parasites. IC50 of Apo-bLf was obtained at a 
very low concentration of 200μg/ml.   
 
In the presence of Fe-bLf the parasites showed less inhibitory activity, instead their growth was 
enhanced. So a synergistic effect of Mz and Lf could be an attractive therapeutic option in the 
future treatment of giardiasis. This could also help in reducing the Mz dose administered to 
patients, which is significant as cases of toxicity and mutagenicity have been found in humans, 
animals and culture cells when the drug have been administered (Kapoor et al. 1999; Mudry et 
al. 1994). Thus the action of Lf alone or combined with low doses of metronidazole could be an 
attractive therapy in humans without leading to drug side effects.  
 
7.3 Non-nano bovine lactoferrin in treatment of salmonellosis 
The research presented in this paper is the first step in the study of the microbicidal action of 
bLf, which could be considered as an excellent candidate to combat and help to cure 
salmonellosis. In this study the two forms of bovine lactoferrin (bLf) (the apo and native forms) 
showed microbicidal effect on the bacteria in vitro and the killing was concentration dependent. 
[Type text] 
 
220 
 
Apo-bLf showed more inhibitory activity against Salmonella than native bLf after incubation 
with the drug overnight. When the effectiveness of bLf was tested in comparison with 
ciprofloxacin, bLf was found to be more effective in killing the bacteria. In the presence of Fe-
bLf the bacteria showed less inhibitory activity. 
 
7.4 Nanoformulated lactoferrin in treatment of giardiasis 
Nanomedicine has been proved in recent years to be an effective medical intervention for 
treating diseases. To study the treatment of an experimental visceral leishmaniasis, transmission 
electron microscopy (TEM) was used to localize the pentamidine-loaded polymethocrylate 
nanoparticles in the liver of mice infected with Leishmania major and the ultrastructural changes 
in the parasites of these mice were compared when they were treated with bound versus free 
pentamidine. This study showed that a dose of bound pentamidine was 13 times smaller than the 
usual dose of free pentamidine and had a similar effect on the parasite (Fusai et al. 1997). 
Investigations have shown that co-encapsulation of autoclaved Leishmania major ALM and 
CpG-ODN (Oligodeoxynucleotides containing unmethylated CpG motifs) in PLGA [poly(D,L-
lactide-co-glycolide)] nanospheres  was an appropriate strategy to induce a potent Th1 immune 
response and improve protection against leishmaniasis (Tafaghodi et al. 2010). A study reports 
the use of chitosan based nanogels as a delivery system for the vaccine candidate recNcPDI 
(recombinant protein disulphide isomerase) both i.n. and i.p. in a nonpregnant mouse model for 
neosporiasis (Debache et al. 2011). Combination therapy of curcumin, chitosan and silver 
nanoparticles was studied as an anti-Giardia agent by Said et al. (Said, Elsamad & Gohar 2012) 
and was found to be successful in complete cure of the disease.   
 
Here we examined whether the Fe saturated form of bLf could show an antigiardial effect in vivo 
and whether its further loading on ACNs would augment the effect after oral administration. This 
would improve its bioavailability at the infection site, given the advantages of nanoparticles as a 
drug delivery system. The nanoformulation was designed for protection against pH variations, 
microflora, proteolytic and gastric enzymes in the intestinal mileau. So the use of such 
nanoformulated Lf was proposed for the first time in this study. In addition, it was decided to 
[Type text] 
 
221 
 
prepare and characterize these nanoparticles for size, shape, loading efficiency and in vitro 
release profile (pH 1.5 and pH 8) was done by Kanwar and coworkers (Kanwar, Mahidhara & 
Kanwar 2012). The study aimed at the incorporation of gut enzyme resistant Fe-bLf in NCs for 
improving its anticancer efficacy by increasing its bioavailability at the tumour sites through 
enhanced permeability retention effect. The alginate layer protected the inner core from getting 
degraded in the GI tract and alginate itself gets degraded in the process, releasing CSC inner 
core. The alginate coating gets degraded in the alkaline and enzymatic environment in the 
intestine and the chitosan coated ceramic particles released in the intestinal milieu to enter the 
blood circulation via endocytosis and/or transcytosis. Based on that study we found that the 
alkaline pH of small intestine facilitated the release of bLf from NCs. Thus it was shown that the 
NC-entrapped protein Fe-bLf can be protected in gastric lower pH (acidic) milieu in the stomach. 
The predominant unionized form of alginate forms the matrix around the inner core in such 
lower pH. When the pH of the milieu changes to the alkaline range in the intestine, sodium 
alginate is formed releasing the contents present inside the alginate layer. 
 
 
Biodistribution studies have shown that the concentration of Fe-bLf in the blood/plasma was 
significantly higher in mice fed with nanoformulated AEC-CP-Fe-bLf NCs than those 
administered with an equimolar concentration of non-nanoformulated Fe-bLf only at various 
time periods. Thus, the AEC–CP–Fe-bLf NCs could enter the blood circulation without affecting 
the gut epithelial cell layer. Thus, the AEC–CP–Fe-bLf NCs could enter the blood circulation 
without affecting the gut epithelial cell layer. After being delivered orally, the NCs reach the 
intestine and are protected from the gastric proteolytic enzymes and microflora in the gut, as well 
as from variations in pH in the GI tract. The alginate covering is degraded in the intestinal 
alkaline pH, releasing C–CP–Fe-bLf NCs (free from alginate) into the main blood stream. 
Pharmacokinetic study after oral administration of Fe-bLf and AEC-CP-Fe-bLf NCs showed that 
oral delivery through chitosan nanoparticals ensured a sustained release of Fe-bLf over 10 days 
post feeding. 
 
[Type text] 
 
222 
 
The parasite load in suckling BALB/c mice infected with trophozoites of the standard strain, 
Portland 1 strain of Giardia lamblia reached a peak of around 107 trophozoites per mouse at 7 
days of post infection and 105 at 9 days of post infection. Comparatively no trophozoites were 
found in the mice after 2 days of treatment with nanoformulated bLf or 9 days of post infection. 
The mice were cleared of Giardia subsequently after drug treatment but the infection persisted in 
mice in the untreated group for 27days. Maximum colonization of the parasite was seen in the 
middle segment, jejunum of the small intestine. Therefore nanoformulated bLf showed better 
response in terms of elimination of cysts and shortening the period of infectivity. Moreover no 
toxic effect of the drug was observed. Studies in rats found active LFpep in the small intestine 
after feeding of bovine Lf , suggesting that the N-terminal peptides may be produced in vivo and 
may be active in mucosal defenses against G. lamblia, especially since they are less susceptible 
to inhibition by divalent metal ions. 
 
In the pathogenesis of giardiasis the parasite secretes enzymes that dissolve the host intestinal 
tissue, killing cells on contact, invading the mucosa and causing dysentery which if not treated 
might lead to fatal outcome. On intestinal mucosa Lf concentration is increased as a result of 
neutrophil secretion and can be used as a parameter to identify inflammatory disorders. Thus the 
histological examination showed that the atrophied microvillus, hyperplasia of the crypts, mild 
inflammation and infiltration of lymphomononuclear cells in the lamina propria, vacuolated 
epithelial cells and reduced goblet cells in the infected mice became normal in the 
nanoformulated treated mice with normal architecture of microvillous, crypt height, epithelial 
and goblet cells. The results of TEM also showed the recovery of the pathological profile in the 
nanoformulated drug treated group of mice as compared to mice infected with Giardia, without 
any drug treatment.  
 
By comparing the clinical score of the Giardia infected and drug treated groups various clinical 
manifestations of the disease like diarrhea, change in skin texture, weight loss etc., were recorded 
to monitor the recovery profile of the mice through various drug treatments. The mice treated 
with nanoformulated bLf showed reduced level of clinical impairment compared with all other 
Giardia infected mice and other drug treated mice. Thus, marked and rapid recovery was noticed 
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in the nanoformulated bLf treated group followed by bovine lactoferrin and metronidazole 
treated group. In addition to other signs and symptoms when the scoring of trophozoites and 
cysts were done in all the groups of mice it was found that the cyst and trophozoite score was 
maximum in the Giardia infected group on day 7 p.i and declined more rapidly in the 
nanoformulated Lf treated group showing the efficacy of the drug. 
 
Haemotological profile showed higher level of Haemoglobin, haematocrit, liver and spleen iron, 
RBC’s, Reticulocytes, Reticulocyte haemoglobin content, Serum iron and calcium in the 
nanoformulated Lf treated group of mice as compared to Metronidazole treated mice. 
Metronidazole had suppressed the haematological profile and serum iron and calcium levels as 
compared to mice fed with control nano diet.  
 
Changes in the levels of immunological parameters in Giardia-infected mice were observed 
thereafter when the mice received various drug treatments. Humoral immune response is induced 
in the hosts infected with Giardia and there is no noticeable granulocytic cell influx into the 
intestine during the acute phase of giardiasis although the immune response to Giardia involves 
activation of T-lymphocytes (Scott et al. 2000). The cytokines profile viewed in the results 
showed the response of innate immunity during the course of Giardia infection. IL-6 appears to 
be important in the early control of acute Giardia lamblia infection; IL-6 deficient mice are only 
able to control infection slowly (Bienz et al. 2003; Zhou et al. 2003). A downregulation of IL-12 
and IL-15 was observed in infected group, but on treatment with bovine lactoferrin and 
nanoformulated lactoferrin the levels of cytokines increased significantly suggesting the role of 
these proinflammatory cytokines in fighting infection. In contrast, metronidazole was found to be 
ineffective as it did not show any increase in the levels of these cytokines. Decreased levels of 
IL-10 were detected in the nanoformulated Lf treated group of mice in this study. Il-10 has been 
found to play a role in counterbalancing inflammatory response (Long et al. 2010), thereby 
helping in resolving the infection where proinflammatory cytokines may be overexpressed, 
causing tissue damage. 
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Another cytokine, IL-23 that is an important part of the inflammatory reaction against infection 
showed higher levels in all the drug treatments but downregulation in the infected group of mice. 
Rise in levels of IL-27, IFN-1α and IFN-III in cases of nanoformulated Lf and bLf treated groups 
in comparison to Mz treated group suggest their role in controlling infection due to Giardia.  
 
Many cytokines also induced adaptive immunity in mice due to G. lamblia infection. 
Considerable levels of IL-4, IL-2, IL-5, IL-17, IL-13 and IFN-γ were detected. IL-2 provides 
body’s natural response to infection, IL-4 and IL-5 helps in diminishing pathological 
inflammation. Molecules like IFN-γ allow for communication between cells to trigger the 
protective defenses of the immune system, actvating macrophages and dendritic cells. Previous 
studies have reported that anti- IFN-γ treatment in C57BL/6 mice results in prolonged infections 
in G. muris (Venkatesan, Finch & Wakelin 1996). In a study (Solaymani-Mohammadi & Singer 
2011), it was reported that spleen cells and MLNs stimulated ex vivo with Giardia extracts 
produced IFN-γ, TNF-α, IL-4, IL-10, IL-13, IL-17 and IL-22. It was also indicated that CD4+ 
cells were the likely source of these cytokines. Proliferation of CD4+ T cells with cytokine 
response such as IFN-γ production was also assessed in giardiasis (Ebert 1999).  This result is 
similar to the detectable levels of CD4+ cells that have been produced by spleen cells in our 
study. 
 
The regulators of many hemopoietic cells, IL-3, IL-7, IL-9, IL-11, G-CSF, M-CSF and GM-CSF 
were also found. The cytokines of Th17 differentiation and activation, IL-17A, IL-17F, IL-21, 
IL-22, TGF-β and TNF-α were also detected in all the groups of mice. They are the regulators of 
many cells of the immune system. Decreased levels of IL-35 were observed, the cytokine which 
causes immune supresssion. NO has been reported to inhibit proliferation and differentiation of 
Giardia lamblia via its cytostatic action (Li, Zhou & Singer 2006). In contrast decreased 
production of NO was found in our study. 
 
The splenocytes also showed increase in the level of Th17 in the Fe-bLf and nanoformulated bLf 
treated mice. Yang et al. (Yang et al. 2008) have described that IL-17A, F released by TH17 
cells is involved in the recruitment, activation and migration of neutrophils which help the body 
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to fight against infection with various bacterial and fungal species. Th17 cells have also been 
involved in tissue repair functions through their production of cytokine IL-22 alongwith IL-10 
(Dong 2008). Anti-infective and anti-inflammatory roles of IL-22 are associated with its 
functions in maintaining the integrity of epithelial barriers (Torchinsky et al. 2009). Th17 cells 
have been described as proinflammatory, playing a role in autoimmunity and chronic 
inflammation.    
 
Intestinal factors and physiologic conditions, including small intestine pH (from 6.0 to 8.5), bile 
salts (10 mM taurocholate or glycocholate), and changing the osmolarity of the assay buffer from 
isotonic (9% sucrose) to hypotonic (4.5% sucrose) or hypertonic (18% sucrose), had no effect on 
killing of G. lamblia by LF or LFpep. In addition, neither human transferrin nor lysosome (4 
mg/ml) had giardicidal activity or any additive or protective effect at concentrations equivalent 
to the LD50s of LF and LFpep (Turchany, Aley & Gillin 1995). 
 
So in the present study, the potential of encapsulated Fe-saturated lactoferrin on ACNs for 
treatment of giardiasis was investigated in vivo. In BALB/c mice the infection with Giardia was 
cleared within 2 days of treatment with this drug and the parasite was completely eliminated 
when 7 days of drug treatment was over. Thus Alginate encapsulated ceramic nanocarriers iron-
saturated bovine lactoferrin preparations (AEC-CP-Fe-bLf NPs) was found to be effective as an 
anti-microbial agent. They control and sustain the release of the drug and target it to its site of 
localization to achieve increase in drug therapeutic efficacy and reduction in side effects. Thus 
the results of the present study reveal for the first time the ability of bLf to show antimicrobial 
effect that is also dependent on its level of iron saturation. 
 
7.5 Nanoformulated lactoferrin in the cure of salmonellosis 
And as such this study has broken ground in proving the efficacy of nanoformulated Lf in the 
cure of salmonellosis in mice. So far this study is believed to be is so far first of its kind in using 
a nanoformation and studying its antibacterial activity. The alginate gel-encapsulated ceramic 
nanocarriers loaded Fe- bovine Lf (bLf) (AEC-CP-Fe-bLf NPs) used in this study have been 
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characterised by Kanwar and coworkers (Kanwar, Mahidhara & Kanwar 2012), and have shown 
promising results in the oral delivery in colon cancer therapy.  
 
The present study was conducted by infecting mice with Salmonella typhimurium (ATCC-
14028), that produced intestinal and extraintestinal infection in mice similar to human typhoid 
infection.  In mice infected with Salmonella typhimurium, nanoformulated lactoferrin was most 
effective as it prevented them from developing secondary infection in liver and spleen within two 
days of treatment by inhibiting the translocation of bacteria to these organs with this drug after 6 
days of post infection. In comparison it took 6 days for Australian bovine lactoferrin and more 
than 6 days for Ciprofloxacin to act against bacteria in the same experimental group. In the 
infected tissues of mice without any drug treatment it was found that bacteria had disseminated 
throughout the reticuloendothelial system where they multiplied in the liver and spleen, also 
spreading infection to the brain. But bovine lactoferrin (bLf) in its native form and 
nanoformulated form was able to clear bacteria within 6 days of drug treatment/10 days post 
infection and 2 days of drug treatment/6 days post infection from the reticuloendothelial system 
and brain. Thiss compared with treatment using Ciprofloxacin, which did not eliminate bacteria, 
even after 6 days of treatment from any of the organs with persistence of bacteria found in small 
intestine, MLN, liver, spleen, sera and brain. The infected group also showed persistence of 
bacteria in all the organs. Various formulations of drugs are being tested on bacteria (Salmonella 
typhimurium, ATCC-14028) - combination of Ciprofloxacin (Cip, 200mg/kg b. wt.) and 
Arginine (Arg, 500mg/kg b. wt.), so when these drugs were administered for 7 days to infected 
mice individually, Ciprofloxacin (400mg/kg b. wt.), Arginine (1000mg/kg b. wt.) and in 
combination after 14 days of infection, maximum decrease was observed in only those given 
ciprofloxacin and in the Arg and Cip combination (Haque, 2011).      
 
Previous studies have reported the preventive action of lactoferrin in animal models of 
experimental infection against the mortality caused by pathogenic bacteria (Edde et al. 2001; 
Zagulski et al. 1998). In the current study the administration of Lf and its nanoformulated drug 
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after 3 days of oral infection with bacteria resulted in efficient cure against mortality at a dose of 
S. typhimurium 1000-fold higher than that the LD50 that was evaluated in another study (105 
CFU, S. typhimurium, 14028 strain) on BALB/c mice. In a study by Drago-Serrano et al. (Drago-
Serrano et al. 2010), when mice were intragastrically administered a sublethal dose of S. 
tyhimurium (104 CFU/ml), bLf treatment led to a decrease in the bacterial load in the intestine, 
spleen and liver. This was the first study that showed a relation between the decrease in bacterial 
load and the increase in antibody response induced by lactoferrin.   
 
Pathological studies showed many abnormalities in the MLN, small intestine, liver, spleen and 
brain tissues of mice in the infected group as compared to all the drug treatment groups and 
control mice. On the third day, the ileum of mice showed ileitis and swelling because of 
lymphocyte infilteration and diffuse expansion of lymphoid cells in the  MLN tissues, as 
compared to control mice which did not show any pathogenesis, various drugs, ciprofloxacin, 
bLf and nanoformulated lactoferrin were administered to all mice except the control group of 
mice. So when tissues of various organs were observed on 6th day post infection or after 2 days 
of drug treatment, the ileum of all the groups of mice, except those in the control group showed 
ulceration, paneth cell hyperplasia etc., lymphoid excess in MLN. However only the liver and 
spleen of the infected group, ciprofloxacin and bLf treated groups, showed pathological changes 
of focal lobular hepatitis, typhoid nodules in liver, excess red pulp and reduced white pulp in 
spleen. The nanoformulated lactoferrin treated group showed normal architecture of the organs 
liver and spleen on the 6th day post infection or 2 days of drug treatment. On the 10th day it was 
clearly observed that infection of Salmonella had finally reached the brain, showing focal 
necrosis in the tissue of mice in the infected group.The ciprofloxacin drug also failed to resolve 
the infection as edema of brain and spongiosis was observed. The infection by Salmonella 
typhimurium reaches the brain using macrophages which cause the hematoencephalic barrier 
(Nilsson et al. 2004). Edema was also observed in the brain of BALB/c mice due to higher 
concentrations of bacteria in a study by Vidal et al. (Vidal et al. 1995). Mosquito et al. (Mosquito 
et al. 2010) also observed edema, gliosis and cerebral macrophages proliferation in the mice after 
7 days of infection with Salmonella typhimurium. In contrast, infection had almost resolved in 
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the nanoformulated and bLf group on the 10th day post infection/ 6 days of drug treatment.  The 
histopathological changes in different groups of mice are explained by the bacterial load in the 
various organs of mice, as mentioned above. In the study by Mosquito et al. (Mosquito et al. 
2010), it was reported that in the gut which is the first organ infected by Salmonella  ser. 
Typhimurium, there was significantly less epithelial damage was observed in the Lf treated 
group, and less inflammation and focal necrosis was observed in the four organs- intestine, liver, 
spleen and brain. Salmonella adheres to and enters into M cells of Peyers patches, reaches the 
basal membrane of the epithelium, where it may get phagocytized by the neutrophils 
/macrophages, which take it to the mesenteric lymph nodes then to the circulatory system 
(Sansonetti 2004; Vazquez-Torres et al. 1999) and to the liver and spleen, where exponential 
replication may occur (Haraga, Ohlson & Miller 2008; Nilsson et al. 2004).            
 
Significant reduction in body weight was observed in the mice in the infected group and also in 
the Ciprofloxacin treated groups, as compared to the normal mice. In contrast, the mice which 
showed compliance with the drugs bLf and nanoformulated lactoferrin gained weight. Thus this 
study was successful in explaining the antimicrobial activity of the drugs bLf and its 
nanoformulation on Salmonella, as they helped in curing the disease in mice by fast clearance of 
bacteria from the infected organs within a few days of treatment as compared to traditional drug 
Ciprofloxacin to which the bacteria have become resistant because of continuous use.    
 
Lactoferrin is well known for its properties such as anti-microbial, anti-viral anti-inflammatory 
and immunomodulatory functions (Kanwar & Kanwar 2012). Leukocyts exposed to Lf modulate 
their cytokine production; proinflammatory cytokines, TNF-α, IL-6, and IL-β can be modulated 
by lactoferrin to increase or decrease (Kruzel et al. 2002; Machnicki, Zimecki & Zagulski 1993; 
Sorimachi et al. 1997; Zimecki et al. 2001). In addition, the role of Lf in the regulation of the 
above mentioned cytokines and IL-12 clearly demonstrates communication between innate and 
adaptive immune responses (Trinchieri, Pflanz & Kastelein 2003). The immune response to 
infection and various drug treatments in mice was due to production of various cytokines in the 
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gastrointestinal tract which helped mice in resisting the infection due to Salmonella. In the 
previous study it was shown that the Salmonella typhimurium porins produce an inflammatory 
effect and release TNF-α, IL-1α and IL-6 by human monocytes and the release of IL-4 and IFN-γ 
by human lymphocytes (Galdiero et al. 1993). Similarly, in our investigation an adaptive and 
immune response was observed due to production of the cytokines IL-1β, IL-2, IL-4, IL-5, IL-6, 
IL-10, IL-12, IL-13, IL-15, IL-17, IL-18, IL-23, IL-27, INF-1α, INF-1β, INF-III and IFN-γ. 
These results are also in line with the previous study by Kincy-Cain and coworkers (Kincy-Cain, 
Clements & Bost 1996) who reported the role of IL-12 in the induction of a protective mucosal 
immune response against Salmonella infections. 
 
IL-1 promotes or enhances the maturation, proliferation and functional activation of the cell 
types involved in immune or inflammatory responses. IL-4 is the product of a subset of activated 
T cells and may act in combination with IL-1 as an autocrine growth factor for antigen-specific T 
cells and enhance antigen presentation in bone-marrow-derived macrophages. IFN-γ is an 
immunoregulatory agent known to induce major histocompatibility complex antigens on many 
cells, Fc receptors on monocytes and macrophages, and IL-2 receptors on T cells and to enhance 
the activity of many cells (Galdiero et al. 1993). 
 
The role of NO in the antimicrobial mechanism against Salmonella typhimurium infection in 
mice has been reported in previous studies (Umezawa et al. 1997). In earlier studies IL-18 was 
found to be a key factor in early host resistance to Salmonella and speculated that it acts via IFN-
γ (Mastroeni et al. 1999). Detectable levels of both these cytokines have been observed in the 
present study.  
 
Combining nanoparticles with antibiotics enhances their bactericidal properties as has been 
shown in this current investigation how the alginate gel-encapsulated ceramic nanocarriers 
loaded Fe- bovine Lf (bLf) (AEC-CP-bLf NPs) proved effective in rapid clearance of bacteria in 
mice within two days. No side effects, toxicity etc. were observed and even a very low dose of 
the drug aided the bacteria, Salmonella, in overcoming the resistance to antibiotics which are 
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otherwise now resistant to many drugs these days. These nanoparticles have been used to deliver 
the required antibiotic like lactoferrin to the site of pathologic process leading to their control 
release, which as mentioned above in turn decreases the dose required to achieve a clinical 
effect. 
 
In a study by Fierer et al. (Fierer et al. 1990), enhanced gentamycin accumulation in Salmonella 
infected liver and spleen in mouse models proved that nanocarriers improved biodistribution of 
drugs in the target organ when they were encapsulated because of phagocytosis by the blood 
monocytes and macrophages of the liver, spleen, and bone marrow (Prior et al. 2000).  
Additionally, this approach can reduce the dosage, frequency of drug administration, as well as 
healthy organ toxicity observed with conventional therapy (Ahmad, Sharma & Khuller 2007; 
Mingeot-Leclercq, Brasseur & Schanck 1995). For example, liposomal encapsulation of 
gentamicin allows a significant reduction (50%) in the total treatment duration in disseminated 
Mycobacterium avium infections in mice, relative to usual antimicrobial therapy (de Steenwinkel 
et al., 2007). Similarly, reduced build-up of gentamicin in the kidneys upon parenteral 
administration in rats has been reported (Abrahams & Hensel 2006). Therefore, the 
nanomedicine approach can limit the distribution of drugs to target organs of infection (Lecaroz, 
Gamazo & Blanco-Prieto 2006). Martínez-Gutierrez et al. (Martínez-Gutierrez et al. 2012) 
reported that the combined antibacterial effects of silver nanoparticles with antibiotics, 
ampicillin, erythromycin, kanamycin and chloramphenicol against E. coli and Salmonella typhi, 
antibacterial activity of all tested antibiotics increased due to the presence of the silver 
nanoparticles.  
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Chapter 8. Conclusion 
Research Outcomes 
The study deals with the exploration of the anti-microbial properties of nanoformulated 
lactoferrin a multifunctional protein involved in the regulation of iron absorption in the bowel 
and because of its anti-oxidant properties aids the immune system in combating inflammation. 
Additionally, on account of its interaction with the components of both the host and a variety 
pathogens it is able to orchestrate effective responses against the latter. Since lactoferrin is a 
naturally occurring molecule its clinical application would be welcome as it is unlikely to have 
harmful side effects.  
 
Also the study has been successful in preparing a biomolecular delivery system consisting of a 
novel alginate enclosed, chitosan coated ceramic antimicrobial nanocarrier containing lactoferrin 
(AEC-CP-Fe-bLf).  
 
Moreover, the study has defined explicitly the scoring system for the infection caused by Giardia 
lamblia infection in mice. In contrast to only about a percent of Fe-bLf that typically becomes 
bioavailable the nanodelivery system described here appears to have here improved the 
bioavailability by more than an order of magnitude and as shown in section 5.3.6 and 5.3.7 by 8-
10 hours there is close to 12 time increase in the bioavailabilityof Fe-bLf. Additionally the 
nanoparticles exhibited a sustained release of Fe-bLf for 10 days in mice AEC-CP-Fe-bLf as 
compared to just about few hours when Fe-bLf alone was fed. Animals fed the nanotised Fe-bLf 
resolve the Giardia infection within 11 days as compared to more than 15 days required for Fe-
bLf alone. Also, the trophozoite counts were resolved in about 2 days on administration of 
nanoformulated lactoferrin diet. These findings are supported by histopathology of both the large 
and small intestine wherein the morphology of the intestine becomes near normal upon the 
treatment with AEC-CP-Fe-bLf. Fe-bLf by itself on the other hand the effect of was only 
marginal.  
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Clinical scoring results validated these findings as well. Blood parameters including serum iron 
and calcium levels in the experimental animals were also restored to the normal. The beneficial 
effects of AEC-CP-Fe-bLf in resolving Giardia infection evaluated at the level of immunity 
using an array of cytokines were consistent with the hypothesis that the nanoformulated Fe-bLf 
exerts its effects by modulating the immune system.  
 
Subsequent to the above study of antimicrobial activity of nanoformulated lactoferrin treating 
infections caused by Salmonella in mice was done. Interestingly even after 2 days of treatment 
Ciproflaxacin and Fe-bLf treatment considerable amount of bacteria were found in liver and 
spleen which virtually disappeared upon treatment with nanoformulated Fe- bLf. Bacterial 
counts in the spleen also reflected a similar trend. Using histopathological studies the intestine, 
liver spleen and brain tissues were found to be cleared of Salmonella upon treatment with 
nanoformulated lactoferrin Fe-bLf whereas the effects with treatments of bLf by itself or 
ciproflaxacin were in comparison moderate. Further the analysis of cytokine levels explains the 
beneficial immunomodulatory effect of nanoformulated lactoferrin Fe-bLf . The studies also 
highlight the potential of treatment with nanoformulated lactoferrin in combination with standard 
drugs for treating these infections. 
 
 
Conclusions and future prospectives 
Lactoferrin is a truly multifunctional protein that has been studied extensively over the past 
decades. The most widely studied function to date is protection against microbial infection 
besides various physiological functions of the protein, including regulation of iron absorption in 
the bowel, immune response, antioxidant, anticarcinogenic and anti-inflammatory properties. 
 
The mechanisms underlying the extensive activities are not only the capacity of Lf to bind iron 
but also interactions of Lf with molecular and cellular components of both host and pathogen. 
Thus Lf should be considered a polyvalent regulator, which accomplishes its task by interacting 
with several components involved in infectious or inflammatory processes. Further 
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investigations are required to study the molecular interactions of this protein with regulator 
elements and other proteins for antimicrobial function. The increase in resistance of microbial 
pathogens to drugs and antibiotics has given rise to the search for new therapeutic alternatives to 
fight pathogens. 
 
An interesting future perspective, which can be foreseen, is the use of lactoferrin or its derived 
peptides in combination with other commercially available antimicrobial compounds and 
lowering the dose of these toxic synthetic compounds. Lactoferrin may also have the potential to 
be combined with probiotic bacteria in biotherapeutic products, which could help to balance 
human gut microflora and limit the overgrowth of certain pathogenic microorganisms, including 
parasites. The new future perspectives in the studies on the antimicrobial activity of Lf appear to 
be linked to its potential prophylactic and therapeutic use against pathogenic parasites in humans 
without leading to drug side effects. The great utility of this functional protein has motivated 
scientists to overexpress and purify Lf from cells as a potential defense against 
pathogens.Lactoferrin is a natural compound and may easily find clinical application. 
 
This study aimed to investigate a safe potent alternative medicine for the cure of infectious 
diseases like giardiasis and salmonellosis. Infection by G. lamblia is considered as a serious 
public health problem due to its pathology (Thompson & Monis 2004). Axenically cultured G. 
lamblia trophozoites are capable of infecting and completing their life cycle in suckling BALB/c 
mice. Also the high prevalence of multidrug resistant bacteria to conventional antibiotics is a 
serious concern for modern medicine. Novel strategies are urgently needed to cope up with this 
problem of decreased effectiveness of current treatments against infections by human pathogens 
like Salmonella causing thousands of deaths.  
 
Despite the use of nitroimidazoles or other chemotherapeutic agents, still the numbers of 
refractory cases are increasing, so efforts are being made to find better current treatment of 
Giardia infection. The greatest recent impact of milk derived products like iron saturated bovine 
lactoferrin (Fe-bLf) and recombinant human lactoferrin for cancers reveals that the potential of 
milk for cancer treatment and prevention are enormous. There is also renewed interest in the role 
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of lactoferrin as an anti-cancer agent as well as anti-bacterial therapy. However, studies with 
parasites are limited and there is some work on the effect of lactoferrin on bacteria. In this study 
for the first time antimicrobial efficacy of buffalo lactoferrin was evaluated against G. lamblia 
and promising results were obtained.  
 
Also, there are no studies available on the use of immobilized iron saturated bovine lactoferrin 
and its nanoformulation for parasitic disease chemoprevention or chemotherapy and further 
analysis in these aspects needs to be carried out. Further entrapping or encapsulating the drug 
within a delivery system provides a greater control of the pharmacokinetic behaviour of the 
active molecule. This study was successful in finding AEC-CP-Fe-bLfs as a valuable tool in 
development of nutraceutical antimicrobial nano drug for the delivery of antimicrobial proteins. 
These were the ideal nanocarriers which had long circulatory half lives, specifically targeted and 
delivered the drug to specific sites, minimising systemic toxicity and also delivered adequate 
doses of drugs. 
 
Combining antibiotics with nanoparticles has great potenial to address the worldwide escalation 
of bacterial resistance by enhancing the therapeutic efficacy of anitimicrobials against infections. 
Thus advances in nanoparticle drug delivery are needed for intracellular bacterial clearance and 
replacing antibiotics for the development of safe drugs. The research presented in this study is 
the novel study as the efficacy of AEC-CP-Fe-bLfs in the treatment of salmonellosis has been 
proved for the first time. Importantly this study will help in formulating new prospects for future 
studies in treatments for antibiotic resistant-bacteria.  
 
There is future potential to build on this research develop effective scientifically validated 
synergistic formulations that would ensure better provision of nanomedicine based therapeutic 
interventions even for the cure of parasitic diseases as giardiasis and future developments of anti-
microbial and/or anti-tumour therapies. Further clinical trials are needed to carry to prove the 
efficacy of drug and the therapeutic doses required for humans. This more efficient use of natural 
compounds such as lactoferrin may diminish the drawbacks of existing antimicrobial and anti-
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tumour agents and provide the basis for shortening the current time required by classical 
treatments. 
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Appendix 
 
A. Composition and preparation of various media, buffers and reagents used in the study: 
 
1. Phosphate Buffer Saline (PBS-0.15M, pH 7.2) 
NaCl    -  8.8gm 
Na2HPO4   -  1.15 gm 
KCL    -  0.20 gm 
KH2PO4   -  0.20 gm 
DDW - 1000 ml. Stored at RT. 
 
2. TYI-S-33 medium 
 
Trypticase 2gm 
Yeast extract 1gm 
Glucose 1gm 
L-cysteine hydrochloride 0.1gm 
Ascorbic acid 0.02 
Sodium chloride 0.2gm 
Potassium phosphate dibasic 0.1gm 
Potassium phosphate basic 0.06gm 
Ferric ammonium citrate 2.28gm 
Double distilled water 75ml 
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The above ingredients were mixed one by one and to this 10ml horse serum, 2.5ml vitamin 
mixture NCTC 107 and 1ml antibiotic (Penicillin and Streptomycin) mixture was added and 
finally pH was adjusted to 7.0 ± 0.1. The medium was sterilized by Seitz filtration and dispensed 
in 10ml quantities in sterile screw capped round bottom tubes. 
 
Vitamin mixture NCTC 107 comprises 5 stocks 
Stock 1: Water soluble vitamin B solution (A+B+C). Total volume was made to 250ml with 
distilled water.  
 
A : 31.25mg Niacin (sigma), 6.25mg P-amino benzoic acid. 
Total volume was made to 75ml with distilled water (D.W.). 
B : Niacin amide 31.25mg, Pyridoxin HCl 3.25mg, Thymine 12.5mg, Calcium 
Pentothenate 12.5mg, Inositol 6.25mg and Chlorine chloride 62.5mg. 
Total volume was made to 75ml with D.W. 
C : Riboflavin (Vitamin B2) 12.5mg in 37.5ml of distilled water adding 0.1N NaOH (drop 
wise). 
Total volume was made to 50ml with distilled water. 
 
Stock 2: Biotin solution 
15mg D-biotin dissolved in 100ml of distilled water by adding 0.1N NaOH (dropwise). Final 
volume was made to 150ml distilled water. 
 
Stock 3: Folic acid solution 
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15mg folic acid dissolved in 100ml distilled water with help of 0.1N NaOH (dropwise). Final 
volume made to 150ml by adding distilled water. 
 
Stock 4: Lipid soluble vitamin A, D, K solution (A+B). Total volume made to 300ml with D.W. 
 
A : 30mg vitamin A in crystalline alcohol was added and then dissolved in 5% v/v aqueous 
solution of tween -80. Final volume was made to 50ml. 
30mg of vitamin D2 (calciferol) was added to 6.3ml of 96% v/v ethanol. Final volume 
was made to 50ml. 
B : 6mg vitamin K (menadioni sodium bisulphate) was dissolved in 30ml of 5% v/v 
aqueous solution of tween -80. Final volume was made to 50ml. 
Stock 5: Vitamin E solution  
12.5mg vitamin E dissolved in 12ml D.W. 
 
Working Mixture: Vitamin mixture 
250ml stock 1 + 125ml stock 2 + 125ml stock 3 + 125ml stock 4  + 125ml of stock 5 was mixed 
and was seize filter sterilized, dispensed into 500ml bottle, kept in fridge till use. 
 
3. Regents for SDS-PAGE: 
 Acrylamide/bis – methylene – acrylamide 
87.6 g acrylamide (29.2g/100ml) 
2.4 g N’N’-bis-methylene-acrylamide (0.8g/100ml) 
Make to 300 ml with deionized water. Filter and store at 4o C in the dark (30 days maximum). 
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1.5 M Tris-HCl, pH 8.8 
27.23 g Tris base (18.15 g/100 ml) 
~80ml deionized water 
Adjust to pH 8.8 with 6N HCL. Make to 150 ml with deionized water and store at 40o C 
 
0.5 M Tris-HCl, pH 6.8 
6 g Tris base 
~ 60 ml deionized water 
Adjust to pH 6.8 with 6N HCl. Make to 100 ml with deionized water and store at 40 o C. 
 
10% SDS 
Dissolve 10 g SDS in 90 ml water with gentle stirring and bring to 100ml with ddH20. 
 
Sample buffer (SDS reducing buffer) (store at RT) 
Deionized water   -  3.8 ml 
0.5 M Tris- HCL, pH 6.8  -  1.0 ml 
Glycerol    -  0.8 ml 
10% (w/v) SDS   -  1.6 ml 
2-mercapto ethanol   -  0.4 ml 
1% (w/v) bromophenol blue  -  0.4 ml 
Total volume    -  8.0 ml 
Dilute the sample at least 1:4 with sample buffer, and heat at 950C for 4 minutes. 
 
5X electrode (Running) buffer, pH 8.3 (enough for 10 runs) 
__________________________________________ 
Tris base 9 g (15 g/l) 
Glycine 14.2 g (72 g/l) 
SDS 3 g (5g/l) 
________________________________________ 
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to 600 ml with deionized water Store at 40 C. Warm to room temperature before use if 
precipitation occurs. Dilute 60 ml 5X stock with 240 ml deionized water for one electrophoretic 
run. 
 
Separating Gel Preparation – 12%, 0.375 M Tris, pH 8.8 
      12%   7.5% 
Deionized water     3.35ml  4.85 ml 
1.5M Tris-HCL<pH 8.8    2.5 ml   2.5 ml 
10% (w/v) SDS stock    100μl   100μl 
(store at room temperature) 
Acrylamide/Bis (30% stock)    4.0 ml   2.5 ml 
(Degas for 3 15 minutes at RT) 
* 10% ammonium persulfate    50 μl   50 μl(0.05%(fresh daily) 
TEMED      5 μl   5 μl (0.05%) 
TOTAL Volume +     10 ml   10 ml 
To make the 10% ammonium persulfate solution, dissolve 100 mg APS in 1 ml deionized water. 
 
Stacking Gel Preparation – 4.0 % gel, 0.125 M Tris, pH 6.8 
_______________________________________________ 
Deionized water 6.1 ml 
0.5 M Tris-HCL, pH 6.8 2.5 ml 
10% (w/v) SDS 100μl 
Acrylamide/bis (30% stock) 1.33 ml 
10% ammonium persulfate 50 μl (.05%) 
(fresh daily) 
TEMED 10 μl (0.1%) 
TOTAL Volume 10 ml 
____________________________________________________________ 
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To prepare the monomer solutions, combine all reagents, except the TEMED and APS, and 
degas under vacuum for 15 minutes. To initiate polymerization and the APS and TEMED, and 
swirl gently to mix. 
 
Stain for SDS-PAGE gels 
Coomassie brilliant blue R-250  0.25g 
Methanol     50ml 
Glacial acetic acid    10ml 
Distilled water    40ml 
 
Gel destaining solution 
Methanol     25ml 
Acetic acid     10ml 
Distilled water    65ml 
 
4. Reagents for WESTERN BLOT ASSAY 
Transfer Buffer 
25 mM Tris, 192mM glycine, 20% v/v methanol, pH 8.3 
Mix 3.03 g Tris, 14.4 g glycine, and 200 ml of methanol; add distilled 
deionized water (dd H2O) to 1 litre. 
Do not add acid or base to adjust pH of the following buffers. 
Methanol should be analytical reagent grade, as metallic 
contaminants in low grade methanol will plate on the electrodes. 
 
Substrate Solution 
3, 31 – diaminobenzidine - 5 mg 
PBS (0.01M ) - 10 ml 
H2O2 - 20 μl (Just before use) 
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10% SDS 
_________________________________________________ 
Final Concentration    Amount 
_________________________________________________ 
SDS (FW 288.38) 10% (w/v)  5.0 g 
Double distilled water to 50 ml 
____________________________________________________ 
Filter solution through a 0.45 μm filter. Store at room temperature. 
 
10% ammonium persulfate in distilled water 
Fresh ammonium persulfate “crackles” when water is added. If it does 
not replace it with fresh stock. Prepare just prior to use. 
 
Gel storage solution (0.375 M Tris-HCl, pH 8.8, 0.1% SDS 200 ml) 
_________________________________________________ 
Final Concentration    Amount 
_________________________________________________ 
4X Resolving gel buffer 1X   50 ml 
10% SDS 0.1%    2 ml 
Double distilled H2O to 200 ml 
__________________________________________________ 
 
SDS electrophoresis buffer* (25 mM Tris- HCl, pH 8.3, 192 mM 
glycine, 0.1% SDS, 10 l) 
 
5. Reagents for ELISA 
Coating buffer or Carbonate-Bicarbonate (pH 9.6, 0.05M) 
Na2 Co3 - 10.6mg 
NaHCo3- 17.85mg 
DDW - 12.5ml 
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Phosphate Buffer Saline (pH 7.2, 0.01 M) 
K2HPO4 - 1.21 gm 
KH2PO4 - 0.34 gm 
NaCl - 8.0 gm 
DDW - 1000ml 
 
Blocking Buffer 
PBS (0.01M) - 10 ml 
BSA - 0.2 gm 
 
Washing Buffer 
PBS (0.01 M) - 1000ml 
Tween 20 - 200μl 
 
Citrate Buffer (pH5.6, 1M) 
Citric Acid - 0.466 gm 
Na2HPO4 - 0.72 gm 
DDW - 100 ml 
 
Substrate solution (PH 5.2, 1M) 
Orthophenylendiamine - 10 mg 
Citrate buffer - 20 ml 
H2O2 - 40μl 
 
Reaction Stopping Solution (1N H2SO4) 
Conc. H2SO4 - 27.8 ml 
DDW - 474.2 ml 
 
6. Hematoxylin and Eosin Staining method (H & E): 
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Scott’s Tap water: 
Magnesium sulphate - 20gm 
Sodium bicarbonate - 2.5 gm 
Tap water - 1000ml 
 
1% Eosin: 
Eosin – 1gm 
Distilled water - 100ml 
CaCl2 - 0.5gm 
 
 
